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   In  breast  cancer  cells,  estradiol  induces  in  rapid  succession  nuclear 
translocation  and  nuclear  exit  of  the  estradiol  receptor  (ERα).  Receptor 
export  depends  on  CRM1.  Experiments  with  constructs  expressing  a 
receptor‐derived  sequence  reveal  the  presence  of  a  nuclear  export 
sequence  (NES)  within  the  hormone‐binding  domain  of  ERα.  This 
sequence  restores  the  CRM1‐dependent  export  of  a  Rev‐HIV  mutant 
protein  in an  in vivo export assay. A peptide mimicking  the ERα  export 
sequence  disrupts  in  vitro  the  ER/CRM1  interaction  and  sequesters  the 
receptor  in  the  nuclear  compartment  of  MCF‐7  cells.  Remarkably,  it 
inhibits  estradiol‐induced DNA  synthesis.  Furthermore,  by  site‐directed 
mutagenesis  of  full‐length  ERα, we  identified  the  ERα‐NES. Mutant  of 
ERα‐NES ectopically expressed in NIH 3T3 fibroblasts does not exit nuclei 
and  is  unable  to mediate  estradiol‐induced  S‐phase  entry.  This mutant, 
however, leaves unaltered receptor‐dependent gene transcription. 
Confocal microscopy analysis shows that ERα colocalizes with forkhead 
in  nuclei  of  estradiol‐treated  MCF‐7  cells.  A  forkhead  mutant, 
unphosphorylatable by Akt, is trapped together with ER wt in nuclei and 
blocks  estradiol‐induced  S‐phase  entry  in MCF‐7  cells.  In  turn,  the ERα 
NES mutant fails to exit nuclei and prevents forkhead wt nuclear export. 
Findings presented in this thesis  identify for the first time an ERα NES, 
which  depends  on  estradiol  and  is  directed  by  CRM1. Moreover,  they 








The  most  important  features  that  differentiate  eukaryotic  cells  from 
prokaryotic  cells  is  the  presence  of  distinct  intracellular  compartments, 
organelles  and  nucleus.  The  spatial  separation  of  mRNA  synthesis, 
occurring  in  the  nucleus,  from  translation  of  proteins,  occurring  in  the 
cytoplasm,  provides  eukaryotes  with  the  possibility  to  achieve  higher 
complexity. Many molecules continuously move between the nuclear and 
the  cytoplasmic  compartments  through nuclear pore  complexes  (NPCs), 
which  essentially  serve  as  gatekeepers  spatially  and  temporally 
segregating  the  genomic  material  from  all  cytoplasmic  processes 
(Sebastian  et al. 2004).  
NPCs constitute high‐order octagonal diffusion  channels  that penetrate 
the  double  bilayer  of membranes  surrounding  the  nucleoplasm.  These 
remarkable structures are estimated to weigh 125 MDa and to contain 50‐
100  different  proteins,  called  nucleoporins  (Nups),  most  of  which  are 
characterized  by  hydrophobic  phenilalanine/glycine  (FG)‐rich  repeat 
motifs  (Meyer  and  Vinkemeier  2005).  The  derived  channels  have  a 
diameter of roughly 9 nm, which is equivalent to a globular protein of 50‐
60  kDA.  Somehow,  however,  the  NPCs  change  conformation  to  allow 
active  transport  of  substrates  (cargoes)  greater  than  25  nm  in  diameter, 
which  is  equivalent  to  a  ribosomal  diameter.  Therefore,  some  small 
molecules  (i.e.  ions and metabolites) passively diffuse across  the nuclear 
pore  complexes  through  a  concentration  gradient,  whereas 
macromolecules are, in most cases, actively transported across the nuclear 
channels  (Yoneda 2000). Thus, NPCs  function as  selective  filters because 







The  nuclear‐pore  complex  consists  of  an  eightfold  symmetric  central  framework.  The 
cytoplasmic  ring moiety  of  the  central  framework  is decorated with  eight  cytoplasmic 
filaments, whereas  the nuclear  ring moiety  is  topped with eight  tenuous  filaments  that 
join distally  into a massive distal ring and  thereby  form a distinct nuclear basket  (from 
Fahrenkrog and Aebi 2003). 
 
  Active  transport  between  nucleus  and  cytoplasm  involves  primarily 
three  classes  of  macromolecules:  substrates,  adaptors  and  receptors 
(Sebastian et al. 2004). The movement of macromolecules  into and out of 
the  cell  nucleus  is  usually mediated  by  soluble  transport  receptors  that 
recognize specific sequences or structural characteristics of  their cargoes. 
Particularly,  these  receptors  recognize  the  nuclear  localization  signal 
(NLS),  which  contains  a  cluster  of  basic  amino  acids  (i.e.  lysine  and 
arginine),  as well  as  the  nuclear  export  signal  (NES), which  is  rich  in 
hydrophobic amino acids (i.e. leucine or isoleucine). Both these sequences 
give  specificity  to  the  transport  (Nigg  1997).  The  majority  of  known 
transport  receptors mediating  interactions with  the NPC  belong  to  the 
importin  β  super‐family  of  RanGTP  binding  proteins,  also  called 
karyopherins. Karyopherins act as  chaperones during nucleocytoplasmic 
translocation  (Rogue 2002). Passage  through  the pore  requires weak and 
transient binding of  importin  β  receptors  to  the nucleoporin FG  repeats 
(Meyer and Vinkemeier 2005). Furthermore, energy consumption confers 
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ensures  the  directionality  of  nucleocytoplasmic  protein  trafficking 
(Izaurralde et al. 1997). Ran switches from a GDP‐ to a GTP‐bound state, 
thus  regulating  the  binding  of  substrates  to  the  transport receptors. 
However, its intrinsic activity of GDP/GTP exchange or GTP hydrolysis is 
very  low.  Therefore,  Ran  GTPase  cycle  is  modulated  by  various 
interacting proteins  that regulate  its guanine nucleotide‐bound state. The 
guanine nucleotide exchange factor, Ran‐GEF (also called RCC1, regulator 
of  chromosome  condensation  1)  accelerates  the  dissociation  of  guanine 
nucleotide from Ran and facilitates the conversion of RanGDP to RanGTP. 
Since  RCC1  is  exclusively  localized  in  the  nuclear  compartment,  the 
generation  of  the  GTP‐bound  form  of  Ran  occurs  in  the  nucleus. 
Conversely, Ran GTPase  activity  is  stimulated by  the GTPase‐activating 
protein,  Ran‐GAP,  which  is  exclusively  localized  in  the  cytoplasm. 
Consequently,  the binding of Ran‐GTP  to an  importin  (import  receptor) 
triggers the release of bound cargo. On the other hand, the binding of Ran‐
GTP  to  an  exportin  (export  receptor)  facilitates  the  assembly  of  the 
exportin‐cargo  complex. This  asymmetry  ensures  the  efficient  release  of 
the  import  cargo within  the nucleus and  that of  the  export  cargo  in  the 
cytoplasm (Yoneda 2000).  
After  traversing  the  nuclear  pore  complex,  importins  and  exportins 
release  their  cargo  and  recycle,  moving  back  to  the  other  side  of  the 
nuclear envelope to begin a new transport event. Thus, transport receptors 
and  Ran  shuttle  continuously  between  nucleus  and  cytoplasm, moving 
rapidly  back  and  forth  across  the  NPCs  (Gama‐Carvalho  and  Carmo‐









In a,  the complex NLS cargo/importin α/importin β  is  translocated  through  the nuclear 
pore complex  into  the nucleus. After entering  the nucleus,  the NLS cargo  is dissociated 
by Ran‐GTP.  Importin  β  and Ran‐GTP  are  recycled  back  out  through  the  pore  to  the 
cytoplasm, where Ran‐GTP  is hydrolyzed  to Ran‐GDP.  Importin α  is carried out of  the 
nucleus  by  the  nuclear  export  receptor CAS.  This  export  involves  complex  formation 
with  Ran‐GTP,  and  then CAS  is  transported  back  into  the  nucleus. NUP50  is  a  Ran‐
binding protein and a co‐factor for importin α/β‐mediated import. In b, NES cargoes bind 
to  the  exportin  β/Ran‐GTP  complex  before  they  are  exported  out  of  the  nucleus. 
Hydrolysis of Ran‐GTP  to Ran‐GDP by RanGAP promotes complex dissociation  in  the 
cytoplasm.  Thus,  the  exportin  is  transported  back  into  the  nucleus, where  it  can  re‐








years  for  the  first  shuttling  protein,  the  nucleolin,  to  be  identified  and 
scientists  have  today  learned  that  a  protein  previously  believed  to  be 
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confined to the cell nucleus actually shuttles between the nucleus and the 
cytoplasm  (Gama‐carvalho  and  Carmo‐Fonseca  2001).  Furthermore,  a 
variety of transport pathways simultaneously operating in cells have been 
identified  (Gorlich and Mattaj 1996).  Importin  β  receptors need  in many 
cases an adaptor, importin α, which binds both, the substrate proteins and 
importin β. In such a way, importin α forms a bridge between the import 




required  for  the  nuclear  import  of  replication  protein A  (RPA;  Yoneda 
2000). It has also been demonstrated that importin β can by itself mediate 
the  nuclear  import  of  certain  karyophiles  without  the  aid  of  adapter 
molecules, such as the viral protein Rev (Yoneda 2000). However, certain 
proteins are translocated through the NPC in a Ran‐independent manner, 
as  occurs  in  the  nuclear  translocation  of  β‐catenin  (Xu  and  Massaguè 
2004).  
The  best  characterized  protein  export  mechanism  is  mediated  by 
Chromosome  Region  Maintenance  1  (CRM1  or  exportin1),  a  protein 
originally  identified  in  the  fission  yeast  Schizosaccharomices  pombe 
(Ossareh‐Nazari  et  al.  1997). The  sequence  similarity  between  exportin1 





inhibitor  of  CRM1‐mediated  nuclear  export  (Kudo  et  al.  1998).  It  was 
isolated from Streptomyces sp strain ATS 1287 and initially implicated in a 
screen for compounds that block the export of HIV Rev protein. To date, 
LMB  is  the  best  characterized  small‐molecule  inhibitor  of  CRM1‐
dependent  nuclear  transport  (Kau  and  Silver  2003).  The  nuclear  export 
inhibition mechanism  involves  the direct binding of LMB  to CRM1  and 
the  consequent  inhibition  of  the  binding  of CRM1  to  its  cargoes. NES‐
CRM1  interaction was  identified on a conserved region near cysteine‐529 
residue  of  human  exportin1  and  this  residue  provides  LMB  sensitivity 






and  the  cytoplasm  through  the modulation of  subcellular  localization of 






this  is  the nuclear  factor κB  (NFκB).  In unstimulated cells,  it  is generally 




the  nuclear  factor  translocates  into  the  nucleus  and  activates  the  target 
genes that promote cell proliferation (Kau and Silver 2003).  
Another  control  mechanism  of  import/export  is  represented  by  the 
anchoring of cargoes on one side of  the nuclear membrane, as occurs  for 





pathway.  The  “canonical” model  of  JAK‐STAT  pathway  proposes  that 
cytokine‐binding to its own receptor induces activation of the JAK family 
tyrosine  kinase, which  phosphorylates  the  STAT molecules  on  tyrosine. 
Once phosphorylated,  STATs   dimerize  in  the  cytoplasm  and  in  such  a 






cyclin  B1  and CRM1. As  a  consequence,  reduction  of  cyclin  B1  nuclear 
export occurs and cell cycle is fostered (Jones et al. 2000).  It has also been 
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related  family of  transcription  factors, sub‐group O;   p27, cyclin‐dependent kinase  inhibitor  that runs as a 27 
kilodalton  protein  on  SDS‐PAGE;  E2F1,  transcription  factor,  member  of  E2F  family  and  activator  of  the 








accepted  that  interference  in  the nucleocytoplasmic  shuttling of proteins 
represents a new approach  to manipulate cellular commitment. Methods 
that  re‐direct  the proteins  to  the correct cellular compartment have been 
developed. They  include  inhibitors of  the  transport machinery as well as 


































Steroid  receptors  belong  to  a  superfamily  of  nuclear  receptors  (NRs). 
These  ligand‐activated  transcription  factors  are  involved  in  normal 
physiology and  in a variety of human diseases (Deroo and Korach 2006). 
The  members  of  this  family  share  common  structural  features. 
Particularly,  they  are  characterized  by  three  principle  distinct  domains: 
the  most  variable  N‐terminal  transactivation  domain;  the  most  highly 
conserved  central  DNA‐binding  domain  (DBD);  and  the  relatively 







The  numbers  above  the  bars  indicate  the  percentage  amino  acid  homology  of  the 
consensus  regions  of  the  DNA‐  and  ligand‐binding  domains.  In  b,  some  important 
functions that are associated with the different domains of nuclear receptors are depicted 
(AF, activation  function; Hsp, heat shock protein; NLS, nuclear  localization signal). The 
three  principle  domains  are  presented  in  the  figure.  They  include  the  transactivation, 
ligand‐independent domain, endowed  in N‐terminal  region,  the DNA‐binding domain, 
endowed  in  the  central  region,  and  the  transactivation,  ligand‐dependent  domain, 
endowed in C‐terminal region (from Tata 2002). 
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The  “classical” mechanism  of  steroid  action  proposes  that  unliganded 
NRs are associated with a chaperone protein complex, made of above all 
heat  shock  proteins  (hsp70,  hsp90)  and  immunophilins  (Ylikomi  et  al. 
1992).  Binding  to  the  hormone  leads  to  a  conformational  change  in  the 
receptor  acting  as  an  on‐switch.  It  therefore  induces  the  release  of NRs 
from chaperone molecules, the dimerization and entrance of NRs into the 
nucleus, where  they  bind  to  palindromic  hormone  response  elements 
(HREs) within the regulatory regions of target genes (Rochette‐Egly 2005). 
The  mechanism  of  gene  transcription  activation  by  liganded  NRs, 
however,  relies on  a  complex network of  interactions between NRs and 
co‐regulatory  proteins  (Mangelsdorf  et  al.  1995).  Depending  on  the 
complexes  that  NRs  form  with  co‐activators  or  co‐repressors,  they 
function both as activators or  inhibitors of  transcription  (Tata 2002). For 
most NRs,  this  network  is directed  by  a  specific domain,  the  activation 
function  2  (AF‐2)  domain,  located  in  the  LBD.  Upon  ligand  binding, 
transactivation  domain  undergoes major  structural  rearrangements.  The 
AF‐2  domain  cooperates with  a  second,  ligand‐independent,  activation 
domain residing in the N‐terminus, the AF‐1 domain. It recruits multiple 
complexes  to alter  the  chromatin  structure  surrounding  the promoter of 
target genes. Finally,  these events pave  the way  for  recruitment of RNA 
polymerase  II  (RNA Pol  II)  and  the general  transcription  factors  (GTFs) 
(Rochette‐Egly 2005). 
 In  addition  to  their  well‐studied  nuclear  function,  steroid  receptors 
participate in extranuclear or membrane‐initiated signaling events.  Such a 
non  genomic  action  has  been  linked  to  the  rapid  responses  elicited  by 
steroid  hormones.  These  events  are  independent  of  RNA  or  protein 
synthesis and occur within minutes or seconds. They involve activation of 
Src,  mitogen‐activated  protein  kinase  (MAPK),  phosphatidylinositol‐3‐
kinase  (PI3‐K), protein kinase C  (PKC)  and  etherotrimeric G‐proteins  in 
cytoplasm  or  membrane  of  target  cells  (Migliaccio  et  al.  2007). 
Interestingly,  important biological  responses such as DNA synthesis and 
cytoskeleton  changes  occur  in  the  absence  of  transcriptional  activity  or 
nuclear  localization  of  steroid  receptors  (Castoria  et  al.  2008). However, 
depending  on  the  cell  type  and  experimental  conditions,  steroid  action 
may depend on integration between extranuclear and nuclear activities of  
their receptors (Vicent et al. 2006). For these and other reasons, analysis of 





been  extensively dissected,  their  export mechanism  is  still obscured. All 
NRs contain nuclear localization sequences in the “hinge” region between 
the  DBD  and  the  LBD.  Glucocorticoid,  estrogen  and  progesterone 
receptors‐NLSs,  for  instance, share similar position and sequence  (Picard 
and Yamamoto 1987; Guiochon‐Mantel et al. 1991; Ylikomi et al. 1992). In 
contrast, no classical nuclear export sequences have so far been identified 
in NRs  and  conflicting data have been  reported on  inhibition of  steroid 
receptor nuclear export by LMB treatment (De Franco 2001). Although it is 
generally  accepted  that  NRs  lack  classic  leucine‐rich  NESs,  they  have 
sequences with  limited homology  to NESs  (Liu and De Franco 2000).  In 
addition, since the exact spacing of the hydrophobic residues (i.e. leucine) 
in NES  of  each  protein  is  subject  to  variation,  it  is  difficult  to  define  a 





protein‐protein  interactions  significantly  influence  the nucleocytoplasmic 
shuttling  of  the  chimeric protein GFP‐ER  (Maruvada  et  al.  2003).  In  the 
presence  of  ligand,  glucocorticoid,  androgen,  thyroid  hormone  and 
progesterone  receptors  (GR,  AR,  TR  and  PR)  rapidly  shuttle  between 
nuclei  and  cytoplasm  (De  Franco  2001).  Hormone  withdrawal  induces 
accumulation of GR and AR  in  the cytoplasm of  target cells  (Tyagi et al. 
2000).  Furthermore,  a  classic  mouse  AR  permanently  localized  in  the 
cytoplasmic  compartment does not activate gene  transcription, even  if  it 
recruits several signaling effectors allowing S‐phase entry and cytoskeletal 
changes  in  fibroblasts  (Castoria  et  al.  2003).  In  addition,  the molecular 
mechanism  responsible  for  cytoplasmic  cross‐talk  between  ER, AR  and 
epidermal growth  factor  receptor  (EGFR) has been  recently dissected  in 




(human  double  minute  2)  in  the  cytoplasm. Upon  dexamethasone 
stimulation  of  HUVEC  cells,  cytoplasmic  sequestration  of  GR  and  p53 




Moreover,  expression  of  a  shortened  form  of  the  metastatic  tumor 
antigen (MTA1s) sequesters estradiol receptor in the cytoplasm and leads 
to  malignant  phenotypes  by  enhancing  ER  extranuclear  signaling  in 
hormone‐dependent  cancer  cells  (Kumar  et al. 2002). On  the other hand 
ER  association  with  the  modulator  of  non  genomic  action  of  steroid 
receptors (MNAR) may help to sequester the receptor in the cytoplasm or 
membrane  of  breast  cancer  cells  (Vadlamudi  et  al.  2005).  Thus, 
tumorigenesis  and  hormone‐resistance  of  breast  cancer  cells  follow 
(Gururaj et al. 2006).   
Altogether,  these  findings point  to  the  critical  role of SR  extranuclear 
localization  in  steroid  action.  Therefore,  further  research  into  steroid 
receptor localization might lead to a better understanding of their roles in 
the  normal  physiology  of  cells.  These  studies  could  also  provide  new 


























It  is well established  that  steroid  receptors  shuttle between  the nuclear 
and  the  cytoplasmic  compartments  of  cells.  Nevertheless,  the  nuclear 
export mechanism  of  estradiol  receptor  is  still  obscure.  Therefore,  this 
thesis  focuses on  the study of  the molecular mechanism underlying ERα 
nuclear export and its role in the estradiol action. 
To  this  end  we  used  MCF‐7  cells,  which  derive  from  human  breast 
cancer  and  express  the  isoform  alpha  of  estradiol  receptor  (ERα).  They 
represent a model for the study of estradiol‐induced biological effects. 
We firstly attempt to identify the sequence responsible for nuclear export 
of  the  receptor,  NES‐ERα,  and  then  to  establish  whether  the  export 
mechanism of ER depends on CRM1.  
Finally, we  attempt  to  gain more  insight  in  the  functional  role  of  ER 
nuclear  export  in  breast  cancer  cells. We previously  reported  that,  once 
activated  by  the  hormone,  cytoplasmic  ER  recruits  various  signalling 





























and NLS‐HEG14) were  in  pSG5  expression  vector  (Tora  et  al.,  1989). 
They were  subcloned  into EcoRI‐pEGFP  (C2, Clontech) or  into EcoRI‐
pSG5 Myc, as reported (Castoria et al. 2004). The Myc‐tagged pSG5 was 
prepared  as described  (Castoria  et  al.  2004). Forkhead  (FKHR),  either 
wild  type  (wt) or  its mutated  form  (AAA‐FKHR), was  in pcDNA‐GFP 
(Addgene). For the export assay, the putative export sequences of ERα 
were  cloned  into  the  BamHI  and  AgeI  sites  of  pREV(1.4)‐GFP  and 
inserted  between  the  REV  and  GFP  coding  sequence  (eGFP‐N1, 
Clontech). To  insert  the putative export ERα sequence  into pREV(1.4)‐












































  All  these  fragments were amplified using Platinum Pfx  (Invitrogen), 
according  to  the  manufacturer’s  instructions.  PCR  products  were 
purified,  digested  with  BamHI/AgeI  and  finally  subcloned  into 
pREV(1.4)‐GFP. The ER  444‐456  sequence was  subcloned  in  the  same 
vector,  as  a  short  fragment  generated  by  annealing  of  specific 
oligonucleotides.  The  same  strategy was  utilized  to  generate  the  ER 
444‐456 mutant. All putative ER NESs were verified by sequencing  to 
confirm  the  exact  reading  frame  between  REV  and  GFP.  The  site‐
directed mutations of ERα were introduced into the pSG5‐HEG0 using 
a  standard  PCR  methodology.  Two  mutants  were  generated:  pSG5‐
HEG4A  (Ile 451 and 452 changed with Ala; Leu 453 and 454 changed 
with Ala) and pSG5‐HEGIL (Ile 452 changed with Ala; Leu 454 changed 






  Human  breast  cancer‐derived MCF‐7  cells  and  low passage  embryo 





Unless  otherwise  stated,  quiescent  MCF‐7  cells  on  coverslips  were 
transfected with  1  μg  of  each  purified  plasmid  using  the  SuperFect 
reagent (Qiagen). After transfection, the cells were incubated at 37°C for 
24 h, and  then used  for  the  indicated experiments. The nuclear export 
assay was performed as described  (Henderson and Eleftheriou, 2000). 
Briefly, each putative NES‐ER sequence was subcloned into the Rev 1.4‐
GFP and  then  transfected  ( at 2 µg) by SuperFect  into growing MCF‐7 
cells.  After  18  h  the  cells were  incubated with  cycloheximide  (at  15 
μg/ml;  Calbiochem)  and  left  untreated  or  treated  for  8  h  with 
actinomycin D (at 5μg/ml; Calbiochem). When indicated, leptomycin B 
(at  5  ng/ml;  Calbiochem)  was  added  30 min  before  the  addition  of 
actinomycin D. Growing NIH3T3  fibroblasts, plated on Petri dishes or 
coverslips, were transfected by SuperFect using 2 μg of either pEGFP or 
pEGFP‐HEG0  or  pEGFP‐HEGIL.  For  transactivation  assay,  2  μg  of 
pGL2  ERE‐Luc  were  cotransfected.  Twenty‐four  hours  after 
transfection,  the  cells were made quiescent and  then  left untreated or 
treated  with  10  nM  estradiol  for  16  h.  Lysates  were  prepared  and 
luciferase  activity  was  measured  using  a  luciferase  assay  system 







factor  was  added  at  100  ng/ml.  When  indicated,  the  Tat  peptide 
conjugated  to  the  444‐456  amino  acid  sequence  of ERα  (Tat‐pep; Ac‐
EFVCLKSIILLNS‐AAA‐RKKRRQRRR‐NH2) as well as  the Tat  control 
peptide  (ctrl)  were  added  at  1  μM.  The  peptides  were  N‐terminal 
acetylated  and  C‐terminal  amidated.  For  S‐phase  entry  analysis,  the 
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cells were made  quiescent  and  then  left  unstimulated  or  stimulated 
with the indicated compounds. Estradiol was used at 10 nM, epidermal 
growth  factor was  used  at  100  ng/ml  and  serum was  added  at  20%. 
After  a  6‐h  pulse  with  100  μM  BrdU  (Sigma,  St.Louis,  MO),  BrdU 
incorporation  was  analyzed  by  immunofluorescence  using  mouse 





w/v  in  PBS),  washed  with  phosphate  buffer  serum  (PBS),  and  then 
analyzed by fluorescence microscopy for the subcellular localization of 
GFP‐HEGO, its mutants as well as putative ER‐NES constructs. Similar 
analysis was  performed  to  detect GFP‐FKHR wt  or  its mutant GFP‐
FKHR‐AAA. In all other experiments, the cells on coverslips were fixed 
and permeabilized as described (Castoria et al. 1999). Endogenous ERα 
was  visualized using  either  the A314 mouse monoclonal  antibody  or 




were  finally  stained  with  Hoechst  33258,  inverted  and  mounted  in 
Mowiol  (Calbiochem, CA).  Fields were  analyzed with  a DMBL Leica 
(Leica) fluorescent microscope using 40, 63 and 100x objectives. Images 






agarose  (Qiagen).  The  recombinant  human  ERα  (2800pmol/ml)  was 
from Panvera. S35‐labeled HA‐CRM1 was produced in vitro using rabbit 
reticulocyte  lysate  (Promega).  In  vitro  protein‐protein  interaction was 
performed  as  described  (Migliaccio  et  al.  2000). When  indicated,  the 
purified peptide 427 NH2‐MLLATSSRFRMMNLQGEEFVCLKSIILLNS‐




1µg/ml)  or  the mouse monoclonal  anti‐HA Ab  (Covance;  at  2µg/ml) 




















   Localization  of  ERα  in  quiescent MCF‐7  cells was  determined  by 
immunofluorescence,  using  two  different  antibodies  directed  against 
either a C‐terminal, H222 MAb (Katzenellenbogen et al. 1987), or an N‐
terminal  epitope of ERα, A314MAb  (Abbondanza  et  al.  1998). Fig.  4a 
shows  that,  regardless  of  the  antibody  used,  30 minutes  of  estradiol 
treatment (10 nM) of cells induces nuclear translocation of ERα, which 
is  followed  by  a  decrease  in  the  nuclear  localization  of  the  receptor 
towards  the  basal  level  upon  1‐hour  hormone  stimulation. 
Immunoblotting  of  cell  lysates  with  anti‐ER  monoclonal  antibodies 




of  proteins.  A  full‐length  ERα  cDNA  was  subcloned    into  a  green 
fluorescent protein encoding plasmid  (pEGFP). Quiescent MCF‐7 cells 
were  transiently  transfected  with  the  obtained  chimera  (GFP‐HEG0; 
HEG0  represents  the  wild  type  ERα).  By  quantitative  score  of  cells 
showing nuclear fluorescence, we observe in Fig. 4b that in the absence 
of  any  significant  change  in GFP‐ERα  expression  (Fig.  4b1),  hormone 
treatment  triggers nuclear accumulation of GFP‐ERα after 30 minutes. 
Thirty minutes later the nuclear GFP‐ERα is reduced towards the basal 
levels.  It  is noteworthy  that  the  estradiol‐regulated  trafficking of ERα 
we observe is reminiscent of ERα cycling onto and off the cathepsin D 
promoter in response to the estradiol treatment of MCF‐7 cells (Shang et 
al.  2000).  In  addition,  no  trafficking  of  GFP‐ERα  was  observed  in 
untreated cells.  
Since  ERα  nuclear  uptake  is  inhibed  by  the  pure  antiestrogen ICI  
182780  (Dauvois  et  al.  1993),  we  analyzed  the  effect  of  a  partial 
antiestrogen, the 4‐hydroxy‐tamoxifen (4‐OH TX). Fig. 4b shows that  
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this  antagonist  prevents  the  observed  nucleocytoplasmic  shuttling  of 
GFP‐ERα  in  response  to hormone  treatment. Fig. 4c shows  that  in  the 
absence  of  any  significant  change  in  GFP‐ER  expression  (Fig.  4c1), 
actinomycin D  (Act D) does not modify  the estradiol‐induced  import‐
export  of  GFP‐ER.  Therefore,  the  observed  cytoplasmic  GFP‐ER 
increase detectable after 60 minutes of hormone  treatment arises  from 
nuclear export rather than from de novo synthesis. Since actinomycin D 











































Quiescent MCF‐7  cells were used.  In a,  cells were untreated or  treated with 10 nM estradiol  (E2)  for  the 
indicated  times  (min).  ERα  localization  was  analyzed  by  fluorescence  microscopy  using  the  indicated 
antibodies.  In b  and  c,  cells were  transfected with pEGFP‐HEG0,  then  left untreated or  treated with  the 
indicated compounds. 4‐OH‐Tamoxifen  (TX) was used at 0.1 μM; actinomycin D  (Act D; at 5 μg/ml) was 
added 1 h before estradiol stimulation. The GFP‐HEG0 localization was determined by fluorescence. Cells 
that  fell  into  the  category  of  exclusively  nuclear  fluorescence  were  scored  and  data  expressed  as  a 
percentage of total cells (in a) or transfected cells (in b and c). For each experiment, data were derived from 
at  least  1000  scored  cells.  The  results  of    several  independent  experiments  (n  represents  the  number  of 
experiments) were averaged; means and SEM are shown. Right panels (a1, b1 and c1) show the Western blot 























between  the  recombinant  proteins  ERα  and  CRM1 when  active  Ran 
(Ran‐GTP;  Askjaer  et  al.  1999)  was  included  as  a  GTP‐ase  deficient 
mutant (RanQ69L; Bischoff et al. 1994). 
























by  fluorescence and data were derived  from at  least 600  scored  cells. The  results of  several  independent 
experiments were averaged  (n  represents  the number of experiments); means and SEM are  shown.  In b, 
images  from  one  experiment  in  a  were  captured.  They  show  the  GFP‐ER  localization  in  MCF7  cells 
stimulated for 60 min with estradiol (E2), in the absence (left panel) or presence (right panel) of LMB. In c, 
35S‐labeled HA‐CRM1 was incubated with recombinant ERα from baculovirus in the absence or presence of 
estradiol  (10 nM). The purified  recombinant RanQ69L  (1 μM) was  included  in  the  incubation mixture of 













4.3  Identification  of  domains  involved  in  the  hormone‐regulated 
nucleocytoplasmic shuttling of ER 




281 HEG0)  contains NLS1.  It  binds  the  hormone,  but  does  not  bind 
DNA  (Ylikomi  et  al.,  1992).  A  schematic  representation  of  resulting 
chimeras,  GFP‐HEG15  and  GFP‐HEG14,  is  shown  in  Fig.  6a.  The 
constructs were  transiently  transfected  into  quiescent MCF‐7  cells.  In 
agreement with previous  results  (Ylikomi et al., 1992), data  in Fig. 6b 
show  that  neither  GFP‐HEG15  nor  GFP‐HEG14  shuttle  between  the 
nucleus and  the cytoplasm. Regardless of hormone  treatment, the  first 
mutant  mostly  resides  in  the  nuclear  compartment.  Although  GFP‐
HEG14 contains the NLS1 sequence and binds the hormone, it does not 
enter nuclei even after estradiol addition (Fig. 6b). From these data, we 
speculated  that  the hormone‐binding domain  endowed  in  the HEG14 
mutant as well as NLSs (2 and 3) of ERα are both required for estradiol‐
induced nuclear import of the receptor. We next subcloned the HE241G 
into  pEGFP.  This mutant  contains  the  hormone‐binding  domain  and 
lacks  the  three NLSs  (Fig. 6a).  It  is  in  fact prevalently  localized  in  the 
cytoplasm regardless of estradiol treatment (Fig. 6c) and similar results 
have been previously obtained by ectopic expression of this mutant  in 
NIH3T3  fibroblasts  (Castoria et al. 1999). The behavior of  this mutant 
confirms that in the absence of NLSs, hormone binding is not sufficient 
to induce nuclear translocation of the receptor.  
   Since  HEG15  is  localized  in  the  nuclear  compartment  and  its 
localization  is unaffected by hormone  treatment of  cells, we  reasoned 
that addition of NLSs to HEG14 might restore estradiol‐induced import 












In  a,  a  schematic  representation  of  cDNAs  encoding wild  type  ERα  (HEG0)  and  its  deletion mutants 
















in  the  NLS/HEG14  construct,  which  is  made  up  of  the  nuclear 
localization signals and the hormone‐binding domain of ERα.  
   It has been  reported  that bi‐directional  transport of RNA‐associated 
proteins depends on M9 motif, which  functions as both NLS and NES 
(Nigg 1997) and  that nucleocytoplasmic  shuttling of proteins  can also 
be controlled by  the emerging class of bi‐directional  transport signals, 
called  nucleocytoplasmic  shuttling  signals  (NSs)  (Michael  2000).  In 
addition,  it has been suggested  that nuclear  localization signals of  the 




According  to  this  assay,  nuclear  export  sequences  are  identified  by 
their ability  to restore  the export activity of  the chimera NES‐deficient 
Rev1.4‐GFP at levels similar to those observed with the wild‐type Rev‐
GFP or  the Rev1.4‐GFP NES  (NES  is  the canonical export sequence of 
the Rev protein). Therefore, NLS  sequences of estrogen  receptor were 
subcloned  into  pRev1.4‐GFP  and  transfected  in  MCF‐7  cells.  After 
transfection,  cells  were  incubated  in  the  absence  or  presence  of 
actinomycin D, since it causes cytoplasmic accumulation of the putative 
NES‐containing  Rev  protein  by  preventing  nuclear  import  of  Rev 
(Henderson  2000).  Fig.  7a  shows  that,  irrespective  of  experimental 
conditions, Rev1.4‐GFP NLS is localized in nuclei of MCF‐7 cells. In the 
same  experiment,  the  Rev1.4‐GFP  NES,  used  as  a  positive  control, 
completely  shifts  to  the  cytoplasm  in  the presence  of  actinomycin D, 
whereas the mutant Rev1.4‐GFP shows a nuclear/nucleolar staining. In 
conclusion, the NLS sequences of ERα are ineffective in this assay.  
   We  then  subcloned  different  sequences  of  ERα  containing  leucine 






the  Rev1.4‐GFP  NES  positive  control,  shifts  the  Rev1.4‐GFP  mutant 




peptide  corresponding  to  the  427‐457 ERα  sequence  (427)  specifically 
displaces  the  estradiol‐induced  interaction  between  recombinants 
CRM1 and ERα (Fig. 7b). Ιn  contrast, a  control peptide  (ctrl) does not 
interfere in ERα/CRM1 interaction.  









































ER NLS and GFP‐Rev 1.4 ER 427). After  transfection,  cells were  left untreated  (no drug) or  treated with 
actinomycin D  (Act D;  5  μg/ml)  alone  or  together with  leptomycin  B  (LMB;  5  ng/ml).  The  subcellular 
distribution  of GFP  proteins was  analyzed  by  fluorescence microscopy  and  images were  captured  and 
shown.  They  are  representative  of  three  independent  experiments  showing  that,  in  the  presence  of 
actinomycin D,  the ERα  427‐457  sequence  rescues  the  nuclear  export  of GFP‐Rev  1.4  by  70%.  In  b,  35S‐
labeled HA‐CRM1 was  incubated with recombinant ERα  in  the absence or presence of estradiol  (10 nM), 
alone or together with a 200‐fold excess of the ERα 427‐457 peptide (427). A 200‐fold excess of a non‐specific 
peptide was used as  control (ctrl). CRM1 was immunoprecipitated with the anti‐HA monoclonal antibody 
and proteins  in  immunocomplexes were revealed by fluorography (upper panel) or  immunoblotting with 
the rabbit polyclonal anti‐ERα antibody (lower panel).  
 
   A  limited  sequence analysis  showed homology between  the 444‐456 






































alanine  instead of  IILL amino acids  in position 451‐454; Fig. 8a) were 
subcloned  in  pRev1.4‐GFP.  Interestingly,  the  ER  wild  type  444‐456 












































sequences were  subcloned  into  pEGFP‐Rev  1.4  and  transfected  into  growing MCF‐7  cells.  In  b,  nuclear 
export  assay was performed  as desribed  in Methods. After  transfection,  the  cells were  left untreated  or 
treated with actinomycin D  (Act D; at 5µg/ml)  for 8 h. The  subcellular distribution of GFP proteins was 
analyzed  by  fluorescence  microscopy.  Number  of    cells  that  fell  into  the  categories  of  nuclear  (N), 









4.5 A  peptide mimicking  the  444‐456  ERα  sequence  sequesters  the 
receptor in the nuclear compartment and inhibits estradiol‐induced S‐
phase entry in breast cancer cells. 
   Following  recent  approaches  (Joliot  and  Prochiantz  2004),  a  Tat‐
conjugated  peptide  construct  corresponding  to  the  444‐456  ERα 
sequence was synthesized (Fig. 9a). The carboxyfluorescein‐conjugated 
peptide  translocated across plasma membrane and  reached  the nuclei 
of MCF‐7 cells within 30 minutes, as assessed by confocal microscopy 
experiments  (data  not  shown).  In  addition,  the  specificity  of  Tat‐
conjugated peptide was analyzed monitoring  its ability  to modify  the 
nuclear  export  of  either  p27  or  a  classic  leucine‐rich NES‐containing 
protein, such as p53 (Stommel et al. 1999). Fig. 9b shows that addition 
of  peptide  does  not  modify  p27  nuclear  export  as  assessed  by 
immunofluorescence  analysis  of  NIH  3T3  cells  treated  with  EGF. 
Moreover, the peptide does not induce nuclear accumulation of p53 in 
estradiol‐treated  MCF‐7  cells  (Fig.  9c).  It  is  also  ineffective  on 
subcellular  localization  of pREV1.4‐GFP NES  ectopically  expressed  in 
MCF‐7 cells (data not shown).  
   Interestingly, data in Fig. 9d and 9e show that that pre‐incubation of 
MCF‐7  cells with  the peptide  specifically blocks  the 60 min  estradiol‐
induced nuclear export of GFP‐ERα,  thus sequestering  the  receptor  in 
nuclei (Fig. 9d and 9e). Similar results were obtained when the dynamic 
redistribution  of  endogenous  ERα  was  followed  by  indirect 
immunofluorescence (data not shown).  
It  is  known  that  the  extranuclear  activity  of  ERα  triggers  hormone‐
dependent  DNA  synthesis  (Castoria  et  al.,  1999).  We  therefore 
investigated  the effect of Tat‐peptide on S‐phase entry  in MCF‐7 cells. 









Interestingly,  addition of  the Tat‐conjugated peptide  after  60 min of 
estradiol  stimulation, when  ERα  is  almost  completely  exported  from 

































































Fig. 9 The  specific peptide mimicking  the  (444‐456)‐ERα  sequence  sequesters estradiol  receptor  in  the 
nucleus and inhibits hormone‐dependent S‐phase entry in MCF‐7 cells. 
In a, the sequence of the Tat‐conjugated peptide mimicking the 444‐456 ERα sequence is shown. In b and c, 






cells were  transfected with GFP‐HEG0. After  transfection  cells were  left untreated or  treated with E2  (10 
nM)  for  the  indicated  times  (min),  in  the  absence  or  presence  of    the  Tat‐conjugated  ERα‐peptide.  The 
peptide was  added  at  1µM  to  cell medium  1  hour  before  cell  stimulation. The  percentage  of  cells with 
prevalent nuclear GFP protein was analyzed by fluorescence microscopy and graphically shown. For each 
experiment, at least 200 cells were scored. The results of several independent experiments (n represents the 
number of  experiments) were averaged; means and SEM are  shown.  Images of one  experiment  in d are 
presented  in panel e.  It  shows  the  intracellular distribution of GFP‐ER  in MCF‐7  cells  treated  for 60 min 






70%.  The  basal  BrdU  incorporation  (almost  10%) was  in  each  case  calculated  and  subtracted.  For  each 
experiment, at least 300 cells were scored. The results of several independent experiments (n represents the 
number  of  experiments) were  averaged; means  and  SEM  are  shown.  In  g,  quiescent MCF‐7  cells were 
stimulated with E2  (10 nM)  for 24 hours and  the Tat‐conjugated ERα peptide   was added after hormone 






















4.6  ERα  NES mutants  do  not  exit  nuclei  and  fail  to  induce  DNA 
synthesis stimulated by estradiol. 
   Based  on  the  findings  in  Fig.  8  and  in  Fig.  9, we prepared  by  site‐
directed mutagenesis two mutants of full‐length ERα‐GFP. A schematic 
representation  of  the  GFP‐HEG0  NES  and  its  mutated  versions  is 
shown in Fig. 10a. The constructs were transiently transfected in MCF‐7 
cells. As expected, estradiol  treatment  induces nuclear export of GPF‐
HEG0.  In  contrast,  both mutants,  GFP‐HEG4A  and  GFP‐HEGIL,  are 
unable to exit nuclei upon hormone stimulation (Fig. 10b). Images in c 
show  a  diffuse,  sometimes  extranuclear  localization  of GFP‐HEG0  in 
MCF‐7  cells  stimulated  for  60  minutes  with  estradiol.  Under  these 
conditions,  a  nuclear/nucleolar  localization  of  both GFP‐HEG4A  and 
GFP‐HEGIL is detected.  
   The  ability of  the mutant GFP‐HEGIL  to activate gene  transcription 
and  induce S‐phase entry  in  response  to estradiol  treatment was  then 
verified.  ERα‐negative NIH  3T3  fibroblasts  (Castoria  et  al.,  1999  and 
2003) were  transiently  transfected with GFP‐HEG0  or GFP‐HEGIL  or 
GFP alone, as a control. ERE‐Luc reporter gene was cotransfected and 
its  activity  assayed. Data  in  Fig.  10d  show  that  the  constructs  GFP‐
HEG0  and  GFP‐HEGIL  are  equally  efficient  in  activating  gene 
transcription upon estradiol stimulation of the cells, with an  induction 
of    the  ERE‐Luc  activity  ranging  from  6‐  to  6,3‐fold.  Transcriptional 
activation  is  almost  undetectable  in  unstimulated  cells  or  cells 
expressing GFP alone as a control.  
   In another  set of experiments, we assessed  the ability of GFP‐HEG0 
and  GFP‐HEGIL  to mediate  DNA  synthesis  induced  by  estradiol  in 
transfected  NIH  3T3  fibroblasts.  In  agreement  with  our  previous 
findings  (Castoria et al. 1999), we observe  that GFP‐HEG0  is a potent 
inducer of  S‐phase entry in cells stimulated with estradiol. Conversely, 
the mutant GFP‐HEGIL  fails to do so. Nevertheless,  the mutant  is still 
able to commit the cells towards the S‐phase upon serum stimulation  
(Fig.  10e). Here  again,  the  Tat‐conjugated  peptide  inhibits  estradiol‐
induced S‐phase entry of GFP‐HEGO transfected fibroblasts, whereas it 
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does  not  interfere  in  serum‐induced  BrdU  incorporation  (bars  with 
asterisks in Fig. 10e). 
  Altogether, data in Fig. 10 show that the leucine rich 444‐456 sequence 
of ERα  contains  a  functional NES. Mutations  in  the  IILL  core  of  this 
sequence affect estradiol‐induced nuclear export of ER as well as DNA 
synthesis, without interfering in gene transcription. These data point to 

















































Fig. 10 Mutations  in  the core of NES‐ERα sequence affect  the estradiol‐induced nuclear export of ERα 
and DNA synthesis.  
In a, a schematic representation of NES‐ERα sequence and  its point‐mutated versions  is shown.  In b,  the 
cDNAs encoding ER wt (HEG0) as well as the mutants (HEG 4A and HEGIL), subcloned  into the pEGFP 
plasmid, were transfected in MCF‐7 cells. After transfection, the cells were left untreated or treated with E2 
(10  nM)  for  the  indicated  times.  The  percentage  of  cells  with  prevalently  nuclear  GFP  proteins  was 
determined by fluorescence microscopy and graphically shown. Data were derived from at least 600 scored 
cells.  The  results  of  several  independent  experiments  (n  represents  the  number  of  experiments)  were 
averaged; means and SEM are shown. Images of one experiment in b are captured and shown in panels c. 
They show the intracellular distribution of GFP proteins in MCF‐7 cells treated with E2 (10 nM) for 60 min. 
In d, growing NIH 3T3  fibroblasts were  transfected with  the ERE‐Luc construct along with  the  indicated 
plasmids. After transfection, the cells were made quiescent and then left unstimulated or stimulated with E2 
(10 nM)  for 16 hours. Luciferase activity was assayed, normalized using β‐gal as an  internal control, and 
expressed as  fold  induction. The  results of  several  independent experiments  (n  represents  the number of 
experiments)  were  averaged;  means  and  SEM  are  shown.  In  e,  growing  NIH  3T3  fibroblasts  were 
transfected  with  the  indicated  constructs.  After  transfection,  the  cells  were  made  quiescent  and  left 
unstimulated  or  stimulated with  either  E2  (10  nM)  or  serum  (20%)  for  18  hours. When  indicated  by  an 
asterisk, the Tat‐conjugate ERα peptide (444‐456) was added (1 μM) to the cell medium 1 hour before cell 
stimulation.  After  in  vivo  pulse  with  BrdU,  DNA  synthesis  was  analyzed  by  immunofluorescence.  In 
transfected  cells, BrdU  incorporation was  calculated by  the  formula: percentage  of BrdU‐positive  cells  = 
(number of  transfected‐positive  cells/number of  transfected  cells)  x  100;  the percentage of BrdU‐positive 
cells was  then compared with  the percentage of BrdU  incorporation of untransfected cells  from  the same 
coverslip.  For  each  plasmid,  data  were  derived  from  at  least  300  scored  cells.  The  results  of  several 





4.7  Estradiol  simultaneously  regulates  nuclear  export  of  ERα  and 
FKHR thereby modulating S‐phase entry in MCF‐7 cells 




Therefore,  it  is not unexpected  to  find  that permanent  localization  of 
transcription factors in the cell nucleus can stop cell cycle.  
    Stimulation of Pak‐1 and ERα by estrogen treatment of breast cancer 
cells promotes  cell  survival by  inducing phosphorylation and nuclear 
exclusion  of  FoxO1  (Mazumdar  and  Kumar  2003).  In  addition,  an 
estradiol‐dependent  interaction  between  ERα  and  FKHR  has  been 
observed  using  both  a  yeast  two‐hybrid  screen  and 
immunoprecipitation  analysis  in  MCF‐7  cells  (Schuur  et  al.  2001). 
Extension of these investigations to other nuclear receptor (NR) family 
members  has  shown  that,  depending  on  the  receptor  type,  FKHR 
represents a bi‐functional NR intermediary protein acting as either a co‐
activator or co‐repressor (Zhao et al. 2001). It is noteworthy that FKHR 
nuclear  export  depends  on  its  phosphorylation  by  Akt  (Biggs  et  al. 
1999).  Interestingly,  a  triple  alanine mutant  of  FKHR  (FKHR  AAA), 
which cannot be phosphorylated by Akt,  localizes  in  the nucleus  thus 
inducing  G1  arrest  in  cells  (Nakamura  et  al.  2000;  Birkenkamp  and 
Coffer, 2003). Moreover, our data have shown that estradiol activation 
of  the  PI3K‐dependent  pathway  is  required  to  drive  cell  cycle 
progression  in breast  cancer  cells  (Castoria  et al. 2001). Therefore, we 






11a  show  that  expression  of  this  FKHR  mutant  greatly  reduces 
estradiol‐induced  S‐phase  entry  in  MCF‐7  cells.  Expression  of  GFP 
alone or GFP‐FKHR wt does not interfere with estradiol‐induced BrdU 
incorporation  of  cells.  In  the  same  experiments we  also  analyzed  by 
confocal microscopy  the  role  of  FKHR  in  sub‐cellular  distribution  of 
ERα. Data  in Fig. 11b  show  that expression of GFP‐FKHR wt or GFP 
alone does not modify  the 60‐min estradiol‐induced nuclear export of 
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ERα.  Interestingly,  expression  of  the  mutant  GFP‐FKHR  AAA 
sequesters ERα in the nuclear compartment of 60‐min estradiol‐treated 
MCF‐7  cells.  Conversely,  over‐expression  of  the  tagged  ERα‐NES 
mutant, Myc‐HEGIL, retains GFP‐FKHR wt in the nuclear compartment 
of 60‐min estradiol‐treated MCF‐7 cells (Fig. 11c). Representative fields 
from  one  experiment  in  b  and  c  are  presented  in  Fig.  11d.  Left  and 
central  panels  show  the  staining  of  endogenous  ERα  (red)  in MCF‐7 
cells  expressing  the  GFP‐FKHR wt  (left  panels)  or  the mutant  GFP‐













Quiescent   MCF‐7 cells on  coverslips were used.  In a,  cells were  transfected with  the  indicated plasmids 
(GFP, GFP‐FKHR wt and GFP‐FKHR AAA) and then left unstimulated or stimulated with 10 nM estradiol 
for  24 hours. After  in  vivo pulse with BrdU,   DNA  synthesis was  analyzed by  immunofluorescence  and 
BrdU  incorporation was calculated as  in Fig.10e.  In b, cells were  transfected with  the  indicated plasmids 
(GFP, GFP‐FKHR wt and GFP‐FKHR AAA) and then left unstimulated or stimulated with 10 nM estradiol 
for  the  indicated  times. Endogenous ERα  localization as well as expression of GFP, or GFP‐FKHR wt or 
GFP‐FKHR  AAA  mutant  was  monitored  by  confocal  microscopy.  Cells  that  fell  in  the  category  of 
exclusively ER nuclear fluorescence were scored and data expressed as a percentage of transfected cells. In 
c, the cells were cotransfected with the indicated plasmids (GFP‐FKHR wt plus myc‐HEG0 or myc‐HEGIL) 
and  then  left unstimulated or stimulated with 10 nM estradiol  for 60 min. Localization of GFP‐FKHR wt, 
Myc‐HEG0 or Myc‐HEGIL mutant was monitored by confocal microscopy. Cells that fell in the category of 
exclusively FKHR nuclear  fluorescence were  scored and data  expressed as a percentage of  cotransfected 
cells. For  each  experiment  in  a, b  and  c data were derived  from  at  least  500  scored  cells. The  results of 
several independent experiments (n represents the number of experiments) were averaged; means and SEM 
are  shown.  In  d,  images  from  one  experiment  in  b  or  c  are  shown.  They  represent  the  staining  of 
endogenous ERα  (red)  in MCF‐7 cells expressing  the GFP‐FKHR wt  (green  in  left panels) or  the mutant, 
GFP‐FKHR AAA (green in middle panels) treated for 60 min with estradiol. Right panels show the staining 










MCF‐7 cells  focusing on  its export  from  the nucleus. We observe  that 
estradiol  induces  nuclear  translocation  followed  by  nuclear  exit  of 
endogenous  ER  or  GFP‐ER,  during  the  initial  60  min  of  treatment. 
Leptomycin B inhibits ER export, which depends on CRM1 as shown by 
in vitro interaction experiments. Estradiol strongly enhances this in vitro 
interaction.  Identification  of ERα  sequence  responsible  for  its  nuclear 
export was then assessed by a nuclear export assay. Our data show that 
an  ER‐derived  leucine‐rich  sequence  (444‐456),  which  is  highly 
conserved among the members of nuclear receptor family, restores the 
nuclear  exit  of  a  GFP‐Rev mutant  viral  protein  in  an  in  vivo  export 
assay.  Furthermore,  a  Tat‐peptide  mimicking  the  same  sequence 
prevents  in  vitro  estradiol‐dependent  ER/CRM1  interaction,  inhibits 




in  full‐length ERα  impairs nuclear export of  receptor as well as DNA 
synthesis  induced  by  estradiol, but does not  affect  receptor‐mediated 
gene  transcription. Altogether,  these data  identify and characterize  for 
the  first  time a  functional NES  in ER. Moreover,  the homology of  the 
NES‐ER  sequence with  sequences  of  several  other  nuclear  receptors 
suggests that a similar export occurs in these receptors. 
Furthermore,  by  confocal  microscopy  we  observe  that  estradiol 
induces  the  simultaneous  release  of  ER  and  FKHR  from  nuclear 
compartment in MCF‐7 cells. ER‐NES mutant traps FKHR in nuclei and 
viceversa  a  FKHR  mutant,  which  cannot  be  phosphorylated  by  Akt, 
retains ER in nuclei. Altogether these data point to a novel link between 
rapid  estradiol  action  and  ER  export,  together with  a  new  estradiol 
action on DNA synthesis in MCF‐7 cells.  
Present  findings  suggest  a  novel mechanism  of  estrogen  action  that 
involves  simultaneous  regulation  of  ER  and  FKHR  nuclear  export. 
Although other possibilities can be envisaged, we propose that the two 
proteins modulate  the  effectiveness  of  their NESs by  interacting with 





Cell  cycle progression  is  fostered by  such mutual  interplay between 
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nuclear  exit  of  the  estradiol  receptor  (ERα).  The  receptor  export  depends  on  the 
PI3K/Akt pathway and is directed by CRM1. Experiments with construct expressing 
a  receptor‐derived  sequence  reveal  the  presence  of  a  nuclear  export  signal  (NES) 
within  the hormone binding domain. This  sequence  restores  the CRM1‐dependent 
export of a REV‐HIV mutant protein  in an  in vivo export assay. A Tat‐peptide with 
the ERα export sequence disrupts  in vitro  the ER/CRM1  interaction and sequesters 
the  receptor  in  the  nuclei  of  MCF‐7  cells.  Remarkably,  it  inhibits  the  estradiol‐
induced DNA  synthesis.  In  addition,  ERα NES mutant  obtained  by  site  directed 
mutagenesis does not exit nuclei and  is unable  to mediate  the estradiol‐induced S‐
phase entry,  leaving unaltered  the  receptor‐dependent gene  transcription. Confocal 
microscopy analysis shows that ERα colocalizes with forkhead  in nuclei of estradiol‐
treated MCF‐7  cells. A  forkhead mutant,  unphosphorylatable  by Akt,    is  trapped 
together with  ERwt  into  nuclei  and  blocks  the  estradiol‐induced  S‐phase  entry  of 
MCF‐7  cells.  In  turn,  the  ERα  NES mutant  fails  to  exit  nuclei  and  prevents  the 
forkhead wt nuclear export. Present  findings  for  the  first  time  identify a ERα NES, 
which  is dependent on  the  estradiol‐regulated PI3K/Akt pathway  and  it  is CRM1‐





There  is  a  growing  body  of  evidences  that  steroid  receptors  in  addition  to 
regulate the transcription of specific genes (Mangelsdorf et al., 1995) trigger rapid 
effects  in  the  extranuclear  compartment  (reviewed  by  Migliaccio  et  al.,  2007). 
Therefore,  it  is  expected  that  hormone  action  depends  on  integration  of  these 
different receptor activities (Vicent et al., 2006).  
Localization  and  action  of  ER  is  regulated  at  multiple  levels,  including 
interaction  with  signaling  effectors  or  other  proteins,  such  as  the  metastatic 
tumor  antigen  (MTA1)  or  the  modulator  of  non  genomic  action  of  steroid 
receptors  (MNAR;  Kumar  et  al.,  2002;  Vadlamudi  et  al.,  2005; Gururaj  et  al., 
2006).  Deregulation  of  these  processes  causes  ER  mis‐localization  and  might 
trigger tumor progression. Overexpression of EGFR, for instance,   is a hallmark 
of  aggressive  human  breast  cancers  (Slamon  et  al.,  1989),  and  a  cross  talk 
between  ER  and  growth  factor  signaling  has  emerged  as  a  critical  factor  in 
endocrine  resistance by  controlling  the  subcellular  localization  of ER  signaling 
components (Gururaj et al., 2006). In addition, ER association with MNAR may 
help to sequester ER in the cytoplasm/membrane (Vadlamudi et al., 2005). Thus, 
enhancement of non‐genomic effects of ER occur, and  tumorigenesis as well as 
anti‐hormone  resistance  of  breast  cancer  cells  follow  (Vadlamudi  et  al.,  2005; 





transducing‐dependent  functions,  such  as  DNA  synthesis  and  anchorage‐
dependent  growth  of  target  cells.  Moreover, they  strongly  suggest  that  ER 




progesterone  receptors  rapidly  shuttle  between  nuclei  and  cytoplasm  (De 
Franco, 2001). Hormone withdrawal from cells induces accumulation of GR and 
AR  in  the  cytoplasm  (Tyagi  et  al.,  2000).  ERα  also  shuttles  from  nuclei  to 
cytoplasm, and the antiestrogen ICI 182, 780 disrupts this process (Dauvois et al., 
1993).  In  addition,  ligand  binding  and  protein‐protein  interactions  can 
  4
significantly  influence  the nucleo‐cytoplasmic shuttling of  the chimeric GFP‐ER 
(Maruvada  et  al.,  2003). However, while  the mechanism  of  nuclear  import  of 
steroid  receptors  is well documented, how  these  receptors are exported  is  still 
unclear (De Franco, 2001). 
  The  best‐characterized  nuclear  export  pathway  uses CRM1  as  a  receptor  for 
proteins  with  leucine‐rich  NESs  (Fornerod  et  al.,  1997;  Fukuda  et  al.,  1997). 
Leptomycin  B  (LMB),  by  covalent  binding  to  CRM1,  inhibits  the  CRM1‐
dependent  nuclear  export  (Kudo  et  al.,  1998).  Conflicting  data  have  been 
reported on inhibition of steroid receptor export by LMB treatment. Although it 
is generally accepted  that  steroid  receptors  lack  classic  leucine‐rich NESs,  they 
have  sequences with  limited  homology  to NESs  (Liu  &  De  Franco,  2000).  In 
addition, since  the exact spacing of  the  leucine/hydrophobic residues  in NES of 
each protein  is subject  to variation,  it can be difficult  to define a NES signal on 
this basis alone (Nigg, 1997). Under some circumstances, LMB treatment, indeed, 




Combining  different  approaches,  we  identified  in  the  ERα  hormone‐binding 
domain  a  hormone‐dependent  and  CRM1‐directed NES.  The  interest  of  these 
findings  is highlighted by  the  observation  that  the ERα NES  shows  significant 
homology with  sequences of other  steroid  receptors. A peptide mimicking  the 
ERα‐NES specifically sequesters  the receptor  in cell nuclei and  interferes  in  the 
hormone‐triggered S‐phase entry of these cells. Site‐directed mutagenesis of ERα 
NES also inhibits estradiol‐induced cytoplasm re‐localization of the receptor and 
DNA  synthesis. Moreover, we  observe  that  the  transcription  factor  Forkhead 
(FKHR) and ERα are  tightly associated. Activation by estradiol of  the PI3K/Akt 







Localization  of  endogenous  ERα  in  quiescent  MCF‐7  cells  was  verified  by 
immunofluorescence,  using  two  different  antibodies  directed  against  either  a  C‐
terminal (H222 MAb; Katzenellenbogen et al., 1987) or an N‐terminal epitope of ERα 
(A314MAb; Abbondanza et al., 1998). Fig. 1a shows that, regardless of the antibody 
used, 30 min of estradiol  treatment of MCF‐7 cells  induces nuclear  translocation of 
ERα, which is followed by a decrease of the nuclear receptor to basal level after 1h of 
hormone  stimulation.  This  decrease  parallels  cytoplasmic  redistribution  of  the 
receptor (not shown). Immunoblot of cell lysates with anti‐ER monoclonal antibodies 
does  not  reveal  any  significant  change  in  ERα  level  (Supplemental  data),  thus 
suggesting that the observed decrease of ERα nuclear  localization  is due to nuclear 
exit of the receptor. 
  Quiescent MCF‐7  cells were  next  transiently  transfected with  a  full‐length  ERα 
cDNA subcloned into the green fluorescent protein plasmid (pEGFP‐HEG0). In Fig. 
1b,  the  quantitative  count  of  cells  with  nuclear  fluorescence  shows  that,  in  the 
absence  of  any  significant  change  of GFP‐ERα  expression  (Supplemental data),  30 
min hormone treatment triggers nuclear accumulation of GFP‐ERα. Thirty min later, 
the nuclear GFP‐ERα decreases  to  the basal  levels, whereas no  trafficking of GFP‐
ERα was observed  in untreated  cells  (Fig. 1b).  In addition, GFP was  insensitive  to 
estradiol  treatment  when  overexpressed  alone  in  MCF‐7  cells  (not  shown).  The 
partial  antagonist,  4‐OH‐tamoxifen,  prevents  the  observed  nucleo‐cytoplasmic 
shuttling of GFP‐ERα in response to hormonal treatment (Fig. 1b).  
  To  exclude  the  potential  contribution  of  de  novo  GFP‐ERα  synthesis  for  its 
reemergence  in  the  cytoplasm  1  hour  after  estradiol  treatment,  we  included 
actinomycin D in the medium during hormone stimulation. Here again, we did not 
observe any  significant  change  in  the  estradiol‐induced  redistribution of GFP‐ERα 
(Fig. 1 c), as well as protein expression (Supplemental data). Therefore, the chimeric 
protein in cytoplasm arose from nuclear export rather than from de novo synthesis.  
  Since  actinomycin  D  inhibits  the  nuclear  import  of  the  NES‐containing  REV 
protein, (Henderson, 2000) and the GFP‐ERα dynamic redistribution is not modified 
by  actinomycin  D  (Fig.  1c),  we  conclude  that  cytoplasmic  re‐localization  of  the 
chimera depends on nuclear export rather than inhibition of nuclear import. 
  We  next transiently transfected quiescent MCF‐7 cells with the dominant negative 
form  of  the  regulatory  subunit  of  PI3K,  p85α  (∆p85α; Dhand  et  al.,  1994),  or  the 
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catalytically  inactive  version  of  Akt  (K179M;  AktK‐).  In  Fig.  1d,  the  quantitative 
count  of  transfected  cells  showing  ER  nuclear  fluorescence  shows  that 
overexpression of both, ∆p85α or Akt K‐ induces nuclear retention of ERα in 60 min 
estradiol‐stimulated MCF‐7  cells.  Transfection  of  cells with  the Myc‐tagged  pSG5 
control plasmid does not  interfere  in  the  trafficking of ERα. Altogether,  these data 
point  to  the  regulatory  role  of  PI3K/Akt  pathway  in  estradiol‐triggered  nuclear 
export of its own receptor. 
  To verify the role of CRM1 export receptor in ERα nuclear exit we used LMB.  This 
anti‐fungal  compound  blocks  the  nuclear  export  of  NES‐containing  proteins  by 
preventing  their  association  with  the  CRM1  export  receptor  (Kudo  et  al.,  1998). 
Therefore, we tested the effect of this inhibitor on the estradiol‐induced shuttling of 
GFP‐ER. Quantitative analysis of transfected cells shows that LMB abolishes the 1h 
nuclear  decrease  of  GFP‐ERα  in  estradiol‐stimulated  cells  (Fig.  1e).  LMB  is 
ineffective when  added  alone  to  the  resting  cells  (Fig.  1f). Representative  images 
from one experiment  in panel e are presented  in panel  f. Thus,  the LMB effect on 
ERα localization suggests that this receptor, when bound to the hormone, is exported 
from nuclei through the CRM1/exportin pathway. To further address this question, 










export  sequence(s)  in  the NLS/HEG14  construct, which  is made up by  the nuclear 
localization  signals  and  the  hormone  binding  domain  of  ERα.  Since  it  has  been 
suggested  that  nuclear  localization  signals  of  the  progesterone  receptor  are 








MCF‐7  cells. After  transfection,  cells were  incubated  in  the absence or presence of 




as  a  positive  control,  completely  shifted  to  the  cytoplasm  in  the  presence  of 
actinomycin  D,  whereas  the  mutant  pREV1.4‐GFP  showed  nuclear,  sometimes 
nucleolar, staining. These data indicate that the NLS sequences of ERα are inactive in 
this export assay.  
  We  then  subcloned  different  sequences  of  ERα  containing  leucine  residues  into 
pREV1.4‐GFP. These constructs were transfected into MCF‐7 cells and then analyzed 




LMB  treatment blocked  the  export activity of 427‐456 ERα  signal  (Fig. 2 a and b). 












residues  of  alanine  instead  of  IILL  amino  acids  in  position  451‐454;  Fig.  2c) were 
subcloned  into  the pREV1.4‐GFP.  Interestingly,  the ER wild  type 444‐456 sequence 
was able  to  shift  the pREV1.4‐GFP  into  the  cytoplasm of MCF‐7  cells, whereas  its 




  These results provide direct evidence  that a small sequence of  the ERα hormone‐
binding domain is responsible for the CRM1‐mediated ERα nuclear export.  
 
A peptide mimicking  the 444‐456 ERα  sequence  sequesters  the  receptor  into  the 
nuclear  compartment  and  inhibits  the  estradiol‐induced S‐phase  entry of breast 
cancer cells. 
Following  recent  approaches  (Joliot & Prochiantz,  2004),  a Tat‐conjugated peptide 
construct corresponding to the 444‐456 ERα sequence was synthesized (Fig. 3a). In a 
preliminary  experiment  (not  shown),  we  observed  that  the  carboxyfluorescein‐
conjugated  peptide  translocated  across  the  plasma membrane  and within  30 min 
accumulated  in  the  nuclei  of  MCF‐7  cells.  This  peptide  displaced  the  estradiol‐
induced interaction between recombinants CRM1 and ERα, while the Tat alone (ctrl) 
did  not  affect  such  an  interaction  (Fig.  3b). Moreover,  the Tat‐conjugated peptide 
blocked the 60 min estradiol‐induced nuclear export of GFP‐ERα, thus sequestering 
the receptor in the nuclei (Fig. 3c and d). Here again, the Tat alone used as a control 
did not modify  the  trafficking of GFP‐ERα  (not  shown). Findings  in Supplemental 
data  show  the  specificity  of  the  Tat‐conjugated  peptide  action.  In 
immunofluorescence  analysis,  it  did  not  affect  the  p27  nuclear  export,  or  the  p53 
subcellular localization. 





alone, as a control.  In addition,  the Tat‐conjugated peptide did not  interfere  in  the 
serum‐induced DNA synthesis of MCF‐7 cells (Fig. 3 e),  indicating that the peptide 
specifically  interferes  in  ERα  action.  Interestingly,  addition  of  the  Tat‐conjugated 







Based on previous  findings  (Fig. 2), we prepared by site‐directed mutagenesis  two 










gene  transcription.  To  this  end,  ERα‐negative NIH3T3  fibroblasts  (Castoria  et  al., 
1999 and 2003) were transiently transfected with GFP‐HEG0 or GFP‐HEGIL or GFP 
alone,  as  a  control.  The  ERE‐Luc  reporter  gene was  cotransfected  and  its  activity 
assayed. Fig. 4d shows  that  the constructs GFP‐HEG0 and GFP‐HEGIL are equally 
efficient in activating gene transcription upon estradiol stimulation of the cells, with 
an  induction  of    the  ERE‐Luc  activity  ranging  from  6  to  6,3  fold.  Transcriptional 
activation was almost undetectable  in unstimulated cells or  in cells expressing GFP 
alone, as a control.  
  In  another  set  of  experiments, we  assessed  the  ability  of  GFP‐HEG0  and  GFP‐
HEGIL  to  mediate  the  estradiol‐induced  DNA  synthesis  in  transfected  NIH3T3 
fibroblasts.  In agreement with previous data  (Castoria et al., 1999),  the GFP‐HEG0 
was  a  potent  inducer  of  the  S‐phase  entry  in  cells  challenged with  estradiol.  In 
contrast,  the mutant GFP‐HEGIL  failed  to do  it, but  it did not prevent  the  serum‐
induced S‐phase entry (Fig. 4e). Here again, the Tat‐conjugated peptide inhibited the 
estradiol‐induced S‐phase entry of GFP‐HEGO transfected fibroblasts, whereas it did 
not  interfere  in  the  serum‐induced BrdU  incorporation  (bars with  asterisks  in Fig. 
4e). 
  Data  in Figs. 2 and 4 conclusively show  that  the  leucine  rich 444‐456 sequence of 
ERα  contains  a  functional NES.  Interestingly, mutations  in  the  core  (IILL)  of  this 





phase  (Migliaccio  et  al.,  2002).  In  addition,  previous  findings  reported  that  an 





estradiol‐induced  DNA  synthesis  and  ERα  nuclear  export.  To  this  end,  we 
transiently transfected quiescent MCF‐7 cells with the wild‐type FKHR (GFP‐FKHR 
wt)  or  its  mutant  containing  a  triple  alanine  substitutions  (GFP‐FKHR  AAA),  a 
version  of  FKHR  that  cannot  be phosphorylated  by Akt  and  localizes  into nuclei, 




by  confocal microscopy  the  role  of  FKHR  in  the  sub‐cellular distribution  of  ERα. 
While  expression  of  GFP‐FKHR  wt  or  GFP  alone  did  not  modify  the  60  min 
estradiol‐induced   nuclear export of ERα, the mutant GFP‐FKHR AAA sequestered 
ERα  in  the  nuclear  compartment  of  60  min  hormone‐treated  cells  (Fig.  5b). 




expressing  the GFP‐FKHR wt  (left panels) or  the mutant GFP‐FKHR AAA  (middle 
panels),  treated  for 60 min with  estradiol. Right panels  show  the  staining of Myc‐
tagged NES‐ERα mutant (red) in 60 min hormone‐treated MCF‐7 cells co‐expressing 
GFP‐FKHR wt. The  lowest microphotographs  in panel d show  the merged  images. 










of ER  (Migliaccio et al., 2007). Ligand stimulation of different cell  types recruits  to 
ERα  or  ERβ  different  extranuclear  signaling  effectors,  which  leads  to  signal 
transduction  pathway  activation  (Migliaccio  et  al.  2000;  Castoria  et  al.,  2001).  In 
addition,  a  transcriptionally  inactive  ERα mutant,  permanently  residing  in  the 
cytoplasm,  mediates  the  S‐phase  entry  triggered  by  estradiol  activation  of  the 
Src/Ras/ERK and PI3‐K/Akt pathways (Castoria et al., 1999 and 2004). These findings 
implicate a proliferative  function of  the extranuclear  receptor. This view  is  further 
supported by the observation that a classic mouse AR, which is expressed at a very 
low  level  in NIH3T3  fibroblasts, does not  enter nuclei and does not activate gene 
transcription in hormone‐stimulated cells. Nevertheless, it recruits several signaling 
effectors that control the androgen‐induced S‐phase entry and cytoskeletal changes 
of  fibroblasts  (Castoria et al., 2003).  In addition,  rat uterine stromal cells, although 
expressing  low  levels  of  transcriptional  incompetent  PgR,  respond  to  progestins 
with active proliferation  (Vallejo et al., 2005). Furthermore,  the extranuclear  cross‐
talk  between  ER/AR  and  epidermal  growth  factor  receptor  (EGFR)  regulates  the 




We  have  now  analyzed  in MCF‐7  cells  the  nucleo‐cytoplasmic  shuttling  of  the 
estradiol  receptor  focusing  on  its  export  from  the  nucleus.  We  observed  that 
estradiol induces a CRM1‐dependent nuclear export of ERα. Thus, identification of 
ERα  sequence  responsible  for  its  nuclear  export  has  been  assessed  by  a  nuclear 
export assay. Previous  findings reported  that  the outward movement of PgR  from 
nuclear  compartment  is  mediated  by  its  NLSs  (Guiochon‐Mantel  et  al.,  1994). 
Therefore, we  firstly assayed  the ability of ERα NLSs  to shift  the REV mutant  into 
cytoplasm. Our data show that NLSs are not involved in the nuclear export of ERα. 





this hypothesis,  the  leucine‐rich 296‐335 ERα  sequence  is unable  to drive  the REV 
mutant  into cytoplasm. Using  the same approach, we observe  that  the  leucine rich 
444‐456  sequence  of  ERα  contains  a  functional  NES,  which  is  sensitive  to  LMB 
treatment.  Furthermore,  a  Tat‐conjugated  peptide  mimicking  this  amino  acidic 
sequence  displaces  the  in  vitro  interaction  between  ERα  and  CRM1. Altogether, 
these data  support each other  the  conclusion  that  the 444‐456  sequence  contains a 





other  steroid  receptors,  such as ERβ, PgR, AR, GR and MR. This  corroborates  the 
hypothesis that this sequence is responsible for CRM1‐dependent nuclear export of 
most  of  the  steroid  receptors.  In  agreement  with  this  hypothesis,  inhibition  of 
nuclear export of different steroid receptors by LMB  treatment has been shown by 
different groups  and under different  experimental  conditions  (Savory  et  al.,  1999; 
Prufer & Barsony, 2002; Maruvada et al., 2003). 
  We  have  also  modulated  the  ERα  localization  using  a  Tat‐conjugated  peptide 









progression modulated by estrogens  in breast  cancer  cells. On  the other hand,  the 
function  of  many  proteins  is  regulated  by  their  subcellular  localization.  These 
proteins  include  cell  cycle  regulators  and  transcription  factors,  such  as NFkB, p53 
and mammalian members of the FHKR transcription factors (Kau & Silver, 2003). A 
triple alanine mutant of FKHR  localizes  into  the nucleus and  induces G1 arrest of 
cells (Nakamura et al., 2000). Therefore, it is not new that permanent localization of 
transcription  factors  into  the  cell  nucleus  can  stop  cell  cycle.  Furthermore, 
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stimulation of Pak‐1 and ERα by estrogen treatment of breast cancer cells promotes 
cell  survival  by  inducing  phosphorylation  and  nuclear  exclusion  of  FoxO1 
(Birkenkamp  &  Coffer,  2003).  In  addition,  an  estradiol‐dependent  interaction 
between ERα and FKHR has been observed using both a yeast  two‐hybrid  screen 
and MCF‐7  cells  (Schuur  et  al.,  2001).  Extension  of  these  investigations  to  other 




S  transition  (Birkenkamp & Coffer, 2003). The  triple alanine FKHR mutant, which 
cannot be phosphorylated by Akt, sequesters ERα in the nuclei and inhibits S‐phase 
entry of cells. Conversely, an NES‐ERα mutant, unable to exit nuclei, retains FKHR 
in  the nuclear compartment of estradiol‐treated breast cancer cells and  in  this way 
blocks  the  cell  cycle.  In  addition  to  the previous described  effects  (Castoria  et  al., 
2001), we now  show  that estradiol  stimulation of  the PI3K/Akt pathway  facilitates 
the export of the two transcription factors in breast cancer cells. Our findings for the 






of  ER  and  impairs  the  estradiol‐induced  S‐phase  entry  of  target  cells.  Therefore, 










pCDNA/HA‐CRM1  (Alt  et  al.,  2000)  was  digested  with  KpnI  and  BamH1  and 
subcloned  into pSG5. cDNA encoding  the wild  type of hERα  (HEG0) was  in pSG5 
expression  vector  (Tora  et  al.,  1989).  It  was  subcloned  into  EcoRI‐pEGFP  (C2, 
Clontech)  or  EcoRI‐pSG5Myc  as  reported  (Castoria  et  al.,  2004).  The  dominant 
negative  form of p85α  (∆p85α) was  in pSG5  (Dhand  et al., 1994). Myc‐His  tagged 
dominant negative form of Akt (K179M) in pUSEAmp plasmid was from UBI (Lake 
Placid, NY). The Myc‐tagged pSG5 was prepared as reported (Castoria et al., 2004). 
Forkhead  (FKHR), either wild  type  (wt) or  its mutated  form  (AAA‐FKHR) were  in 
pcDNA‐GFP (Addgene). For the export assay, the putative export sequences of ERα 
were cloned into the BamHI and AgeI sites of pREV(1.4)‐GFP and inserted between 
the  REV  and  GFP  coding  sequence  (eGFP‐N1,  Clontech).  To  insert  the  putative 




sequence  (286‐311  aa)  forward  primer  5’‐
GATCGGATCCAATGAGAGCTGCCAACCTTTGGCCAAGCCCG‐3’  and  reverse 
primer  5’‐GCGACCGGTGGGGCCGTCAGGGACAAGGCCAGGCTGTTCT  ‐3’;  286 
sequence  (286‐382  aa)  reverse  primer  5’‐
GCGACCGGTGGGGCACATTCTAGAAGGTGGACCTGATCATG3’;  296  sequence 
(296‐335aa)  forward  primer  5’‐
GATCGGATCCAATGATCAAACGCTCTAAGAAGAAC‐3’  and  reverse  primer  5’‐
GCGACCGGTGGGGGTCTGGTAGGATCATACTCGGAATAGA‐3’;  316  sequence 
(316‐335aa)  forward  primer  5’‐
GATCGGATCCAAGTGCCTTGTTGGATGCTGAGCCCCCCAT‐3’;  341  sequence 
(341‐361  aa)  forward  primer 
5’GATCGGATCCATCGATGATGGGCTTACTGACCAACCTGGC‐3’and  reverse 
primer  5’‐GCGACCGGTGGCGCCCAGTTGATCATGTGAACCAGCTCCC‐3’;  368 
sequence  (368‐394  aa)  forward  primer  5’‐
GATCGGATCCAGTGGATTTGACCCTCCATGATCAGGTCCA‐3’  and  reverse 
primer  5’‐GCGACCGGTGGGCGCCAGACGAGACCAATCATCAGGATCT‐3’;  381 




sequence  (395‐412  aa)  forward  primer 
5’GATCGGATCCATCCATGGAGCACCCAGTGAAGCTACTGTT‐3’;  427  sequence 








fragments  were  amplified  using  the  Platinum  Pfx  (Invitrogen),  according  to  the 
manufacturer’s  instructions.  The  PCR  products  were  purified,  digested  with 
BamHI/AgeI  and  finally  subcloned  into pREV(1.4)‐GFP. The ER  444‐456  sequence 
was  subcloned  in  the  same vector,  as  a  short  fragment generated by  annealing of 
specific oligonucleotides. The same strategy was utilized to generate the ER 444‐456 
mutant.  All  putative  ER  NES  were  verified  by  sequencing  to  confirm  the  exact 
reading  frame  between  REV  and  GFP.  The  site‐directed mutations  of  ERα were 
introduced  into  the pSG5‐HEG0 using a standard PCR methodology. Two mutants 
were generated: pSG5‐HEG4A (Ile 451 and 452 changed with Ala; Leu 453 and 454 
changed with Ala)  and pSG5‐HEGIL  (Ile  451  changed with Ala; Leu  454  changed 











the  cells  were  incubated  at  37°C  for  24h,  and  then  used  for  the  indicated 
experiments. The nuclear  export  assay was performed as described  (Henderson & 
Eleftheriou, 2000). Briefly,  each putative NES‐ER  sequence was  subcloned  into  the 
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REV (1.4)‐GFP and then transfected (at 2 µg) by SuperFect into growing MCF‐7 cells. 
After 18 h  the  cells were  incubated with  cycloheximide  (at 15 µg/ml; Calbiochem) 








The  results  were  corrected  using  CH110‐expressed  β‐galactosidase  activity 













localization  of  GFP‐HEGO,  its  mutants  as  well  as  putative  ER‐NES  constructs. 
Similar analysis was done to detect GFP‐FKHR wt or its mutant GFP‐FKHR‐AAA. In 
all  other  experiments,  the  cells  on  coverslips  were  fixed  and  permeabilized  as 
described  (Castoria  et  al.,  1999).  Endogenous  ERα  was  visualized  as  described 
(Castoria et al., 1999), using  the A314 mouse monoclonal antibody or  the H222  rat 
monoclonal  antibody.  The  dominant  negative  ∆p85α  and Myc‐His  tagged Akt K‐ 
were visualized as reported (Castoria et al., 2001). The Myc‐tagged pSG5 or HEG0 or 
HEGIL were detected as reported  (Castoria et al., 2004), using  the mouse anti‐Myc 
tag monoclonal antibody  (Clontech). Coverslips were  finally  stained with Hoechst 












done  using  the  rabbit  polyclonal  anti‐ER Ab  (G‐20  Santa Cruz,  at  1µg/ml)  or  the 




All performed  as described  (Migliaccio  et  al.,  2000). The  rabbit polyclonal  anti ER 
antibody (G‐20; Santa Cruz) was used to detect ERα. Expression and production of 
Ran Q69L was verified using the mouse monoclonal anti‐His tag antibody (Qiagen). 
ERα  and  the  chimera GFP‐ERα  (see  the  Supplemental  data) were  detected  using 
either the rat monoclonal (H222 from Abbott Laboratories) anti ERα antibody or the 
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(E2)  for  the  indicated  times  (min). ERα  localization was analyzed by  immunofluorescence 
using  the  indicated antibodies.  In b and c, cells were  transfected with pEGFP‐HEG0,  then 
left untreated or  treated with  the  indicated compounds. OH‐Tamoxifen  (TX,  from Zeneca) 
was used at 0.1 µM; actinomycin D  (Act D) was added at 5 µg/ml, 1h before  the estradiol 




as described  in Methods. ERα  localization was analyzed by  immunofluorescence using  the 
rat  anti‐ER monoclonal  antibody  (H222 MAb).  In  e,  cells were  transfected with  pEGFP‐
HEG0 and then left untreated or treated with 10 nM estradiol, in the absence or presence of 
LMB  (at 5 ng/ml). LMB was added 30 min before  the hormone  treatment. Cells were also 
treated with LMB in the absence of hormone. The GFP‐HEGO localization was determined 
by  fluorescence.  In a, b,  c, d, and e,  cells  that  fell  into  the  category of exclusively nuclear 
fluorescence  were  scored  and  data  expressed  as  a  percentage  of  total  cells  (in  a)  or 
transfected cells (in b, c, d, e). Data were derived from at least 1000 scored cells. The results 
of  more  independent  experiments  have  been  averaged;  means  and  SEM  are  shown.  n 
represents the number of experiments. In f, images from one experiment in e were captured. 
Panels  show  the GFP‐ER  localization  in MCF‐7  cells  stimulated  for  60 min with  estradiol 
(E2),  in  the absence  (left picture) or presence  (right picture) of LMB.  In g,  35S‐labeled HA‐
CRM1 was incubated with recombinant ERα in the absence or presence of estradiol (10 nM). 
The purified recombinant RanQ69L (at 1 µM) was included in the incubation mixture of each 








µg/ml), alone or  together with  leptomycin B  (5 ng/ml). The subcellular distribution of GFP 
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proteins was determined by fluorescence microscopy and graphically shown in panel a, with 
mean values  taken  from at  least  three  experiments, and a  standard deviation of  less  than 





described  in  Methods  and  then  transfected  (d  and  e)  in  growing  MCF‐7  cells.  After 
transfection, the cells were left untreated (‐), or treated with 5 µg/ml actinomycin D (+). The 
percentage of  cells with nuclear  (N), nuclear/  cytoplasmic  (N/C) and  cytoplasmic  (C) GFP 
protein was determined by fluorescence microscopy and graphically shown in d. Data were 





interaction,  sequesters  the  receptor  into  the  nuclei  and  inhibits  the  S‐phase  entry  of 
estradiol‐treated MCF‐7.  
Panel  a  shows  the  aminoacidic  sequence of  the Tat‐conjugated ERalpha  (444‐456) peptide 
(Tat‐pep).  In  b,  35S‐labeled  HA‐CRM1  was  incubated  with  recombinant  ERα  from 
baculovirus in the absence or presence of estradiol (10 nM), alone or together with a 200‐fold 
excess of  the Tat‐conjugated peptide  (Tat‐pep). A 200‐fold excess of a non‐specific peptide 
(Tat)  was  used  as  a  control  (ctrl).  CRM1  was  immunoprecipitated  with  the  anti‐HA 
monoclonal  antibody  and  proteins  in  immunocomplexes were  revealed  by  fluorography 
(upper panel) and immunoblotting with the anti ERα antibody (lower panel). In c, quiescent 













alone  (ctrl).  After  in  vivo  pulse  with  BrdU,  DNA  synthesis  was  analyzed  and  BrdU 
incorporation  expressed  as  percent  of  control.  In  estradiol‐stimulated  cells  (E2),  BrdU 
incorporation  ranged  from  55  to  65%  of  total  cells,  whereas  in  serum‐stimulated  cells 
(serum)  it  ranged  from  65  to  70%.  The  basal  BrdU  incorporation  (7%) was  in  each  case 
calculated and subtracted. For each experiment, at least 200 cells were scored. The results of 
more  independent  experiments  have  been  averaged;  means  and  SEM  are  shown.  n 
represents the number of experiments. In f, quiescent MCF‐7 cells were stimulated with 10 
nM estradiol for 24 h and the Tat‐conjugated peptide was added after the hormone addition, 
at  the  time points  indicated  in Figure. After  in vivo pulse with BrdU, DNA synthesis was 






sequence  between  amino  acids  444‐456  is  highlighted  in  bold. Mutated  amino  acids  are 
underlined.  The NES mutants, GFP‐HEG4A  and GFP‐HEGIL, were  prepared  from GFP‐
HEGO  as  described  in Methods.  In  b,  quiescent MCF‐7  cells were  transfected with  the 
indicated plasmids and  then  left unstimulated or  stimulated with 10 nM  estradiol  for  the 
times  indicated  in  the  Figure.  The  percentage  of  cells  with  nuclear  GFP  protein  was 
determined  by  fluorescence microscopy  and  graphically  shown.  For  each  experiment,  at 
least  150  cells were  scored.  The  results  of  different  independent  experiments  have  been 
averaged; means and SEM are shown. n  represents  the number of experiments.  Images of 
one experiment  in b are presented  in panel c, which shows the  intracellular distribution of 
GFP‐HEGO or GFP‐HEG 4A or GFP‐HEG IL in MCF‐7 cells treated for 60min with estradiol. 
In d and e, growing NIH3T3 fibroblasts were used. In d, cells were transfected with an ERE‐
Luc  construct,  along with  the  indicated plasmids. After  transfection,  the  cells were made 
quiescent  and  then  left  unstimulated  or  stimulated with  10  nM  estradiol.  The  luciferase 
activity was assayed, normalized using β‐gal as an  internal control, and expressed as  fold 
induction. In e, cells on coverslips were  transfected with  the  indicated plasmids and made 
quiescent. The cells were left unstimulated or stimulated for 18 h with either 10nM estradiol 
or  20%  serum. When  indicated  by  the  asterisk,  the  Tat‐conjugated  ERalpha  peptide was 









Fig. 5. Estradiol  regulation of FKHR nuclear export and  role of FKHR  in  the hormone‐
induced DNA synthesis of MCF‐7 cells. 
Quiescent MCF‐7 on  coverslips were used.  In  a,  cells were  transfected with  the  indicated 
plasmids and  then  left unstimulated or stimulated  for 24 h with 10 nM estradiol. After  in 
vivo  pulse with  BrdU, DNA  synthesis was  analyzed  by  immunofluorescence  and  BrdU 
incorporation was  calculated  as  in  Fig.  4.  In  b,  cells were  transfected with  the  indicated 




transfected  cells.  In  c,  cells were  co‐transfected with  the  indicated plasmids  and  then  left 
unstimulated or stimulated with 10 nM estradiol for 60 min. Localization of GFP‐FKHR wt, 
Myc‐HEG0  or Myc‐HEGIL mutant was monitored  by  confocal microscopy. Cells  that  fell 
into the category of exclusively FKHR nuclear fluorescence were scored and data expressed 
as a percentage of co‐transfected cells. For each experiment in a, b and c, data were derived 
from  at  least  500  scored  cells. The  results  of  several  independent  experiments  have  been 
averaged; means and SEM are shown. n represents the number of experiments. In d, images 
from one experiment  in b or c are shown. They represent  the staining of endogenous ERα 
(red)  in MCF‐7  cells  expressing  the GFP‐FKHR  (green  in  left panels) or  the mutant, GFP‐
FKHR AAA  (green  in middle panels) and  treated  for 60 min with estradiol.   Right panels 
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Rev 1-4 ER-444 wild-type
(444-456)  EFVCLKSIILLNS
Rev 1-4 ER-444 mutant EFVCLKSAAAANS
























































































































































































































































GFP-HEGO NES      EFVCLKSIILLNS
HEG4A             EFVCLKSAAAANS
HEGIL             EFVCLKSIALANS
A















































































































































































































The wild type ERα (HEGO) and its mutants, HEG14, HEG15 and HEG241 into pSG5 (Tora 
et al. 1989; Ylikomi et al. 1992) were digested with the EcoRI and ligated into the pEGFP 
plasmid (C2 from Clontech, CA). pEGFP-NLS/HEG14 was obtained by digestion of pEGFP-
HEGO with MspI and BamHI and subcloned into SmaI/BamHI pEGFP. All junctions were 




EXPERIMENTAL DATA SUPPORTING THE TEXT 
Identification of domains involved in the hormone regulated nucleo-cytoplasmic 
shuttling of ER 
Two ER mutants, HEG15 and HEG14, were subcloned into pEGFP. HEG15 (∆282-595 
HEG0) contains  highly conserved nuclear localization signals (NLS 2 and 3; Guiochon-
Mantel et al., 1991). It binds DNA but is unable to bind estradiol (Ylikomi et al. 1992). In 
turn, HEG14 (∆ 1-281) contains NLS1. It binds the hormone, but does not bind DNA 
(Ylikomi et al., 1992). The resulting chimeras, GFP-HEG15 and GFP-HEG14, were 
transiently transfected into quiescent MCF-7 cells. In agreement with previous results 
(Ylikomi et al., 1992), our data show that neither GFP-HEG15 nor GFP-HEG14 shuttle 
between the nucleus and the cytoplasm. Irrespective of the hormone treatment, the first 
mutant mostly resides in the nuclear compartment. Although GFP-HEG14 contains the NLS1 
sequence and binds the hormone, it does not enter nuclei even after estradiol addition. From 
these data, we speculated that the hormone binding domain localized in the HEG14 mutant as 
well as NLSs (2 and 3) of ERα are both required for the estradiol-induced nuclear import of 
the receptor. We next subcloned the HE241G into pEGFP. This mutant contains the hormone 
binding domain and lacks the three NLSs. It is indeed prevalently localized in the cytoplasm 
regardless of estradiol treatment. Similar results were obtained by ectopic expression of this 
mutant in NIH3T3 fibroblasts (Castoria et al., 1999). The behavior of this mutant confirms 
that in the absence of NLS, hormone binding is not sufficient to induce nuclear translocation 
of the receptor. Since HEG15 is localized in the nuclear compartment and its localization is 
unaffected by hormonal treatment of cells, we reasoned that addition of NLSs to HEG14 
might restore the estradiol-induced import of ERα. Analysis of transfected cells with the 
resulting chimera, GFP-NLS/HEG14, showed not only nuclear import but also export similar 
to GFP-HEG0 in response to the estradiol treatment.  
Data collected in Fig. 2 show that the 241-595 AA sequence of ERα is responsible for the 
estradiol-regulated nucleo-cytoplasmic shuttling of ER in MCF-7 cells. 
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Legend to Fig. 1- MCF-7 cells were used. In A, untransfected cells were untreated or treated 
with estradiol (10 nM), for the indicated times. Lysates were prepared and analysed by 
Western blot using the rat monoclonal H222 anti ER antibody. In B and C, cells were 
tnasfected with GFP-HEGO and untreated or treated with 10 nM estradiol for the indicated 
times. Lysates were analysed by Western blot using the antibodies against the indicated 
proteins. 
 
Legend to Fig. 2- Wild-type and mutants of ERα were subcloned into pEGFP as described in 
Supplemental Experimental Procedures. Fig. 2 a shows a schematic representation of the 
mutants. As shown in Fig. 2 b and c, quiescent MCF-7 cells were transfected with the 
indicated plasmids and then left untreated or treated for the indicated times with estradiol (10 
nM). The localization of the indicated mutants as well as GFP-HEG0 was determined by 
fluorescence. The score was performed as described in the text (see the legend to Fig.1). For 
each plasmid, data were derived from at least 500 cells. The results of more independent 
experiments have been averaged; means and SEM are shown. n represents the number of 
experiments.  
 
Legend to Fig. 3-  
The Tat-peptide does not affect the EGF-induced p27 nuclear exit in mouse fibroblasts 
NIH3T3 (A), and does not interfere in sub-cellular distribution of p53 in MCF-7 cells 
(B). 
In A, quiescent NIH3T3 fibroblasts on coverslips were unstimulated or stimulated for 14h 
with EGF (100 ng/ml). When indicated the Tat-peptide (Tat-pep) was added at 1 µM together 
with EGF. Nuclear localization of p27 was revealed by immunofluorescence (Castoria et al., 
2004) and expressed as % of total cells. 
In B, quiescent MCF-7 cells on coverslips were unstimulated or stimulated with 10 nM 
estradiol for the indicated times. When indicated, the Tat-peptide (Tat-pep) was added at 1 
mM, together with estradiol. Nuclear localization of p53 was revealed by 
immunofluorescence and expressed as % of total cells.  
The putative NES sequence of ERα shows homology with the p53 NES and is shared by 
other steroid receptors.  
In C, the sequence alignment between the indicated regions of ERα and p53 is shown, with 
the conserved amino acids in bold. 
In D, the sequence alignment between the indicated regions of ERα and other steroid 
receptors is depicted. Sequences were obtained from The National Center for Biotechnology 
Information Data Library: ERα (estrogen receptor α) accession no. NP000116; 
ERβ (estrogen revìceptor β) no. NP001035366; PgR (progesterone receptor) no. NP000917; 
AR (androgen receptor) no. NP000035; GR (glucocorticoid receptor) no. P04150; MR 
(mineralocorticoid receptor) no.P08235. Conserved amino acids are in bold; the core of ER-









References not cited in the text 
 
Guiochen-Mantel, A., Lescop, P., Christin-Maitre, S., Loosfelt, H., Perrot-Applanat, M., and 
Milgrom, E. (1991) Nucleocytoplasmic shuttling of the progesterone receptor. EMBO J. 10, 
3851-3859. 
 
Ylikomi, T., Bocquel, M.T., Berry, M., Gronemeyer, H. and Chambon, P. (1992) Cooperation 






































































































































































time of treatment (min) time of treatment (min)
n=3n=3




































































time of estradiol treatment (min)
E2 + Tat-pep
E2


































[Frontiers in Bioscience 13, 1318-1327, January 1, 2008]  
1318 
Integrating signals between cAMP and MAPK pathways in breast cancer 
 
Gabriella Castoria1, Antimo Migliaccio1, Loredana D’Amato1, Rosina Di Stasio1, Alessandra Ciociola1, Maria Lombardi1, 
Antonio Bilancio1, Marina Di Domenico1, Antonietta de Falco1, Ferdinando Auricchio1 
 
1Department of General Pathology, II University of Naples, Via L. De Crecchio, 7, 80138 Naples, Italy 
 




3. Breast cancer: a general overview 
 3.1. Steroid receptors in breast cancer 
4. Signaling by steroid receptors 
 4.1. Classical and rapid response models of steroid action 
 4.2. Role of cAMP in breast cancer 
 4.3. MAPK pathway in breast cancer 
 4.4. Integration between cAMP and MAPK pathways in breast cancer 

















 Breast cancer is one of the most common 
malignancies in Western society. Localized breast cancer, 
before it spreads, can be cured by surgery. However, the 
high mortality rate associated with breast cancer is due to a 
propensity of the tumor to metastasize when the primary 
tumor is small or undetectable. Although steroid receptor 
status has been recognized as the most precise predictor of 
response to hormone therapy, a significant number of tumors 
expressing these receptors metastasize and patients do not 
respond to the antihormone therapy. The mechanism leading 
to breast cancer progression and resistance to the hormone 
therapy is not completely understood at the present time. 
Compelling evidence shows that hormone-bound steroid 
receptors in breast cancer cells activate complex signaling 
networks, which include MAPK- and G protein-dependent 
pathways. These responses, which occur within seconds or 
minutes after steroid administration, are not due to changes 
in gene expression. Depending on cell systems, steroid 
activation of these networks leads to different and profound 
effects on extra nuclear and nuclear events. In such a way 
steroids foster cell cycle, reduce apoptosis and stimulate cell 
migration of target cells. All these processes are deregulated 
in breast cancer. In this review we will discuss new aspects 
of signaling pathways activated by steroids and their 
integration with other pathways in breast cancer. Recent 
findings on the discovery of compounds specifically 















 Breast cancer is very common in developed 
countries, with one in ten women developing the disease and 
half of those dying of it. The status of steroid receptors is a 
well-established prognostic marker in breast cancer. 
Estradiol receptor alpha (ER alpha) has been implicated in 
the progression of breast cancer, and this is corroborated by 
the finding that about 60-70% of human breast cancers are 
ER alpha-positive (1). ER alpha status predicts a favorable 
disease outcome. Most patients with ER alpha-positive 
breast cancer receive tamoxifen as adjuvant endocrine 
therapy (2). Survival of tamoxifen-treated patients is longer 
for women with cancer with ER alpha amplification than for 
women with ER alpha expressing cancer without 
amplification (3). However, although tamoxifen treatment 
has improved the outcome from breast cancer, many patients 
become resistant to the hormone therapy and develop 
metastatic breast tumors. Several mechanisms have been 
proposed to explain the causes of breast cancer resistance to 
endocrine therapy. These include expression of steroid 
receptor variants, ligand-independent activation of steroid 
receptors, over-expression and activation of tyrosine kinases, 
most notably ErbB2 (4), and signaling effectors, such as 
AKT (5). 
 
  Steroid hormones control proliferation and 
survival of breast epithelial cells. This activity has been so 
far attributed to the interaction of steroids with their cognate 
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receptors and the consequent regulation of gene transcription 
(6). In addition to the well-studied nuclear function, ERs, 
progesterone receptor (PgR) and androgen receptor (AR) 
participate in extranuclear and membrane-mediated 
signaling events (7). Such a non genomic action has been 
linked to rapid responses elicited by steroid hormones 
and involves activation of Src, mitogen-activated protein 
kinase (MAPK), phosphatidylinositol-3-kinase (PI3-K), protein 
kinase C (PKC) and etherotrimeric G-proteins in cytoplasm or 
membrane of target cells (8). Furthermore, the extra-nuclear 
mechanism regulating the cross talk between ER alpha and 
EGFR in cytoplasm of breast cancer cells has been recently 
analyzed (9). Interestingly, important biological responses such 
as DNA synthesis and cytoskeleton changes leading to cell 
migration can occur in the absence of transcriptional activity or 
nuclear localization of steroid receptors (10-12). Depending on 
the cell type and experimental conditions, steroid action may 
depend on integration between extranuclear and nuclear 
receptor activities (13). 
 
  In this review, we discuss new concepts of cross 
talk between steroid receptor and signaling effectors 
accounting for the non genomic actions of steroids. In 
particular, we highlight recent developments unraveling the 
intricate signaling network regulated by steroids in breast 
cancer and the integration of these pathways in the cell. 
Elucidating the details of these programs should provide a 
more rational approach to breast cancer therapy.  
 
3. BREAST CANCER: A GENERAL OVERVIEW 
 
 Breast cancer remains a widespread disease. In 
2004, there were 371,000 new cases of breast cancer 
diagnosed and 129,900 breast cancer-related deaths in 
Europe (14). Nevertheless, a decline in mortality rate has 
been observed during the last few years (15). This decline is 
due to mammographic screening, more precise diagnosis, 
and an increase in the number of women receiving the best 
treatment for their condition, like the extensive use of 
tamoxifen (16). 
 
The causes leading to breast cancer and the 
identification of prevention strategies are still elusive. 
Association of the risk of breast cancer with age at first birth 
and parity was proposed several years ago (17) and 
confirmed by subsequent studies (15). Additional risk 
factors have been added in recent years. These include 
genetic factors, geographical location, exposure to ionising 
radiation, particularly during puberty, absence or short 
lifetime duration of breastfeeding (typical of women in 
developed countries), use of oral contraceptives, 
hormone-replacement therapy, high body-mass index and 
dietary factors, such as alcohol abuse. Progression from 
healthy mammary tissue to invasive carcinoma is still a 
debated process. The pre-neoplastic potential of benign, 
proliferative lesions of breast and dysplastic changes 
present in different non-malignant breast diseases is not 
defined. To date, in situ carcinomas (either ductal or 
lobular) are morphologically identifiable as neoplastic 
transformation, whereas stromal invasion and metastasis 
to regional lymph nodes or distant organs are the 
hallmarks of developed breast cancer.  
  The best approach to breast cancer therapy 
remains targeting the disease at the earliest stages of 
development. Tamoxifen, a selective estrogen receptor 
modulator (SERM), has been largely used because of the 
data from laboratory models and its ability to prevent 
contro-lateral breast cancer (18). Although the role of 
tamoxifen as a chemopreventive for women with high risk 
of breast cancer is generally accepted, what degree of risk is 
appropriate for its use remains unclear. In addition, 
tamoxifen induces increased risk of endometrial cancer and 
other side effects because of its partial agonist activity (19). 
Thus, other molecules such as Raloxifene and aromatase 
inhibitors have been developed. Raloxifene is also a SERM 
largely used in the treatment of osteoporosis in 
postmenopausal women. It reduces the incidence of breast 
cancer in osteoporosis trials and does not exert estrogen-like 
activity in uterus of rodents. Unfortunately, like tamoxifen, 
it increases thromboembolic events. Aromatase inhibitors 
are more effective than tamoxifen in preventing contro-
lateral breast cancer and in the adjuvant treatment of early-
stage disease. Aromatase inhibitors, however, do not 
suppress the levels of estradiol in premenopausal patients 
(18). It is noteworthy that tamoxifen acts through ER, and 
that only ER-positive breast cancers were reduced in the 
tamoxifen prevention trials. Its use is not suitable for women 
with BRCA1 mutations who develop ER-negative breast 
cancer or in patients with ER-negative breast cancers 
overexpressing ErbB2/HER2/neu. Drugs targeting other 
pathways involved in breast carcinogenesis, such as 
trastuzumab (Herceptin), an antibody against ErbB2, or oral 
tyrosine kinase inhibitors are used in therapy and new 
molecules with more specific action are being investigated 
in laboratory models of breast cancer (8, 20). 
 
  In conclusion, the general trend is now to identify 
new molecular targets in tumors and their neighboring cells 
and to increase targeted therapy of breast cancer. 
 
3.1. Steroid receptors in breast cancer 
 Several years ago, Beatson observed that 
oophorectomy caused tumor regression in advanced breast 
cancer (21). This seminal finding opened the way to the 
study of the role of estradiol in this disease. After 70 years, 
an ER was identified (22) and purified by affinity 
chromatography (23). This receptor was detected in breast 
tumors (24) and is now an established prognostic marker. Its 
expression determines whether or not tamoxifen should be 
given as adjuvant endocrine therapy.  
 
 A second ER was later identified (25) and named 
ER beta to distinguish it from the original receptor, ER 
alpha. Two human ER beta isoforms of 530 and 485 amino 
acids have been described (26-28). The 530 amino acid form 
is generally believed to be the mature full-length ER beta 
(27-29).  
 
 Although estradiol is the main steroid implicated 
in breast cancer progression, much evidence points to 
progesterone as an important factor in the progression and 
maintenance of the neoplastic phenotype in the mammary 
gland (30). In fact, clinical data have demonstrated a higher 
risk of breast cancer in patients under hormone replacement 
Signaling activation by steroid hormones in breast cancer 
1320 
therapy using a combination of estrogens and progestins as 
compared with those using estrogens alone (31, 32). PgR, 
like ER, represents a target in the therapeutic approach to 
breast cancer (33). Accordingly, recent data raise the 
possibility that anti-progesterone treatment may be useful 
for breast cancer prevention in individuals with BRCA1 
mutations, which predispose to breast and ovarian cancers 
(34).  
 
 PgR in rodents and humans exists as two isoforms, 
PgR-A and PgR-B. The two isoforms are produced from a 
single gene by translation initiation at two distinct start 
codons under the control of separate promoters (35). PgR-A 
is a truncated form of PgR-B. In humans, the N-terminal 164 
amino acids of PgR-B are missing in PgR-A. Although the 
two forms of PgR have similar structures and identical DNA 
and ligand binding domains, in vitro studies using a 
progesterone-responsive transcription system reconstituted 
in mammalian cells revealed that PgR-A and PgR-B are 
functionally different. In most cases, PgR-B acts as a potent 
activator of transcription of target genes, whereas PgR-A 
acts as a dominant repressor of transcription regulated by 
PgR-B as well as other nuclear receptors (36). 
 
 Although a multitude of molecules involved in 
breast cancer biology, particularly ErbB2 and mutated 
BRCA1, are used as markers, determination of steroid 
receptor status remains an important prognostic assay. 
Overexpression of ER alpha is a well-established prognostic 
and predictive factor in breast cancer patients (2). More 
importantly, a large subset of breast cancers shows a single-
gene amplification of the ER alpha gene, thus suggesting 
that this amplification may be a common mechanism in 
proliferative breast disease and a very early genetic 
alteration in breast cancer progression (3). Expression of 
PgR serves as a functional assay because it indicates that the 
ER transcriptional pathway is intact. When biochemical 
ligand binding assays indicate concentrations of 10 fmol/mg 
cytosol protein or more, breast cancers are generally 
considered ER-positive and PgR-positive for clinical 
purposes. ER and PgR status can also be evaluated using 
immunohistochemistry (IHC). Unlike chemical assays, IHC 
does not require destruction of tissue specimens; in addition, 
it shows ER tissue distribution. For these reasons, it has 
become the preferred method for determining ER/PgR status 
in breast cancer specimens. Quantitative methods using 
computer-aided image analysis are being developed to 
improve the accuracy of IHC.  
 
4. SIGNALING BY STEROID RECEPTORS  
 
4.1. Classical and rapid response models of steroid action 
 Steroid hormones influence many processes in 
mammals, including cell growth, cardiovascular health, bone 
integrity, immunity, cognition, and behavior. Evidence 
collected in the last few years indicates that regulation of 
these effects may be mediated by a complex interface 
between modulation of signaling cascades and control of 
gene expression. Receptors in the cell nucleus regulate gene 
expression, whereas classical receptors localized in close 
proximity to the cell membrane or in the extranuclear 
compartment of cells activate signal transduction (7, 10). 
Transcriptional effects of steroid hormones usually occur via 
ligand-dependent binding of receptors to target gene 
promoters as part of a pre-initiation transcription complex, 
which leads to chromatin remodeling and ultimately 
regulates gene expression (37). The resulting fluctuations in 
mRNAs and the proteins they encode take place within 
hours following hormonal exposure. In contrast, steroid 
activation of signal transducing pathways occurs within 
seconds or minutes. These rapid effects are insensitive to 
RNA and protein synthesis inhibitors. Almost all the 
members of the steroid hormone family, from the 
corticosteroids (glucocorticoids and mineralocorticoids) to 
the sex steroid hormones (estrogens, progestins, and 
androgens), exhibit rapid, non genomic actions. These range 
from activation of Src, MAPKs, adenylyl cyclase and PI3-K 
to rises in intracellular-calcium concentrations (38-45). 
 
 Much evidence shows that steroid stimulation of 
breast cancer cells rapidly induces G-protein activation and 
generation of a second messenger such as cAMP and cGMP 
(46). Although controversial findings have been reported 
about the nature of receptors mediating these responses, G 
protein activation by steroids leads to stimulation of various 
signaling effectors (46) and release of growth factors with 
consequent activation of their cognate receptors (47). 
Depending on the cell context, these signals are related to 
different effects of steroid hormones, such as proliferation, 
survival, migration and differentiation. 
 
4.2. Role of cAMP pathway in breast cancer 
 Several years ago, Szego & Davis reported a rapid, 
acute elevation of uterine cAMP by estradiol treatment of 
rats (48). Subsequent studies indicated that estradiol 
treatment of human prostate tissue greatly increases the 
intracellular cAMP (49), and findings in ER-positive MCF-7 
breast cancer cells showed that estradiol enhances 
intracellular cAMP production through adenylyl cyclase 
activation and stimulates cAMP response element (CRE)-
mediated gene expression (50). In agreement with these 
observations, a role for cAMP/protein kinase A (PKA)-
dependent pathway in the estradiol-regulated cyclin D1 
transcription of ER-positive ZR-75 breast cancer cells has 
been proposed (51). Altogether, these studies show that 
signals resulting from activation of G-protein and cAMP-
signaling pathways contribute to gene regulation by 
estradiol. 
 
 In addition to being produced in response to 
steroids and to regulating CRE-mediated genes, cAMP plays 
a role in the ligand-independent activation of steroid 
receptors. In fact, 8-Br cAMP treatment of cells 
transfected with a chicken PgR expression vector and a 
PgR-responsive reporter causes hormone-independent, 
but receptor-dependent activation of the reporter (52). 
These findings have been explained by the observations 
that cAMP increases phosphorylation of the steroid 
receptor coactivator-1 (SRC-1; 53-54). In addition, 
cAMP is also involved in resistance to steroid antagonists 
that frequently develops in breast cancer, since it 
enhances the ability of antiprogestin to activate gene 
transcription mediated by PgR-B in T47D breast cancer 
cells (55, 56).  




Figure 1. Estradiol activation of signaling effectors is 
responsible for cell cycle progression in ER-positive breast 
cancer cells. In breast cancer cells, estradiol rapidly induces 
the assembly of a complex made up by ER, Src and PI3-K. 
Through PKC zeta, Ras is also recruited to the complex and 
the Ras-dependent kinase cascade activated. Stimulation of 
PI3-K and Ras-dependent cascade leads to increased cyclin 
D1 transcription and p27 nuclear exclusion. These events are 
responsible for the G1/S transition of cells.  
 
The role of cAMP in mammary carcinoma cell 
proliferation has also been investigated. Initial reports 
indicated that dibutryl-cAMP in conjunction with arginine 
suppresses the proliferation of MCF-7 cells (57). 
Subsequently, it was confirmed that elevation of cAMP 
levels produces substantial effects in MCF-7 cells. Addition 
of 8Br-cAMP or expression of mutant (Q227L)-activated G 
alphas in MCF-7 cells did indeed block the ability of these 
cells to grow in an anchorage-independent manner, and 
stable transfection of activated-G alphas in MCF-7 cells 
reduced the ability of these cells to form tumors in athymic 
mice (58). These findings indicate that cAMP may be crucial 
in preventing the expression of transformed phenotype in 
mammary epithelial cells. In addition, G protein coupled 
receptor 30 (GPR30) expression correlates with progestin-
induced growth inhibition in different breast cancer cells and 
GPR30 is critical for progestin-induced growth inhibition 
(59).  
 It is now largely accepted that estradiol and 
progestin treatment of breast cancer cells rapidly generates 
cAMP. This action results from G protein activation and 
signaling is then transmitted to various effectors, including 
PKA, PKC, MAPK and PI3-K (46). Although the 
importance of these signals in the cellular action of sex 
steroids in vitro and in vivo is well documented, the nature 
of receptors mediating these events is still debated. Some 
models propose the involvement of classical steroid 
receptors, which initiates signaling cascades by association 
with the scaffold protein, caveolin-1 (60) and a variety of 
proximal signaling molecules, including G proteins (61-63), 
Src (39, 42, 64), PI3-K (11, 43, 65), MNAR (66), PKC zeta 
(45) and Shc (67). Other candidates in mediating these 
events are represented by traditional G protein-coupled 
receptors (GPRs). One of these receptors has recently been 
identified by different groups as GPR30, an orphan GPR 
(68, 69).  
4.3. MAPK signaling in breast cancer 
 MAPK circuits transmit and amplify signals 
involved in a plethora of cell responses. These pathways are 
indicators of the intensity and length of signals induced by 
growth factor, steroid hormones, and ligands of G protein 
coupled receptors. Three major MAPK pathways exist in 
human tissues, but ERK-1 and -2 are the most relevant to 
breast cancer, and several studies demonstrate that they are 
frequently activated in breast cancer (70). A number of 
investigators have now studied the expression of activated 
MAPK in human breast cancer tissues by enzymatic assay 
and immunohistochemical techniques. In one half of breast 
tumors MAPK is more active than in the surrounding benign 
tissue. Studies also show a trend toward higher MAPK 
activity in primary tumors of node-positive than in node-
negative patients; this up-regulation is not caused by Ras 
mutations, but results from enhancement of growth factor 
pathway activation (70).  
 
 Estradiol, progesterone and androgens very rapidly 
activate MAPK in breast, prostate and colon cancer cells 
(39, 40, 42, 64, 71, 72). This activation depends on the 
stimulation of the Src/Ras cascade by sex steroids and has a 
proliferative role as demonstrated by experiments with 
chemical inhibitors and signaling effector mutants (10, 12, 
42). In breast cancer cells, estradiol triggers direct 
interaction of classical ER alpha with the SH2 domain of 
Src, whereas androgens trigger AR interaction with the 
SH3 domain of Src (42). Estradiol activation of the Src 
axis occurs alongside PI3-K. Hormone stimulation of 
MCF-7 cells induces the assembly of a multi-molecular 
complex made up by ER, Src and p85 alpha, the 
regulatory subunit of PI3-K, which triggers activation of 
the Src and PI3-K-dependent pathways. Hormone-
activated PI3-K targets Akt and PKC zeta. Once 
activated, Akt increases cyclin D1 transcription, whereas 
PKC zeta controls Ras recruitment to the ER/Src/PI3-K 
complex, Erk-2 nuclear translocation and the consequent 
release of p27 from cell nuclei. By this interplay between 
signaling effectors and cell cycle regulators, cells enter the 
S-phase (43, 44). These conclusions have been highlighted 
by recent findings showing that specific interference in the 
sex steroid receptor/Src interaction by new, cell-
permeable molecules inhibits the growth of mammary 
tumor and prostate tumor cells in vitro and in nude mice 
(8, 20). 
 
 Figure 1 depicts the estradiol control of cell cycle 
progression through signaling effectors in breast cancer 
cells. 
 
Progesterone activation of MAPK was initially 
reported in T47D breast cancer cells (40). Progesterone 
stimulation of cells induces cross talk between cytoplasmic 
PgR-B and ER alpha, which in the absence of estradiol 
triggers ER alpha/Src association with consequent activation 
of the Src/Ras/MAPK pathway (40). Activation of MAPK 
by progestins is needed for the S-phase entry of T47D cells 
(10). Subsequent studies in in vitro reconstituted systems 
further clarified the molecular mechanism underlying 
progesterone activation of MAPK cascade by cross talk 
between PgR-B and ER alpha (41). Such cross talk is also




Figure 2. Model of estradiol action through GPR30 and 
cross talk between cAMP and MAPK pathways in ER-
negative breast cancer cells. In ER-negative breast cancer 
cells, estradiol (E2) directly binds to GPR30 and induces, 
through Gβγ-subunit protein activation, a Src-mediated 
activation of metalloproteinase (MMP) and release of HB-
EGF. Transactivation of EGFR then occurs and Erk 
activation is triggered. Estradiol binding to GPR30 also 
activates adenylyl cyclase (AC) and increases cAMP levels. 
PKA activation occurs and Raf is blocked. Erk signaling is 
then switched off. 
 
responsible for progestin stimulation of endometrial 
stromal  cell proliferation mediated by non genomic 
pathway activation (73). More recently, it has been 
shown that activation of MAPK cascade by progesterone 
through the PgR-B and ER alpha cross talk leads to 
phosphorylation of histone H3 with the consequent 
induction of progesterone target genes, thus pointing to 
the regulatory role of MAPK in the integration between 
non genomic and genomic signaling activated by steroids 
(13). Under different experimental conditions, it has been 
observed that PgR can directly activate Src, without the 
contribution of ER (64). Rapid activation of MAPK by 
steroids has been observed in different cell systems, 
including in vivo models (74, 75).  
 
 MAPK are also implicated in the ligand-
independent activation of ER alpha, as shown by findings 
demonstrating that activation of MAPK by growth factors 
phosphorylates and potentiates the transactivation 
function of ER alpha (76). In addition, expression of 
constitutively activated MEK-1 in MCF-7 breast cancer 
cells increases ER alpha-mediated transcriptional 
activation and accelerates tumor growth in vivo (77). 
Altogether, these data indicate that MAPK pathway can 
also intersect with steroid receptors at the transcriptional 
level. 
 
4.4. Integration between cAMP and MAPK pathways in 
breast cancer  
 The complexity of signaling pathways, the cross 
talk between multiple pathways and the presence of 
feedback loops occurring within the circuits has been 
actively investigated (78). Integration between different 
signaling pathways activated by steroid hormones in breast 
cancer has been explored. As described in the previous 
section, estradiol treatment of MCF-7 cells triggers 
activation of PI3-K and Src-dependent pathways with a 
proliferative final effect. Signaling of steroid hormones 
can also be regulated by adenylyl cyclase. Traditionally, 
adenylyl cyclase activity is modulated by receptors that 
couple to GPRs, and data from different groups have 
shown that GPR30, an orphan GPR, plays a critical role 
in steroid signaling (68-69). It binds estradiol and 
regulates MAPK activation in a transient way, since it is 
involved in both the rapid activation of MAPK and its 
subsequent inactivation. These findings indicate that the 
estradiol control of MAPK axis occurs even in the 
absence of classical ER. In fact, estradiol treatment of 
ER-negative cells triggers GPR30 activity that, through 
Gβγ-subunit protein activation, induces the Src-mediated 
release of heparin- bound EGF (HB-EGF) from the cell 
surface. Once released, HB-EGF activates EGFR, which, 
in turn, triggers MAPK activation (79). A similar 
pathway, however, can be activated by estradiol 
occupancy of the classical ER (46 and refs therein). 
Furthermore in cells lacking ER, estradiol also through 
GPR30 activation and Gα-subunit protein, stimulates 
adenylyl ciclase and increases cAMP levels. This event 
leads to activation of PKA and PKA-mediated block of 
Raf. In this way, MAPK inactivation follows to the initial 
MAPK activation (80, 81). Recent work supports such a 
model. Addition of cAMP in MCF-7 cells activates PKA, 
which, in turn, phosphorylates the regulatory subunit p85 
of PI3-K in serine 83. In this way, cAMP intersects with 
estradiol by facilitating the binding of ER to PI3-K. This 
results in a selective increase in Ras/PI3-K association 
and a net decrease in the Ras/Raf-1 complex. Thus, Ras 
signaling is mainly channeled to PI3-K rather than to 
Raf-1/MAPK (82). These data offer an example of how 
cAMP may act as an inhibitor of MAPK.  
 
The cross talk between cAMP and MAPK 
signaling pathways is involved in cell transformation. In 
fibroblasts, elevation of cAMP blocks signaling through the 
Ras/Raf/MEK pathway and therefore blocks Ras-induced 
transformation through PKA. Thus, Raf appears to be the 
major target of PKA in inhibiting signal transmission to 
MAPK. In this regard, it has been described that elevation of 
cAMP levels reduces both EGF stimulation of MAPK in 
MCF-7 cells and the ability of the same cells to form tumors 
in nude mice (58). Subsequent studies have shown that 
expression of G protein alpha inhibits the growth of 
established human tumors of breast cancer cells in athymic 
mice by inhibiting the MAPK pathway (83). In addition to 
indicating that interactions between the cAMP and MAPK 
signaling pathways regulate proliferation of breast cancer in 
vivo, these data also imply that targeting of the 
cAMP/MAPK axis (i.e. by continuous elevation of cAMP) 
could be used to block tumor formation. 
 
Figure 2 illustrates the GPR30-mediated actions of 
estradiol and the cross talk between adenylyl cyclase and 
MAPK (Erk) in ER-negative breast cancer cells. The initial 
estradiol activation of Erk is followed by PKA/Raf-mediated 
inactivation of the same enzyme. 
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5. SUMMARY AND PERSPECTIVES 
  
To date, most of the studies investigating the non 
genomic action of steroid hormones have been conducted in 
vitro using cancer-derived cells, and only a small number of 
these studies concern non-reproductive cells, mainly stromal 
cells, which strongly contribute to cancer progression. We 
have to learn much more about the role of steroid-activated 
pathways as well as their integration in vivo with pathways 
activated by different ligands, such as non-steroid hormones 
and growth factors. The proteomic approach, in association 
with the use of animals expressing genetically modified 
signaling effectors, will be of great help in this complex 
analysis. Another promising line of research has been 
initiated by laboratories seeking for ER ligands that 
preferentially act on the  transcriptional or non-
transcriptional signaling of ERs. A synthetic compound 
termed estren mainly induces the non-transcriptional actions 
of ER, whereas another pyrazole compound induces the 
transcriptional activity of ER, with minimal effects on its 
rapid signaling action (84, 85). It is expected that other 
similar receptor ligands will be found and employed in the 
study of steroid receptor action as well as in the therapy of 
receptor-associated diseases.   
 
The emerging field of steroid receptor-mediated 
signaling activation in breast cancer is very promising and 
one of the reasons for this mounting interest is offered by the 
potential use of signalosoma-based approaches to cancer 
therapy. Recently, new molecules have been identified and 
used to inhibit the proliferation of breast and prostate cancer 
cells in vitro as well as in immune-depressed mice (20, 45 
and submitted). These molecules act at nano-molar 
concentrations by specifically interfering in the interaction 
of steroid receptors and Src. They leave unaltered the 
receptor-mediated gene transcription as well as the signaling 
transduction that does not depend on steroid receptors. 
Further investigation is required to validate these approaches 
to cancer therapy in preclinical and clinical studies and find 
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In human mammary and prostate cancer cells, steroid
hormones or epidermal growth factor (EGF) trigger
association of the androgen receptor (AR)-estradiol
receptor (ER) (a or b) complex with Src. This interaction
activates Src and affects the G1 to S cell cycle
progression. In this report, we identify the sequence
responsible for the AR/Src interaction and describe a 10
amino-acid peptide that inhibits this interaction. Treat-
ment of the human prostate or mammary cancer cells
(LNCaP or MCF-7, respectively) with nanomolar con-
centrations of this peptide inhibits the androgen- or
estradiol-induced association between the AR or the ER
and Src the Src/Erk pathway activation, cyclin D1
expression and DNA synthesis, without interfering in the
receptor-dependent transcriptional activity. Similarly, the
peptide prevents the S phase entry of LNCaP and MCF-7
cells treated with EGF as well as mouse embryo
ﬁbroblasts stimulated with androgen or EGF. Interest-
ingly, the peptide does not inhibit the S phase entry and
cytoskeletal changes induced by EGF or serum treatment
of AR-negative prostate cancer cell lines. The peptide is
the ﬁrst example of a speciﬁc inhibitor of steroid receptor-
dependent signal transducing activity. The importance of
these results is highlighted by the ﬁnding that the peptide
strongly inhibits the growth of LNCaP xenografts
established in nude mice.
Oncogene advance online publication, 7 May 2007;
doi:10.1038/sj.onc.1210487
Keywords: androgen receptor; estrogen receptor; receptor
antagonist; Src; xenografts
Introduction
Prostate and mammary cancers are among the most
frequently diagnosed cancers and are major causes of
cancer death. These cancers are frequently androgen
receptor (AR) positive (Lopez-Otin and Diamandis,
1998), and express the a- or b-forms of the estradiol
receptor (ER). AR and ER expression is maintained
even in hormone-independent cancers, although their
role under these conditions is still poorly understood.
More than 80% of clinically androgen independent
human prostate tumors show high levels of AR (Zhao
et al., 2000). There appear to be different possible
mechanisms for acquiring androgen-independence in the
presence of AR expression. An increased level of AR
could sensitize cancers to low levels of residual andro-
gens, and antiandrogens could promote androgen
activation rather than inhibition (Chen et al., 2004).
Also, growth factors, such as epidermal growth factor
(EGF), could bypass the hormone requirement by
directly activating the AR (Culig et al., 1994, Migliaccio
et al., 2005). Alternatively, non-androgenic steroids
could promote androgen-independent growth of pros-
tate cancer cells through a mutated AR (Zhao et al.,
2000). Estrogen independence in the presence of ER
might arise via other mechanisms including the ligand-
independent ER activation, expression of ER variants,
and increased expression of co-activators (Gururaj
et al., 2006). In addition, alteration of the complex
interactions between ER and membrane-associated
or cytoplasmic effectors might be involved in breast
tumor progression as well as resistance to hormonal
therapy (Vadlamudi et al., 2005).
Previous studies have shown that sex steroid hor-
mones activate signal transducing pathways that are
frequently upregulated in human breast tumors (Cato
et al., 2002; Levin, 2003). In human prostate and
mammary cancer-derived cells, treatment with androgen
or estrogen rapidly induces association of Src with AR
and ER, leading to Src activation and stimulation of
DNA synthesis (Migliaccio et al., 2000). AR association
with Src has also been observed in androgen-stimulated
immortalized ﬁbroblasts (Castoria et al., 2003), raising
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the possibility that, in response to androgens, stromal
cells facilitate the malignant outgrowth and the meta-
static spread of prostate epithelial cells. In addition,
EGF signaling, which induces S phase entry and
cytoskeletal changes of prostate and breast cancer
cells, requires AR/ER association with Src (Migliaccio
et al., 2005).
On the basis of our previous ﬁndings (Migliaccio
et al., 2000) and establishment of new functional assays
for AR deletion mutants, in this report, we deﬁne the
amino-acid sequence responsible for the human AR
(hAR) interaction with Src. A synthetic 10 amino-acid
peptide that mimics this sequence prevents the AR/ER
complex from associating with Src. This peptide inhibits
the G1 to S transition of androgen- or estradiol-
stimulated prostate and mammary cancer cells in vitro
as well as the growth of LNCaP prostate cell xenografts
established in nude mice. Because of the role of AR in
EGF-elicited signaling (Migliaccio et al., 2005), the
peptide also prevents EGF-dependent DNA synthesis in
normal and cancer cell lines. Use of this peptide, alone
or in association with other compounds, potentially
offers a novel approach to speciﬁcally inhibit human
prostate and breast cancers.
Results
Deletion of the 371–422 sequence of the hAR abolishes
the in vitro association of the receptor with the Src SH3
domain (Migliaccio et al., 2000). To better deﬁne the
AR-interacting sequence, different human AR-deletion
mutants were prepared. Three deletions were separately
introduced within the proline-rich 372–379 region and
the contiguous sequence including arginine (Figure 1a).
Arginine is either contiguous or adjacent to proline in
Src, Yes and Lyn SH3-binding peptides (Kay et al.,
2000). The wild-type (wt) AR and its three mutants were
transiently transfected in Cos cells, which do not express
endogenous AR, and the ectopically expressed AR was
detected by immunoblotting the cell lysates with an anti-
AR antibody (Figure 1b, upper panel). To assess the
interaction of Src with AR, lysates from Cos cells
treated with the synthetic androgen R1881 for 3min
were incubated with anti-Src antibodies and the
immunocomplexes blotted with antibodies against either
Src or AR. In the presence of the synthetic androgen
R1881, a strong association of wt AR with Src was
detected, whereas a much weaker association, similar to
that found in the absence of hormone, was observed in
cells expressing the AR mutants (Figure 1b, lower
panel). As expected (Migliaccio et al., 2000), Src
immunoprecipitated with the wt AR from the lysate of
Cos cells treated with R1881 for 3min actively
phosphorylated acidiﬁed enolase. In contrast, no in-
crease of Src activity over the basal level was observed
when the AR constructs with a deletion of either the
372–385 residues (ARD1) or the 372–378 sequence
(ARD2) were overexpressed in the same cells
(Figure 1c). The AR deleted of the 380–386 (ARD3)
sequence only weakly activated Src (Figure 1c).
In contrast to Src activation, Cos cells transfected
with the deleted AR did not show reduction of AR-
dependent gene transcription. To verify this issue, an
androgen enhancer (the 3416 construct; Verrijdt et al.,
2000) was transiently co-transfected in Cos cells and the
effect of R1881 on reporter gene transcription was
evaluated (Figure 1d).
To characterize further the functional role of the AR
proline-rich region, four peptides derived from the
sequences deleted in the AR mutants were chemically
synthesized. The peptides were N-terminal acetylated
and C-terminal amidated (Figure 2, upper panel). They
were analysed for the ability to reduce the DNA
synthesis induced by R1881 in LNCaP (Figure 2, middle
panel) or estradiol in MCF-7 (Figure 2, lower panel)
cells. A peptide corresponding to the amino acids 377–
386 of the hAR (Ac-PPPHPHARIK-NH2; S1 peptide)
was ﬁnally selected because of its slightly stronger
inhibitory action and its smaller size. In addition, a
peptide containing the same amino-acid composition of
the S1 peptide, but with a shufﬂed sequence (Ac-
HPKPARIPHP-NH2) was synthesized (Ss peptide)
and analysed in parallel. The uptake of both carboxy-
ﬂuorescein-conjugated S1 and Ss peptides was ﬁrstly
analysed by confocal microscopy in quiescent, unﬁxed
LNCaP cells. Figure 3a shows that in 30min at 371C the
peptides are delivered similarly into the cells (upper
panels). No dependence on the temperature was
observed, thus excluding an energy-dependent mechan-
ism of peptide internalization (lower panels in
Figure 3a). Similar results were obtained in ﬁxed
LNCaP cells (not shown). To assess the effect of the
peptides on association between Src and AR, or ER, we
used quiescent LNCaP and MCF-7 cells. As expected,
R1881 or estradiol triggered the interaction of the
corresponding receptor with Src in LNCaP or MCF-7
cells, respectively, (Figure 3b and c, upper panels).
Notably, treatment of these cells with the S1 peptide or
the steroid antagonists Casodex (Figure 3b) or ICI
182 780 (Figure 3c) prevented the receptor/Src interac-
tion (Figure 3b and c, upper panels). The Ss peptide did
not abolish the hormonal-induced assembly of Src with
AR or ER, although a decrease of the complex assembly
was observed. The S1 peptide also prevented the
hormonal activation of Src and Erk assayed as enolase
(en) and myelin basic protein (MBP) phosphorylation,
respectively. Such an effect supports the evidence
that the S1 peptide action on the association of the
steroid receptors with Src is responsible for the
inhibition of the mitogenic Src/Erk pathway triggered
by hormones. The Ss peptide effect on the activity of Src
and Erk is negligible or absent (Figure 3b and c, upper
and lower panels).
In agreement with our previous ﬁndings (Castoria
et al., 2001), LNCaP or MCF-7 cells treated with R1881
or estradiol for 8 h show an increase in cyclin D1
expression and the Src-kinase inhibitor, PP2, abolished
this hormonal effect (Figure 4a and c). The increased
expression of cyclin D1 was clearly prevented by the S1
peptide and slightly decreased by the Ss peptide
(Figure 4a and c). At this point it is clear that the S1
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peptide prevents an entire sequence of events: AR/Src
association, Src/Erk activation, cyclin-D1 expression.
This conclusion suggested that AR/Src interaction
might be a target for inhibition of the AR/Src-
dependent cell proliferation by this peptide. Such a
possibility was veriﬁed by treating LNCaP or MCF-7
cells with either R1881 or estradiol (Figure 4b and d), in
the presence or absence of the corresponding steroid
antagonists and comparing the inhibitory response to
that observed in the presence of the peptide. The S1
peptide and the steroid antagonists inhibited to a similar
extent DNA synthesis in LNCaP and MCF-7 cells,
whereas the scrambled peptide slightly reduced the
hormonal effect.
It has been recently reported that, in LNCaP and
MCF-7 cells, EGF-induced signaling requires the
association of AR and ER with Src (Migliaccio et al.,
2005). In addition, AR or ER inhibition by steroid
antagonists or siRNA prevents EGF-triggered DNA
synthesis and cytoskeletal changes (Migliaccio et al.,
2005). This is conﬁrmed by the experiments in Figure 5
showing that steroid antagonists inhibit EGF-induced
DNA synthesis in LNCaP and MCF-7 cells. Interest-
ingly, the S1 peptide also abolished the EGF effect in
these cells, whereas the Ss peptide had no effect (Figure 5a
and b). Since the NIH3T3 ﬁbroblasts express AR
(Castoria et al., 2003), the effect of the S1 peptide on
the S phase entry of NIH3T3 ﬁbroblasts stimulated with
R1881 or EGF was also evaluated (Figure 5c). The S1
peptide substantially reduced the R1881- and EGF-
induced DNA synthesis in NIH3T3 ﬁbroblasts, while
the Ss peptide showed again little or no effect
(Figure 5c). Experiments in Figure 6a show that
serum-induced DNA synthesis in NIH3T3 ﬁbroblasts,
LNCaP or MCF-7 cells is unaffected by the S1 peptide,
thus implicating that the inhibitory effect of the peptide
is restricted to AR-dependent DNA synthesis. This
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Figure 1 Identiﬁcation of the AR domain responsible for the receptor association with Src. (a) Diagram of the wt hAR as well as its
mutants engineered as described in Materials and methods. The wt hAR (wt) or its mutants (D1, D2 and D3) were transiently
transfected in Cos cells. In (b and c), cells were made quiescent and then left untreated or treated for 3min with 10 nM R1881. In (b),
lysates were either analysed for expression of AR and its mutants using the anti-AR antibody (upper panel) or immunoprecipitated
with anti-Src MAb (lower panels). Immunocomplexes were then immunoblotted with the antibodies against the proteins indicated by
the arrows. In (c), lysates were immunoprecipitated with the anti-Src MAb and the Src kinase activity assayed using acidiﬁed enolase as
a substrate (lower panel). Immunocomplexes were also blotted with the anti-Src MAb to control the protein loading (upper panel). In
(d), cells were co-transfected along with ARE3416 construct, then left unstimulated or stimulated for 18 h with 10 nM R1881. The
luciferase activity was assayed, normalized using b-gal as internal control and expressed as fold induction. Wt, wild-type.
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of the same ﬁgure, showing that addition of the S1
peptide does not affect EGF or serum-induced DNA
synthesis of AR-negative PC3 or DU145 cells. Another
ﬁnding against the possibility that the effect of the S1
peptide is due to interference in intrinsic Src activity is
shown in Figure 6d. Clearly, the peptide has no effect on
a typical Src-dependent effect, such as the cytoskeletal
changes in EGF-treated DU 145 cells. In contrast, the
Src inhibitor PP2 completely abolishes the induction of
fan-like protrusions by EGF (Figure 6d). These data
together with previous results clearly demonstrate that
the S1-peptide speciﬁcally targets Src activation depen-
dent on AR, but does not affect the intrinsic activity of
this kinase.
The effect of the S1 peptide on steroid receptor-
dependent transcription was then analysed. Therefore,
the stimulatory effect of R1881 on the AR-dependent
transcriptional activity in LNCaP cells transfected with
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Figure 2 Identiﬁcation of a small peptide mirroring the AR 377–
386 sequence. The upper panel is a diagram of peptides mimicking
the AR sequences deleted in the AR mutants shown in (a) of Figure
1; a peptide with the scrambled sequence of the peptide S1 (Ss) is
also shown. Quiescent LNCaP (middle panel) or MCF-7 (lower
panel) cells on coverslips were left unstimulated or stimulated with
either R1881 (10 nM) or estradiol (10 nM) in the absence or presence
of the indicated peptides (at 1 nM) for 24 h. After in vivo pulse with
BrdU, the cells were stained for BrdU incorporation. DNA
synthesis was calculated by the formula: percentage of BrdU-
positive cells (number of BrdU-positive cells/number of total
cells) 100. Data are derived from at least 1000 scored cells. The
results of two independent experiments have been averaged; means
and s.e.m. are shown. BrdU, bromodeoxyuridine.
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Figure 3 A peptide mimicking the AR 377–386 sequence inhibits
the association between the receptor and Src and the Src/Erk
pathway in prostate and breast cancer-derived cells. (a) The 30min
uptake of ﬂuorescein-conjugated S1 or Ss (upper microphoto-
graphs) peptides in quiescent, unﬁxed LNCaP cells analysed by
confocal microscopy is shown. Lower images of (a) show the
ﬂuorescent conjugated S1 peptide incubated at 41C (left micro-
photograph) or 371C (right microphotograph). In (b), quiescent
LNCaP cells were left unstimulated or challenged for 3min with
10 nM R1881, in the absence or presence of the indicated
compounds. The antiandrogen Casodex (Cdx) was used at 10mM,
whereas the S1 (S1) and the shufﬂed (Ss) peptides were used at
1 nM. In (c), quiescent MCF-7 cells were left unstimulated or
stimulated for 3min with 10 nM estradiol in the absence or presence
of the indicated compounds. The antiestrogen ICI (ICI) was used
at 10 mM; the S1 (S1) and the shufﬂed (Ss) peptides were used at
1 nM. Lysates in (b and c) were immunoprecipitated with either
anti-Src MAb (upper panels) or anti-Erk-2 Ab (lower panels). In
the upper panels, immunocomplexes were either blotted with
antibodies against the proteins indicated by the arrows or assayed
for Src activity, using enolase as a substrate (en). In the lower
panels, immunocomplexes were either blotted with anti-Erk-2
antibody, or assayed for Erk-2 activity using MBP as a substrate.
AR, androgen receptor; ER, estradiol receptor; MBP, myelin basic
protein.
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estradiol effect on the ER transcriptional activity in
MCF-7 cells transfected with an ERE-luciferase gene
reporter (Figure 7b) were examined. In contrast with
classic androgen (Casodex) or estradiol (ICI) antago-
nists, the S1 or the Ss peptide did not signiﬁcantly affect
the hormonal action in both cell lines. This supports the
view that the S1 peptide inhibits only the non-genomic
action of AR or ER on DNA synthesis but has no
effect on transcriptional activation mediated by these
receptors.
Next, we analysed the effect of the S1 peptide on
LNCaP xenografts established in nude mice. Interest-
ingly, treatment with S1 peptide strongly inhibited
tumor growth of LNCaP cells, whereas a negligible
effect was observed upon treatment with the Ss
peptide (Figure 8a). At the conclusion of the
experiments, tumor tissues were analysed by immuno-
histochemistry for cell proliferation and apoptotic
index. The proliferation status of cancer cells was
determined by Ki67 positivity, which was signiﬁcantly
decreased (Po0.005) in LNCaP tumors treated with the
S1 peptide (Figure 8b and C2). In addition, the number
of terminal deoxynucleotidyl transferase biotin-dUTP
nick end labeling (TUNEL)-positive nuclei was also
signiﬁcantly increased (Po0.001) in the same tumors
(Figure 8b and 8d2), indicating that the peptide
treatment acts on both proliferation and apoptosis.
The peptide-treated mice did not show a decrease in
weight (not shown).
Discussion
The current therapy of prostate and mammary cancers
is based on the use of steroid antagonists. However, this
approach is limited by the mixed, antagonist and agonist
action of these molecules, their side effects, and the
appearance of hormone resistance. Estradiol, progestins
and androgens induce G1 to S transition of cells derived
from human mammary and prostate cancers through
activation of signal transducing pathways (Castoria
et al., 1999; Migliaccio et al., 2000). These ﬁndings open
potential new approaches to the therapy of hormone-
dependent cancers. In principle, such new therapy could
be more speciﬁc than the classical therapy with steroid
antagonists. This is because the classic antagonists, in
addition to abolish the receptor-dependent signaling
pathways, also inhibit the receptor transcriptional
action. This action is not required for the steroid-
stimulated DNA synthesis of mammary and prostate
cancer-derived cells in vitro (Castoria et al., 1999;
Migliaccio et al., 2000) but is relevant to positive actions
of sex-steroid hormones, such as neuroprotection and
bone preservation.
Simultaneous ER and AR association with Src is the
initial event triggered during sex steroid-induced G1 to S
transition of MCF-7 and LNCaP cells (Migliaccio et al.,
2000). The same association is required in the same cells
for EGF-induced DNA synthesis (Migliaccio et al.,
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E2 − + + + +
Inhib. − − PP2 S1 Ss
cyc D1
MCF-7
R1881 − + + + +
Inhib. − − PP2 S1 Ss
cyc D1
E2 − + + + +
Inhib. − − PP2 S1 Ss
b d
a c
Figure 4 The S1 peptide inhibits the hormone-stimulated G1 to S progression of human prostate and breast cancer-derived
cells. LNCaP (a and b) and MCF-7 (c and d) cells were made quiescent, and then left untreated or treated with the indicated
compounds at the following concentrations: 10 nM of R1881 or estradiol, 10mM of the Src inhibitor, PP2 (Calbiochem), 1 nM of the S1
or Ss peptides. The antiandrogen Casodex and the antiestrogen ICI were used at 10 mM. In (a and c), lysates were collected after 8 h and
analysed for cyclin D1 expression. In (b and d), quiescent cells on coverslips were left unstimulated or stimulated with the indicated
compounds for 24 h. After in vivo pulse with BrdU, the cells were stained for BrdU incorporation. DNA synthesis was calculated as in
Figure 2. Data are derived from at least 3000 scored cells. The results of six independent experiments have been averaged; means and
s.e.m. are shown.
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receptors with Src in response to a single signal is due to
the presence of an ER/AR complex in unstimulated
mammary and prostate cancer-derived cells (Migliaccio
et al., 2005). Therefore, a single steroid antagonist
(antiestrogen or antiandrogen) can equally block the
androgen or the estradiol-induced association of the
ER/AR complex with Src (Migliaccio et al., 2000, 2005).
Because of the crucial role of receptor/Src interaction in
steroid- or growth factor-triggered cell proliferation
(Migliaccio et al., 2000, 2005), we speculated that this
association might be a target for speciﬁc anticancer
drugs. These drugs, in contrast to general signal
transducing inhibitors, should spare signal-transducing
pathways not involved in the steroid receptor action.
Parallel use of deletion AR mutants and synthetic
peptides mirroring the deleted sequences in functional
assays show that the entire 372–379 proline stretch or a
part of it and the adjacent sequence including the
arginine amino acid plays an important role in the AR/
Src association. Use of the S1 peptide directly proves the
link between the association, Src/Erk activation, cyclin
D1 expression and the S phase entry. Similar concentra-
tions of a peptide with the same composition but a
shufﬂed sequence show a weak inhibition of the same
processes suggesting that, although many peptides
containing prolines might be slightly inhibitory, only
peptides exactly repeating the AR proline-rich sequence
can exert a strong negative effect. Remarkably, experi-
ments in AR-negative cells stimulated by EGF show
that the peptide does not interfere in the DNA synthesis.
In the same cells, EGF-induced cytoskeletal changes,
which also depend on Src activity, are unaffected by the
peptide. These data show that AR is required for the
observed inhibitory effects of the peptide treatment.
Furthermore, the steroid receptor-dependent transcrip-
tional activity is unaffected by the peptide. All together,
these ﬁndings show that this compound is a speciﬁc
antagonist of the signaling activation dependent on
steroid receptors.
NIH3T3 cells as well as mouse embryo or mouse
female adult ﬁbroblasts express a very low amount of
AR (Castoria et al., 2003). This receptor mediates a
robust DNA synthesis induced by androgens in these
cells. Such a response also requires AR/Src association
and Src activation. Interestingly, NIH3T3 cells, unlike
the mammary and prostate cancer cells, do not respond
to androgen with receptor dependent transcriptional
activity. Therefore, they represent a model useful for the
analysis of receptor antagonist action independently of
the receptor transcriptional activity. We are additionally
interested in these cells since stromal cells, through a
cross talk with epithelial cells, have a role in the
development and carcinogenesis of both the prostate
and the mammary gland (Coussens and Werb, 2002;
Cunha et al., 2002). For this reason, interference of the
inhibitory peptide in AR/Src complex assembled upon
androgen or growth factor stimulation of ﬁbroblasts
might also affect the interactions between stromal and
epithelial cells, and in such a way contribute to slow
down cancer growth. The ability of the peptide to inhibit
the G1 to S transition of NIH3T3 ﬁbroblasts stimulated
by androgen is additional evidence that this inhibitory
effect does not require the receptor transcriptional
activity.
Furthermore, the S1 peptide inhibits DNA synthesis
induced by EGF in prostate and breast cancer cells. This
is an important point, since many human malignancies
express high levels of growth factors and their receptors.
Activation of growth factor receptors by autocrine or
paracrine mechanisms has also been described in human














































Figure 5 The S1 peptide inhibits the S phase entry induced by
EGF in LNCaP, MCF-7 and NIH3T3 cells. LNCaP (a), MCF-7
(b) and NIH3T3 (c) cells on coverslips were made quiescent, then
left untreated or treated with the following compounds: R1881
(1 pM), EGF (Roche, Basel, Switzerland; 100 ng/ml), S1 and Ss
peptides (1 nM). The antiandrogen Casodex and the antiestrogen
ICI were used at 10 mM. After in vivo labeling with BrdU, the cells
were stained for BrdU incorporation. DNA synthesis was
calculated as in Figure 2. Data are derived from at least 2000
scored cells. For LNCaP and MCF-7 cells, the results of two
independent experiments have been averaged. For NIH3T3
ﬁbroblasts, the results of four independent experiments have been
averaged. Means and s.e.m. are shown. BrdU, bromodeoxyuridine;
EGF, epidermal growth factor.
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factor action by the S1 peptide may contribute to the
observed strong inhibition of the xenografts growth.
The peptide treatment signiﬁcantly increases the number
of cells undergoing apoptosis in LNCaP tumor xeno-
grafts in agreement with the view that hormonal
activation of Src protects target cells from apoptosis
(Singer et al., 1999; Kousteni et al., 2001).
In recent years, much evidence has shown that in
multiple cell types under different experimental condi-
tions, steroid receptors directly interact with several
signaling effectors and trigger various biological effects.
In addition to Src, these effectors include calmodulin
(Castoria et al., 1988), the regulatory subunit of the
phosphoinositide 3-kinase, p85a (Simoncini et al., 2000;
Castoria et al., 2001), Shc (Song et al., 2002), modulator
of non genomic activity of receptor (Wong et al., 2002),
protein kinase Cz (Castoria et al., 2004), EGF receptor
(Marquez et al., 2001; Migliaccio et al., 2005), and many
other signaling or signaling-related proteins. Therefore,
approaches similar to those followed in this report,
that is, recognition of new receptor/signaling effector
interactions and identiﬁcation of new inhibitors of such
interactions, could enable us to speciﬁcally inhibit
different hormone actions mediated by signal transduc-




The cDNA coding hAR was cloned into the pSG5 expression
vector, as reported previously (Chang et al., 1988). The hAR
deletion mutants D1, D2 and D3, lacking part of the proline-
rich region spanning from 372 to 386 AA, were generated
using in vitro site-directed mutagenesis. The mutants D2
(D372–378) and D3 (D380–386) were constructed from the
hAR using the Gene Tailor Site-direct Mutagenesis System
(Invitrogen, Carlsbad, CA, USA) and the mutagenic primers
50-TTTCCACTGGCTCTGGGCGGACCCCATCCCC-30 and 50-
CCCCCTCCGCCGCCTCCCCTGGAGAACCC-30, respectively.
The mutant D1 (D372–385) was generated from AR mutant D2,




























































































S1 Ss− S1 Ss−
S1 Ss− S1 Ss−
Figure 6 The S1 peptide does not affect the serum-induced S phase entry of AR-positive cells and the EGF- or serum-induced DNA
synthesis and the EGF-induced cytoskeletal changes of AR-negative cells. NIH3T3, LNCaP and MCF-7 cells on coverslips were made
quiescent and then left untreated or treated with the following compounds: 1 pM (NIH3T3) or 10 nM (LNCaP) R1881, 20% serum,
1 nM of S1 or Ss peptide (a). AR-negative PC3 (b) or DU145 (c) cells on coverslips were made quiescent by serum starvation (0.5%
serum) and then untreated or treated with the following compounds: 100 ng/ml EGF, 20% serum, 1 nM S1 or Ss peptide. After in vivo
labeling with BrdU, DNA synthesis was evaluated as in Figure 2. Data are derived from at least 500 scored cells. The results of two
independent experiments have been averaged. Means and s.e.m. are shown. DU145 cells (d) on coverslips were made quiescent by
serum starvation (0.1% serum) and then untreated or treated for 30min with 100 ng/ml EGF in the absence or presence of 1 nM S1
peptide or 5mM PP2. PP2 was added 10min before EGF stimulation. Cells were labeled with Texas red-conjugated phalloidin and then
visualized by ﬂuorescence microscopy. BrdU, bromodeoxyuridine; EGF, epidermal growth factor.
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GAAAGCTGGAGAAC-30. All constructs were veriﬁed by
sequencing. The 3416 construct, containing four copies of the wt
slp-HRE2 (50-TGG-TCAgccAGTTCT-30), was cloned in the NheI
site in pTK-TATA-Luc (Verrijdt et al., 2000).
Cell culture, transfection and transactivation assay
Human mammary cancer MCF-7 cells, fast growing human
prostate cancer LNCaP cells, Cos cells and low-passage mouse
embryo NIH3T3 ﬁbroblasts were grown and made quiescent
as reported (Castoria et al., 1999, 2003; Migliaccio et al., 2000).
Human prostate carcinoma-derived PC3 and DU145 cells were
cultured as described (Pandini et al., 2005; Bonaccorsi et al.,
2006). Cos cells were made quiescent and transfected as
reported (Migliaccio et al., 2000), using 2 mg of puriﬁed
plasmids. Twenty-four hours later, transfected cells were left
unstimulated or stimulated with the indicated compounds. The
androgen-stimulated transcriptional assay in Cos cells
was carried out as described (Castoria et al., 2003). For
androgen- and estradiol-stimulated transcriptional analysis,
LNCaP and MCF-7 cells were made quiescent and then
transfected by Superfect (Qiagen, Hilden, Germany) with 4mg
of puriﬁed plasmids. Twenty-four hours later, transfected cells
were left unstimulated or stimulated with the indicated
compounds. Lysates were prepared and the luciferase activity
was measured using a luciferase assay system (Promega,
Madison, WI, USA). The results were corrected using CH110-
expressed b-galactosidase activity (Amersham Bioscience,
Bucks, UK).
Mouse xenografts
LNCaP cells suspended in 50% (v/v) Matrigel solution in
phosphate-buffered saline (PBS) (pH 7.4) were subcutaneously
injected in the dorsal posterior region at 2.5 106 cells/male
athymic mice (CD mice, Charles-River Italia, Milano, Italy)
without hormone priming. After 14–21 days, animals with
tumors of similar size were randomly selected for the treatment
with the Src-S1 peptide (S1-peptide) or the Ss peptide
or vehicle alone for an additional 5 weeks. Treatment
was initiated with tumors at approximately 200–400mm3 in
size. Tumor volumes of LNCaP cells xenografts were
measured by a caliper and recorded according to the formula
D d2 0.5 (D represents the length and d the width of
tumor). For the peptide treatment of each animal, 200 ml of
20 nM S1 peptide dissolved in 0.1% dimethylsulfoxide or the
same amount of Ss peptide or vehicle alone were intraper-
itoneally administered on alternate days to the mice. No
difference in body weight was detected between control mice or
peptide-treated mice.
Ki67 antigen and TUNEL assays in tumor specimens
At the end of the treatments, the mice were killed and tumor
specimens assayed for Ki67 antigen and apoptotic index.
Sections from each specimen were cut at 3–5mm, mounted on
glass and dried overnight at 371C. They were then depar-
afﬁnized in xylene, rehydrated through a graded alcohol series
and washed in PBS, which was used for all the subsequent
washes as well as the antibody dilution. After the staining with
hematoxylin/eosin and hematoxylin/Van Gieson, the sections
were analysed by light microscopy. For immunohistochemis-
try, tissue sections were heated two times in a microwave oven
for 5min at 700W in citrate buffer (pH 6), and then processed
with the standard streptavidin–biotin–immunoperoxidase
method (DAKO Universal Kit, DAKO Corporation, Carpin-
teria, CA, USA). Rabbit anti-human Ki67 (DAKO) was used
(at ﬁnal dilution 1:100) for 1 h at room temperature.
Diaminobenzidine was used as chromogen, and hematoxylin
as the nuclear counterstain. For each tissue section, negative
and positive controls were performed, either leaving out the
primary antibody or using tissue expressing the antigen of
interest. TUNEL reaction was performed using the peroxidase-
based Apoptag kit (Oncor, Gaithersburg, MD, USA).
TUNEL-positive cells were detected with diaminobenzidine
and H2O2, according to the supplier’s instructions. For each
specimen, the staining pattern as well as the score of Ki67 or
apoptotic cells was evaluated by scanning the entire section
and estimating the number of positive cells visible for high-
power ﬁeld 10 20.
DNA synthesis analysis and cytoskeletal changes
For bromodeoxyuridine (BrdU) incorporation analysis,
quiescent cells on coverslips were left unstimulated or
stimulated for 24 h with the indicated compounds. After a
6 h pulse with 100mM BrdU (Sigma, St Louis, MO, USA),








































R1881 − + + + +
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Figure 7 The S1 peptide does not interfere in the steroid receptor-
dependent transcriptional activity in human prostate and breast
cancer-derived cells. ARE 3416 or ERE/luc constructs were
transiently transfected into LNCaP (a) or MCF-7 (b) cells. Cells
were made quiescent, and then left unstimulated or stimulated for
18 h with 10 nM of either R1881 or estradiol, in the absence or
presence of the indicated compounds. The S1 and Ss peptides were
used at 1 nM. The antiandrogen Casodex and the antiestrogen ICI
were used at 10mM. The luciferase activity was assayed, normalized
using b-gal as an internal control and expressed as arbitrary units
of luciferase activity.
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1999) using Alexa Fluor 594-conjugated mouse monoclonal
anti-BrdU antibody (Molecular Probes, Eugene, OR,
USA). The coverslips were ﬁnally stained with Hoechst
33258, inverted and mounted in Mowiol (Calbiochem, CA,
USA). For cytoskeletal analysis, cells on coverslips were
made quiescent by serum starvation (0.1% serum) for
24 h. They were then left unstimulated or stimulated for
20min with the indicated compounds. F-actin was visualized
using Texas red-labeled phalloidin as reported (Castoria et al.,
2003). Coverslips were mounted in Mowiol (Calbiochem,
Darmstadt, Germany). The ﬁelds were analysed with a DMLB
ﬂuorescent microscope (Leica) equipped with  40 and  63
objectives. Images were generated using FW4000 (Leica)
software.
Uptake analysis of labeled peptides
For this analysis, exponentially growing cells were dissociated
with a non-enzymatic cell dissociation medium (Sigma). About
2.5 105 cells were plated and cultured overnight on 30mm
plates on a glass coverslips. The cells were then made
quiescent. The medium was discarded, and the cells were
washed with NaCl/Pi (pH 7.3). NaCl/Pi was discarded, and the
cell monolayer was incubated with the S1 and the Ss peptides
conjugated to 5-(6)-carboxyﬂuorescein succinimidyl ester
(Molecular Probes). Fluorescein-conjugated peptides were
dissolved in Opti-MEM and added (at 1 nM) at 371C or 41C
for 30min to the cell medium. For direct detection of
ﬂuorescein-labeled peptides, the cells were washed three times










































































Figure 8 The S1 peptide inhibits the growth of LNCaP xenografts. In (a), LNCaP xenografts were established in nude mice as
described in Materials and methods. Tumors were treated with either S1 peptide (S1) or the shufﬂed sequence peptide (Ss) or vehicle
alone (vehicle) and tumor volume was measured. n represents the number of experiments. Means and s.e.m. are shown. Tumor
specimens in (a) were analysed by immunohistochemistry for Ki67 and apoptotic index by TUNEL. In (b), the score of Ki67 was
evaluated (upper panel) and expressed according to the formula: number of Ki67-positive cells (number of Ki67-positive cells/number
of total nuclei) 100. The score of apoptotic cells (lower panel) was evaluated by estimating the number of TUNEL-positive cells/ﬁeld.
In (c), photomicrographs of Ki67 immunoreactivity of the mice treated with vehicle alone (C1) or S1 peptide (C2) are shown. In (d),
photomicrographs of apoptotic cells of the mice treated with vehicle alone (D1) or S1 peptide (D2) are presented. TUNEL, terminal
deoxynucleotidyl transferase biotin-dUTP nick end labeling.
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medium (Vector Laboratories, Burlingame, CA, USA). The
distribution of ﬂuorescence was analysed by a confocal LSM
510 Zeiss microscope.
Lysates, immunoprecipitation and kinase assays
Lysates were prepared as described previously (Migliaccio
et al., 1996), and protein concentration was measured with a
Bio-Rad protein assay kit (Bio-Rad, Hercules, CA, USA).
Equal amounts of cell lysates (at a protein concentration of
2mg/ml) were immunoprecipitated with either mouse mono-
clonal anti-Src antibody (clone 327; Calbiochem) or rabbit
polyclonal anti-Erk-2 antibody (C-14; Santa Cruz Biotechno-
logy, Santa Cruz, CA, USA). Src and Erk-2 kinase assays were
performed as described (Migliaccio et al., 1996, 1998).
Electrophoresis and immunoblotting
The electrophoresis and immunoblotting procedures were
performed as described elsewhere (Migliaccio et al., 1998).
Src was revealed using the mouse monoclonal anti-Src
antibody (clone 327; Calbiochem), and Erk-2 was detected
using rabbit polyclonal anti-Erk-2 antibody (C14; Santa
Cruz). Cyclin D1 was detected using the mouse mono-
clonal antibody (AM20; Zymed, San Francisco, CA, USA).
The rabbit polyclonal anti-AR antibodies (either C-19 or
N-20; Santa Cruz) were used to reveal AR. ERa was
immunoblotted using the rabbit polyclonal anti-ER
(HC-20; Santa Cruz) antibody. Immunoreactive proteins
were revealed with the ECL detection system (Amersham
Bioscience).
Abbreviations
BrdU, bromodeoxyuridine; EGF, epidermal growth factor;
EGFR, epidermal growth factor receptor; ER, estradiol
receptor; hAR, human androgen receptor.
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p85 regulatory subunit of PI3K mediates cAMP–PKA and estrogens
biological effects on growth and survival
C Cosentino1, M Di Domenico2, A Porcellini3,4, C Cuozzo1, G De Gregorio4, MR Santillo5,
S Agnese1, R Di Stasio2, A Feliciello1, A Migliaccio2 and EV Avvedimento1
1Dipartimento di Biologia e Patologia Molecolare e Cellulare, Istituto di Endocrinologia ed Oncologia Sperimentale del CNR,
Universita` Federico II, Napoli, Italy; 2Dipartimento di Patologia Generale, II Universita` di Napoli, Napoli, Italy; 3Dipartimento di
Medicina Sperimentale e Patologia, Universita` di Roma ‘La Sapienza’, Roma, Italy; 4INM Neuromed, Pozzilli, Italy and
5Dipartimento di Neuroscienze-Sezione di Fisiologia, Universita` Federico II, Napoli, Italy
Cyclic adenosine 3050 monophosphate (cAMP) and protein
kinase A (PKA) cooperate with phosphatidylinositol 30
kinase (PI3K) signals in the control of growth and
survival. To determine the molecular mechanism(s)
involved, we identiﬁed and mutagenized a speciﬁc serine
(residue 83) in p85aPI3K, which is phosphorylated in vivo
and in vitro by PKA. Expression of p85aPI3K mutants
(alanine or aspartic substitutions) signiﬁcantly altered the
biological responses of the cells to cAMP. cAMP
protection from anoikis was reduced in cells expressing
the alanine version p85aPI3K. These cells did not arrest in
G1 in the presence of cAMP, whereas cells expressing the
aspartic mutant p85D accumulated in G1 even in the
absence of cAMP. S phase was still efﬁciently inhibited by
cAMP in cells expressing both mutants. The binding of
PI3K to Ras p21 was greatly reduced in cells expressing
p85A in the presence or absence of cAMP. Conversely,
expression of the aspartic mutant stimulated robustly the
binding of PI3K to p21 Ras in the presence of cAMP.
Mutation in the Ser 83 inhibited cAMP, but not PDGF
stimulation of PI3K. Conversely, the p85D aspartic
mutant ampliﬁed cAMP stimulation of PI3K activity.
Phosphorylation of Ser 83 by cAMP–PKA in p85aPI3K
was also necessary for estrogen signaling as expression of
p85A or p85D mutants inhibited or ampliﬁed, respec-
tively, the binding of estrogen receptor to p85a and AKT
phosphorylation induced by estrogens. The data presented
indicate that: (1) phosphorylation of Ser 83 in p85aPI3K is
critical for cAMP–PKA induced G1 arrest and survival in
mouse 3T3 ﬁbroblasts; (2) this site is necessary for
ampliﬁcation of estrogen signals by cAMP–PKA and
related receptors. Finally, these data suggest a general
mechanism of PI3K regulation by cAMP, operating in
various cell types and under different conditions.
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Introduction
Cyclic adenosine 3050 monophosphate (cAMP) regulates
the growth of many cells types (Pastan et al., 1975).
Although cAMP can promote the growth of some cells,
such as Swiss 3T3 ﬁbroblasts and thyrocytes (Lee et al.,
1998; Ariga et al., 2000), it inhibits proliferation in
most cells (Magnaldo et al., 1989). However, the precise
mechanism by which cAMP inhibits cell cycle entry
and progression remains undeﬁned (Houslay and
Kolch, 2000). cAMP prevents cells from entering S
phase and arrests the cells in G1 (Kato et al., 1994).
Furthermore, cAMP inhibits proliferation stimulated by
either G protein-coupled receptors or receptor tyrosine
kinases (Magnaldo et al., 1989), suggesting that it
targets a signaling pathway that is central to cell cycle
progression.
Stimulation of growth by cAMP–protein kinase A
(PKA) in selected cell types, as thyroid cells, is tightly
dependent on Ras and phosphatidylinositol 30 kinase
(PI3K) (Ciullo et al., 2001). Also, cAMP and PKA are
powerful survival signals in several cell types (Affaitati
et al., 2003). To date the mechanism(s) and the relevant
players mediating cAMP effects on growth and survival
are not completely known.
We have previously shown that cAMP and PKA
regulate Ras signaling, by selectively stimulating Ras–
PI3K complex. Also, we have found that p85aPI3K was
an efﬁcient PKA substrate in vitro (Ciullo et al., 2001).
Here we report that Ser 83 in the p85aPI3K is
phosphorylated in vivo by PKA and that the corre-
sponding mutants (p85A or p85D) inhibit or amplify
cAMP biological effects on growth and survival. This
site is also relevant for the interaction of p85aPI3K with
estrogen receptor a, as the mutants inhibit or amplify
estrogen signaling to PI3K. Finally, we demonstrate that
cAMP in the absence of serum stimulates PI3K and that
p85aPI3K mutants selectively interfere with cAMP stimu-
lation of PI3K activity.
These data provide a molecular framework that
explains the synergism between cAMP and different
types of receptors, and add another level of com-
plexity to the regulation of PI3K and Ras p21 by
cAMP–PKA.
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Results
PKA phosphorylates Ser 83 in p85aPI3K
p85a subunit of PI3K can be efﬁciently phosphorylated
by PKA in vitro (Ciullo et al., 2001). A possible PKA
target sequence is Ser 83, which is highly conserved
in evolution and is preceded by basic residues in
bovine/human (KKIS) and mouse/rat (KRIS)
sequences.
To determine the relevance of this site in vivo, we have
substituted Ser 83 with alanine (p85A) to prevent
phosphorylation or with aspartic acid (p85D) to mimic
the phosphorylated residue. The tagged recombinant
proteins were transiently expressed in HeLa or NIH3T3
cells and immunoprecipitated with anti-ﬂag antibody.
Immunoprecipitates were incubated in vitro with pur-
iﬁed catalytic PKA subunit in the presence of [32g-
P]ATP. p85aPI3K wild type was efﬁciently phosphory-
lated by PKA whereas p85A was not, indicating that Ser
83 was the site phosphorylated by PKA in vitro
(Figure 1a). PKA-phosphorylated p85aPI3K was also
identiﬁed in vivo in breast cancer cells MCF7 extracts
immunoblotted with an antiphosphoserine antibody.
Figure 1b shows that p85aPI3K, not p85A, was recognized
by the phosphoserine antibody in extracts of MCF7 cells
treated with cAMP. Figure 1c shows the same experi-
ment performed in NIH3T3 cells expressing p85aPI3K
and p85A. The p85A protein was not recognized by the
antiphosphoserine antibody. Phosphorylation of
p85aPI3K was prevented by incubating the cells with the
PKA kinase inhibitor H89 (Figure 1c). The endogenous
protein p85aPI3K was also phosphorylated in NIH3T3
cells stimulated with cAMP. Phosphorylation was
inhibited by pretreating the cells with H89 (Figure 1d).
Taken together these data indicate that PKA phos-
phorylates p85aPI3K at Ser 83.
p85aPI3K mutants alter cAMP cytoprotection and growth
inhibition
To test the biological relevance of Ser 83 phosphoryla-
tion of p85aPI3K, we determined in mouse ﬁbroblasts the
rate of anoikis, a speciﬁc apoptotic pathway triggered by
loss of cell adhesion to the extracellular matrix (Frisch
and Francis, 1994; Khwaja et al., 1997). We co-
transfected NIH3T3 cells with a GFP encoding vector
and the wild type or the mutant versions of p85aPI3K
(Figure 2a and b). At 48 h after transfection, the cells
were plated on 2% agarose in a medium containing
0.1% calf serum in presence or absence of 200 mM
cAMP. After 5 h, we determined the fraction of
apoptotic cells by ﬂuorescent activated cell sorter
(FACS) analysis. Figure 2b shows that treatment with
cAMP signiﬁcantly reduced the number of apoptotic
cells. cAMP cytoprotection was abolished by wortman-
nin, a PI3K inhibitor (data not shown and Khwaja
et al., 1997). Expression of wild-type p85aPI3K ampliﬁed
cAMP response (see n in Figure 2b), whereas expression
of p85A completely eliminated cAMP ampliﬁcation,
displayed by wild-type p85aPI3K (Figure 2b). Cells
expressing p85D, on the other hand, were signiﬁcantly
more resistant to anoikis in the absence of cAMP (see nn
in Figure 2b). The low response to cAMP of these cells
was probably dependent on the low levels of p85D
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Figure 1 Phosphorylation in vivo and in vitro of Ser 83 in p85aPI3K by cAMP–PKA. (a) In vitro phosphorylation of wild-type p85aPI3K
or p85A. HeLa cells were transiently transfected with p85aPI3K-ﬂag wild type or p85A; 48 h after transfection, cell lysates were
immunoprecipitated with non-immune IgG or anti-ﬂag antibody for 15 h. A/G bound immunoprecipitates were in vitro
phosphorylated with cPKA as described in Material and methods. Sample aliquots were run on SDS–PAGE and subjected to
immunoblot (upper panel) or autoradiography (bottom panel). (b) In vivo phosphorylation of wild-type p85aPI3K or p85A. MCF7 cells
were made quiescent using charcoal-treated serum and medium lacking phenol-red for 3 days. Quiescent cells were transfected with
p85aPI3K or p85A. At 24 h after the transfection cells were treated with 100 mM cAMP. Protein lysates were immunoprecipitated with
anti-ﬂag antibody for 15 h, separated on 10% SDS–PAGE and immunoblotted with anti-p85PI3K (upper panel) or antiphosphoserine
(lower panel) antibodies. The arrow indicates p85aPI3K band. (c) NIH 3T3 were transfected with p85aPI3K or p85A. At 24 h after
transfection, the cells were treated with 100 mM cAMP in the presence or absence of the protein kinase A inhibitor, H89 (10mM). In
parallel cultures (d) un-transfected (nt) NIH3T3 cells, starved in DMEM 0.1% calf serum for 16 h, were treated with 100 mM cAMP for
10min in the presence or absence of 10mM H89. Cell lysates were immunoprecipatated with anti-p85a antibody and immunoblotted
with anti-p85a (upper panel) or anti-phosphoserine (lower panel) antibodies.
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mediates cAMP inhibition of anoikis and that phos-
phorylation of Ser 83 is an important signal for cAMP-
induced-survival.
To test if p85aPI3K mediated also cAMP inhibition of
growth in mouse NIH3T3 ﬁbroblasts, we analysed the
biological effects of p85aPI3K mutants on growth arrest
induced by cAMP. NIH3T3 ﬁbroblasts were cultured in
low serum in the presence or absence of cAMP. Under
these conditions, cAMP induced a robust and reversible
inhibition of cell growth by accumulating the cells in G1
phase and reducing the fraction of cells entering S phase
(see n in Figure 2c and d). Cells expressing p85A did not
efﬁciently arrest in G1 in the presence of cAMP
(Figure 2c). Conversely, in cell lines expressing the
aspartic mutant, cAMP response was lost and the
fraction of cells accumulating in G1 was signiﬁcantly
higher than in cells expressing p85A (see nn in
Figure 2c). The fraction of cells arrested in S phase in
the presence of cAMP was robustly stimulated in the
control and cells expressing the wild-type p85aPI3K (see n
in Figure 2d). Cells expressing the mutant versions of
p85aPI3K did not respond to cAMP and the fraction of
cells transiting S increased (see Figure 2d, p85Annn) or
decreased (see Figure 2d, p85Dnnn) relative to control
or wild-type p85aPI3K cells. These data indicate a higher
(p85D) or lower rate of G1 arrest (p85A) of these cell
lines, independently on cAMP presence in the medium.
The high statistical signiﬁcance of S phase values,
relative to G1, is due to the lower value of S phase cell
fraction. To discriminate more precisely the effects of
cAMP in G1 or S phases in cells expressing p85aPI3K
mutants, we performed a kinetic analysis of the cell cycle
by labeling the cells with BrdU. Under these conditions,
the entry and the progression in S phase of transfected
cells can be precisely determined. Figure 2e shows that










































































































Figure 2 Phosphorylation of p85aPI3K Ser 83 mediates cAMP biological effects on growth and survival. NIH3T3 cells were transiently
transfected with p85aPI3K-ﬂag wild type or mutant versions. A GFP expression vector encoding green ﬂuorescence protein was used as
reporter. At 48 h after transfection, cells were plated on 2% agarose in DMEM 0.1% CS without or with cAMP 200 mM for 5 h and the
fraction of apoptotic cells was determined by FACS analysis. (a) Extracts of transfected cells immunoblotted with anti-p85aPI3K
antibody. Exogenous p85aPI3K is represented by the upper band in the doublet. (b) Quantitative analysis of FACS data. White and
black columns represent, respectively, untreated or cAMP-treated samples. The data are the mean of four independent experiments; n
indicates Pp0.01 comparing cell death in the presence of cAMP in all samples. The p85A (ALA) sample is signiﬁcantly different from
p85aPI3K (WT), but not from CTRL or p85D (ASP). To analyse the growth, NIH3T3 cells were transiently transfected with the
constructs indicated above. At 24 h after the transfection, the cells were serum-starved 15 h and induced into the cycle with 2% serum in
the presence or absence of cAMP (200 mM for 6 h). After 12 h the cells were subjected to FACS analysis. The quantitative analysis of
FACS data relative to G1 phase (c) or S phase (d) was derived from three independent experiments and analysed by Student paired T-
test. Black and gray columns represent respectively untreated or cAMP-treated samples. n indicates Pp0.01 basal versus cAMP;
nnPp0.01 basal p85A versus p85D; nnnPp0.01 basal p85a wild type, A or D-transfected cells versus control plasmid-expressing cells.
(e) Pulse (300)-chase of BrdU incorporation in transfected cell lines in the presence or absence of cAMP. The columns represent the
fraction of labeled cells stained with propidium iodide at 0 (black columns), 90 (gray columns) and 270min (white columns) from the
initial cell cycle induction (10% serum). The data are the mean of three independent experiments.
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although p85A-expressing cells transited S phase very
rapidly, compared to control or p85D expressing lines in
the presence of cAMP. Cells expressing p85A were
unrestrained in G1 in the presence of cAMP and entered
S phase more efﬁciently than control or p85D-expres-
sing cells. Taken together, these data indicate that Ser 83
in the p85aPI3K is critical for cAMP-induced G1 arrest on
cell cycle progression. Alanine substitution of Ser 83
abolished G1 arrest by cAMP. p85D, on the other hand,
increased the number of cells arrested in G1 in the
absence of cAMP (see nn in Figure 2d).
p85aPI3K (ser83) phosphorylation increases association of
to p21 Ras
We have previously shown that cAMP PKA selectively
increased the association between PI3K and p21 Ras
(Ciullo et al., 2001). As this complex can mediate
cAMP–PI3K effects on growth and survival, we set out
to determine the formation of p21 Ras–PI3K complex in
cells expressing wild-type p85aPI3K or p85A or p85D.
NIH3T3 were transfected with p85aPI3K wild type or
p85A or p85D and 36 h after transfection, the cells were
serum starved for 16 h before 10min treatment with
cAMP. Cell lysates were immunoprecipitated with anti-
ﬂag antibody and then analysed by Western blot with
anti-Ras antibody. In the presence of cAMP, p85aPI3K
wild type efﬁciently was found associated with p21 Ras.
This association was signiﬁcantly inhibited in cells
expressing p85A and stimulated in p85D expressing
cells. In the absence of cAMP, Ras–PI3K complex was
barely detectable in all the samples. In p85D-expressing
cells, however, cAMP stimulated robustly association of
PI3K to p21 Ras, suggesting that Ser 83 in p85aPI3K
cooperates with another cAMP–PKA signal to regulate
PI3K association with p21 Ras (Figure 3a and b). We
also tested the effects of H89 on the formation of the
Ras–PI3K complex. H89 treatment reduced the complex
Ras–PI3K to the levels found in p85A-expressing cells
(Figure 3c). These data indicate that under conditions of
cAMP stimulation, the interaction Ras–PI3K is sig-
niﬁcantly favored.
p85aPI3K (Ser 83) phosphorylation selectively ampliﬁes
PI3K signaling by cAMP
To directly test the hypothesis that cAMP stimulation
ampliﬁed Ras–PI3K signalling, we stimulated the cells
with cAMP or PDGF and determined AKT and GSK
phosphorylation, downstream targets of PI3K.
Figure 4a shows that cAMP and PKA stimulated the
phosphorylation of AKT and GSKa and that H89
reversed cAMP effects. To test if p85aPI3K mutants
interfere also with other pathways that signal to PI3K,
we determined PDGF stimulation of AKT and ERK1/2,
the two major kinases downstream to PDGFR.
Figure 4b shows that expression of p85A and p85D
did not signiﬁcantly inﬂuence PDGF stimulation of
ERK1/2 or P-AKT accumulation. p85A-expressing
cells, on the other hand, poorly phosphorylated AKT
or GSKa in response to cAMP. Conversely, expression
of p85D increased the basal P-AKT and P-GSKa and
robustly ampliﬁed cAMP response (Figure 4c and d).
So far we have analysed the effects of p85aPI3K
variants on indirect effectors of PI3K signaling. To
directly test the relevance of cAMP induced phosphor-
ylation of p85aPI3K on PI3K activity, we have measured
the activity of the enzyme in cells expressing wild type or
the mutant versions of p85aPI3K. We have previously
reported that cAMP in the presence of serum did not
stimulate PI3K activity (Ciullo et al., 2001). As the
presence of serum can mask some important biological
effects of cAMP–PKA (Porcellini et al., 2003) and (De






























+ - + - +
cAMP - -+ + +
H89 - -- + -






Figure 3 cAMP stimulates the formation of PI3K/Ras complex. NIH-3T3 cells were transiently transfected with wild type or mutant
versions of p85aPI3K-ﬂag. At 36 h after transfection, the cells were starved for 16 h in DMEM, 0.1% calf serum and treated with cAMP
200mM for 10min. (a) Cells lysates were immunoprecipitated with anti-ﬂag antibody and blotted with anti-Ras or anti-p85aPI3K
antibodies. (b) The histograms represent the ratio of Ras-p85aPI3K bands in the p85aPI3K immunoprecipitates, derived from three
independent experiments. (c) NIH-3T3 were transiently transfected with wild-type p85aPI3K-ﬂag or p85A. At 36 h after transfection, the
cells were starved for 16 h in DMEM, 0.1% calf serum and treated with cAMP 200mM for 10min in the presence or absence of H89.
Cells lysates were immunoprecipitated with anti-Ras antibody and blotted with anti-Ras or anti-ﬂag antibodies.
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stimulation of transfected cells with cAMP in low serum
(0.2%). Figure 5 shows that cAMP stimulated PI3K
activity. The activation of PI3K was inhibited by
treatment of the cells with the PKA inhibitor, H89.
Moreover, cells expressing p85A did not activate PI3K
in response to cAMP, whereas efﬁciently activated
PI3K, when treated with PDGF. Conversely, p85D
ampliﬁed PI3K activity induced by cAMP and did not
signiﬁcantly inﬂuence PI3K stimulated by PDGF
(Figure 5, lower inset).
To determine if p85A altered the structure of the
protein and inhibited the formation of the PI3K
complex, we tested the ability of in vitro synthesized
p85aPI3K to interact and form a stable complex with
p110aPI3K. Supplementary Figure 1S shows that co-
translated p85aPI3K and p110aPI3K interact very efﬁ-
ciently. When tested under the same conditions, p85A
ability to interact with p110aPI3K was comparable to
that of the wild-type p85aPI3K (Supplementary
Figure 1S). p85D, on the other hand, formed a complex
with p110aPI3K synthesized in vitro, with a higher afﬁnity
than p85aPI3K wild type or p85A. These data indicate
that p85A does not disrupt the folding of p85aPI3K
protein or the ability to interact with p110aPI3K, whereas
p85D induces a conformational change that improves
the interaction with p110aPI3K. As p85D stimulates
cAMP-induced PI3K activity, we suggest that this
conformational change activating the enzyme is
mediated by phosphorylation of p85aPI3K in Ser 83
by PKA.
cAMP–PKA amplify estrogen binding and signaling to
PI3K
PI3K mediates also AKT activation by estrogens
(Simoncini et al., 2000; Castoria et al., 2001). As
p85aPI3K was efﬁciently phosphorylated by PKA in
MCF7, the breast carcinoma cell line, we asked whether
p85aPI3K phosphorylation on Ser 83 also affected PI3K
interaction with upstream effectors such as estrogen
receptor. Therefore, we analysed the phosphorylation of
AKT stimulated by estrogen. Cells expressing p85aPI3K
wild type or p85A or p85D were treated with estrogens
and stimulation of AKT was monitored with speciﬁc P-
AKT antibodies. Figure 6a shows that p85D ampliﬁed
AKT phosphorylation induced by estrogens and that
p85A abolished this stimulation. Also, induction of
GSK phosphorylation by estrogens was inhibited by
p85A expression (data not shown).
As estrogen stimulation of AKT was inhibited in cells
expressing p85A, we measured the fraction of the
estrogen receptor a bound to wild type and mutant
versions of p85aPI3K. Figure 6b shows that wild-type
p85aPI3K immunoprecipitated efﬁciently the receptor.
The binding of estrogen receptor to p85aPI3K was
stimulated by estrogens, as expected. cAMP did not
stimulate the binding per se in the absence of estrogens,
but ampliﬁed the action of estrogens on p85aPI3K
binding. H89, a PKA inhibitor, eliminated the binding
of the receptor to p85aPI3K. The p85A protein did not
bind the estrogen receptor in the presence or in the
absence of estrogens. Expression of p85D substituted
Figure 4 Serine phosphorylation of p85 selectively ampliﬁes cAMP signaling to AKT and GSK. (a) NIH3T3 cells were stimulated
with 8-Cl-cAMP (100mM) in the presence or absence of H-89 (10mM) for 10min. Total extracts were prepared and immunoblotted with
the speciﬁc antibodies indicated. (b and c) Immunoblots of extracts derived from cells transiently transfected with the p85aPI3K
expression vectors indicated. In (b) the cells were stimulated with PDGF (100 ng/ml) for 15min, 48 h after the transfection; in (c) the
cells were stimulated with 8-Cl-cAMP (100 mM) for 10 and 90min, respectively. (d) The histograms of the pGSKa/GSK ratio, evaluated
by densitometric analysis of Western blot with appropriate antibodies of extracts derived from cells transfected with the indicated
p85aPIK plasmids and stimulated with (black) or without (white) cAMP (100 mM) for 10min. Basal P-AKT in cells expressing p85D is
lower in (b) than in (c), because the cells were starved 24 h (b), instead of 16 h (c).
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cAMP by amplifying estrogen stimulated binding of the
receptor to p85aPI3K. H89 inhibited the binding of p85D
to estrogen receptor, indicating that another phosphor-
ylation PKA-dependent was necessary for the formation
of the complex estrogen-p85aPI3K.
These data indicate that phosphorylation by cAMP–
PKA of Ser 83 in p85aPI3K is required for estrogen
binding and signalling to PI3K.
Discussion
The data presented here indicate that the phosphoryla-
tion of p85aPI3K in a critical serine residue mediates
cAMP action on growth and survival. More speciﬁcally,
phosphorylation of Ser 83 in p85aPI3K shifts the signaling
ﬂow towards PI3K-driven pathways. Such a conclusion
is supported by several observations. The substitution of
Ser 83 with alanine inhibited cAMP effects on cell
survival and G1 arrest in NIH 3T3 ﬁbroblasts.
Conversely, the aspartic mutant of Ser 83 in p85aPI3K
stimulated cell survival in the absence of cAMP and
slowed down cell cycle cycle progression, replicating the
effects of cAMP. Ras binding to PI3K and AKT
phosphorylation were inhibited by expressing p85A
and were stimulated by p85D.
cAMP effects on growth and cell cycle progression are
very selective. cAMP–PKA act on at least three phases
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Figure 6 cAMP phosphorylation of p85aPI3K ampliﬁes estrogen
binding and signaling to PI3K. MCF-7 cells were made quiescent
by charcoal-treated serum and medium lacking phenol-red for 3
days. (a) Quiescent cells were transfected with p85aPI3K wild type or
p85A or p85D. After 24 h, the cells were treated with 10 nM E2 for
3min. Cell lysates were analysed by Western blot with anti-p85aPI3K
(upper panel), P-AKT (middle panel) or AKT (lower panel). (b)
Quiescent cells were transfected with the wild type or the mutant
versions of p85aPI3K. After 24 h, the cells were treated with 10 nM E2
for 3min or for 10min with 200mM cAMP, or with 10 nM E2 for
3min following a 10-min stimulation with 200mM cAMP. The cell
lysates were immunoprecipitated with anti-ﬂag antibody 15 h, as
described above. Sample aliquots were immunoblotted with anti-
ERa and anti-p85aPI3K antibodies to detect the PI3K/ER complex.
Lanes 5 and 14 show the complex estrogen receptor-p85aPI3K in
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Figure 5 cAMP stimulates PI3K activity in the absence of serum. Effects of p85aPI3K mutants on PI3K catalytic activity. NIH3T3 cells
were transfected with the p85aPI3K expression vectors indicated and stimulated with cAMP (100 mM) 20min in the presence or absence
of H89 (10mM) or PDGF (100 ng/ml) 15min, 48 h after transfection. Total extracts were prepared and subjected to
immunoprecipitation with anti-ﬂag antibody. Immunoprecipitates were quantiﬁed by immunoblot with anti-p85aPI3K antibodies
(p85aPI3K-ﬂag) and assayed for PI3K activity by using a mixture of lipids containing PI4-5 (see Materials and methods). PI-4-5 labeled
at position 3 is indicated by the arrow. The upper inset (a) shows PI3K activity associated with p85aPI3K-ﬂag wild type and the
immunoblot with anti-p85aPI3K antibody of the p85aPI3K-ﬂag immunoprecipitate. The lower inset (b) shows PI3K activity associated
with p85A and p85D, immunoprecipitated with the anti-ﬂag antibody. The immunoblot with the p85aPI3K antibody is shown below.
The histograms on the right show the statistical analysis of (a) and (b) derived from three experiments.
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of cell cycle. cAMP slows down G1, blocks S phase and
G2–M transition (Kato et al., 1994; Kurokawa and
Kato, 1998; Houslay and Kolch, 2000). Our data
indicate that p85aPI3K phosphorylation of Ser 83 controls
selectively G1–S transition (Figure 2).
PI3K is an important regulator of cell growth as it
links cell size, growth and cycle progression. For
example, constitutive expression of p110a increases cell
mass and size by stimulating the biosynthetic capacity of
the cells. However, if not restrained, p110 activity
impairs exit from the cell cycle (Alvarez et al., 2003).
We suggest that Ras–PI3K signals regulate the length of
G1 phase. cAMP by amplifying and stabilizing PI3K,
lengthens G1 and slows down G1–S transition. The net
result is an apparent G1–S block, which results in
increased biosynthetic activity and cell mass prior to
division. This is better shown in thyroid cells, FRTL5,
which are exquisitely dependent on TSH and cAMP for
growth and differentiation. In these cells, Ras and PI3K
are selectively required for G1 phase progression (Ciullo
et al., 2001). In thyroid cells, TSH induces PI3K activity
and stabilizes the complex Ras–PI3K. Also, expression
of p85 mutant (p85A) inhibits selectively the stimulation
of growth and PI3K activity induced by TSH (De
Gregorio et al., in press). In thyroid cells and in cells
expressing high levels of the regulatory subunit of PKA,
RIIb, p85aPI3K binds and anchors PKA. This binding is
ampliﬁed in cells expressing p85D and it is H89 resistant
(De Gregorio et al., in press). This suggests that
anchoring PKA to the membrane is a prerequisite for
cAMP–PKA biological effects.
Also, cAMP–PKA stimulate in the absence (Figure 5),
not in the presence of serum (Ciullo et al., 2001), PI3K
activity. This stimulation requires phosphorylation of
Ser 83 in in p85aPI3K, probably because phosphorylated
p85aPI3K induces a conformational change in the
p110aPI3K molecule (Supplementary Figure 1S) or
increases its afﬁnity to PKA (De Gregorio et al., in
press). The stimulation of PI3K activity by cAMP
appears to be very selective, as p85A or p85D mutants
did not interfere with PDGF (Figure 4) or EGF (De
Gregorio et al., in press) induced PI3K activity.
Although the cell lines we have used are not robustly
dependent on cAMP signaling for growth or differentia-
tion, our data indicate that PI3K-Ras signals are
ampliﬁed by cAMP both in cAMP-independent
(NIH3T3 ﬁbroblasts or breast MCF7 cells) or depen-
dent (thyroid) cells. In these latter cells, ampliﬁcation of
PI3K by cAMP is mainly triggered by TSH and PKA,
which binds p85aPI3K. The ampliﬁcation of the pathway
Ras–PI3K induced by cAMP is redundant in 3T3, but
not in thyroid cells, because in these latter cells
expression of p85A triggers apoptosis (De Gregorio
et al., in press).
We suggest that Ser 83 in p85aPI3K is an important
point of convergence of two parallel pathways: cAMP–
PKA and PI3K signals. In this framework, it is worth
noting that in Saccharomyces cerevisiae inactivation
of PI3K–TOR signalling is partly compensated by
iper-activation of cAMP–PKA (Rohde et al., 2004;
Zurita-Martinez and Cardenas, 2005).
Our data indicate that estrogen receptor signalling
was profoundly altered when p85A was expressed.
Accordingly, p85aPI3K binding to estrogen receptor was
severely impaired. Although PKA phosphorylates di-
rectly AKT and estrogen receptor (Cui et al., 2004), the
effects we described were mainly dependent on p85aPI3K,
as they were inhibited or ampliﬁed by expressing the
p85aPI3K alanine or aspartic mutants, respectively.
Moreover, we have data indicating that also induction
of estrogen responsive genes is inhibited by H89 and it is
signiﬁcantly altered in p85A-expressing cells (data not
shown). Estrogens stimulate adenylyl cyclase (Aronica
et al., 1994) and cAMP–PKA stimulate differentiation
of granulosa cells (Knecht et al., 1984). Our data
indicate that phosphorylation of Ser 83 in p85aPI3K by
cAMP PKA stabilizes the binding of activated receptor
to PI3K and stimulates PI3K activity.
General implications
The data presented above have broad implications
because they point to p85aPI3K as the physical link
between Ras, estrogen receptor and cAMP–PKA
(Figure 7). Also, we ﬁnd in many and unrelated cell
types that cAMP ampliﬁcation of PI3K is essential for
negative or positive cAMP effects on growth and
survival. Apparently, all receptors binding p85aPI3K can
cooperate with cAMP–PKA signals via phosphorylation
of Ser 83 in p85aPI3K. This may explain the pleiotropic
nature of the effects exerted by cAMP–PKA on several,
apparently unrelated, signaling cascades and illustrates




The cDNA encoding for p85aPI3K-ﬂag wild type was generated












Figure 7 Ampliﬁcation of estrogen and Gs protein-coupled
receptors (GPCR) signaling to PI3K. A scheme outlining the
effects of cAMP–PKA activation by Gs protein coupled receptors
on PI3K signaling by estrogens. PKA and cAMP arrows on the
right side indicate other cAMP–PKA targets that amplify Ras–
PI3K interaction. p85aPI3K links receptors coupled to G proteins to
estrogens and Ras–PI3K signals.
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Terminus of bovine p85aPI3K cDNA in the pSG5 vector (gift of
Dr J Downward). The region of p85aPI3K from the XhoI
restriction site in position 1014 (Acc. No: 163476) was
ampliﬁed by PCR with a 30 end primer containing the ﬂag
sequence and a BamHI restriction site. The PCR product was
subcloned in the II-TOPO vector (Invitrogen), digested with
XhoI and BamHI, extracted and ligated to a pSG5-p85aPI3K
vector previously digested with the same restriction enzymes.
The vector encoding p85aPI3K-ﬂag was then used as template
for site-directed mutagenesis (QuickChange Site-Directed
Mutagenesis Kit, Stratagene) to convert Ser 83 in alanine or
aspartic acid. All the plasmid constructs were veriﬁed by DNA
sequence analysis.
Cell culture and transfections
HeLa and NIH3T3 cells were grown in RPMI with 10% fetal
calf serum or Dulbecco’s modiﬁed Eagle’s medium (DMEM)
with 10% calf serum, respectively. MCF-7 cells were grown in
DMEM with 5% fetal bovine serum, supplemented with:
penicillin/streptomycin 100mU/ml, 2mM glutamine, 6 ng/ml
insulin and 3.75 ng/ml hydrocortisone. Cells were transfected
with lipofectamine (Gibco-Invitrogen, Carlsbad, CA, USA). In
all transfections, RSV-LacZ was included to determine and
normalize transfection efﬁciency. Experiments varying in the
transfection efﬁciency above 20% were discarded.
Antibodies, immunoprecipitation and immunoblot
The antibodies used were: anti-Ras (mouse monoclonal pan-
Ras clone 10, UBI (an afﬁliate of Millipore, Billerica, MA,
USA)), anti-p85PI3K (rabbit polyclonal, UBI), anti-P-Serine
(rabbit polyclonal, Zymed, San Francisco, CA, USA), anti-
Erk 1/2 (rabbit polyclonal, Santa Cruz, Santa Cruz, CA,
USA), anti-P-Erk 1/2 (mouse monoclonal, Santa Cruz), anti-
P-Akt Ser 473 (rabbit polyclonal, Cell Signaling, Beverly, MA,
USA), anti-Akt (rabbit polyclonal, Cell Signaling), anti-P-Gsk
Ser 21/9(rabbit polyclonal, Cell signaling), anti-GSKa/b
(mouse monoclonal, UBI). The anti-ﬂag antibody was the
mouse monoclonal Sigma M2 antibody.
Immunoprecipitation
Total extracts were prepared by lysing the cells on ice 5min
with 50mM Tris-HCl pH 7.4, 1% Nonidet NP-40, 100mM
NaCl, 2mM EDTA 50mM NaF, 0.1mM NaVO3 1mM b-
glycerophosphate, 2.5mM sodium pyrophosphate and a
protease inhibitor cocktail. Cell lysates (2mg/ml) were
incubated with 4mg of antibody/0.5–1mg of protein at 41C
in gentle rock agitation 15 h. At the end of incubation, 20ml of
A/G plus were added to samples and the immunoprecipitates
were collected by centrifugation. SDS–PAGE and immuno-
blots were performed as previously described (Feliciello et al.,
2000).
Anoikis
At 48 h after transfection, the cells were collected and
maintained in suspension on dishes covered with a thin layer
of 2% agarose. Cells were plated in medium containing 0.1%
serum with or without 200mM CPT-cAMP (Sigma) for 5 h. At
the end of incubation, the cells were collected, washed twice
with phosphate-buffered saline (PBS) and incubated 5min
with propidium iodide and analysed by FACS.
Analysis of DNA content and 50-bromo-20-deoxyuridine (BrdU)
incorporation
2 106 transfected cells (48 h after transfection) were plated in
100mm dishes and grown in low serum (0.5% fetal bovine
serum) for 18 h in the presence or in absence of 50mM 8-Cl
cAMP. Cells were labelled for 30min with BrdU to a ﬁnal
concentration of 20mg/ml and harvested at 0, 90 and 270min.
After treatment, the cells were ﬁxed in ice-cold 70% ethanol
for 4 h at þ 41C and washed three times in PBS. Cells were re-
suspended in 0.25ml of 1N HCl and maintained 20min at
room temperature. After acidic denaturation of DNA, the cells
were washed two times in phosphate/citric buffer (0.2M
Na2HPO4; pH 7.4). BrdU incorporation was revealed by
anti-BrdU-FITC (Becton Dickinson, Franklin Lakes, NJ
USA) and then stained for 30min at room temperature in
0.1% Triton X-100, 0.2mg/ml DNase-free RnaseA, 20 mg/ml
propidium iodide. Fluorescence was determined by using the
FACScan Flow Cytometer (Becton Dickinson). Experiments
were performed in triplicate. The data were acquired and
analysed by CELLQuest software (Becton Dickinson) and by
Cell Fit Cell-Cycle Analysis Version 2 for bivariate analysis of
DNA content versus BrdU incorporation.
In vitro phosphorylation
HeLa cells were transiently transfected with p85aPI3K-ﬂag and
p85A. At 48 h after transfection, cell lysates were immunopre-
cipitated with non-immune IgG or anti-ﬂag antibody 15 h at
41C. Protein A/G bound immunoprecipitates were washed
twice with lysis buffer and ﬁnally with kinase buffer (N-2-
hydroxyethylpiperazine-N0-2-ethane sulfonic acid (HEPES)
20mM, MgCl2 10mM, pH 7.4). The washed immunoprecipi-
tates were treated with 0.4 mg of partly puriﬁed catalytic
subunit of protein kinase A. Each aliquot was incubated in a
ﬁnal volume of 30 ml of kinase buffer containing 105 M cAMP,
100 mM ATP and 10 mCi[g32P-ATP] for 30min at 301C. The
reaction was terminated by adding 2 Laemmli buffer.
Lipid kinase assay
Lipid kinase activity was determined as described by Maier
et al. (1999). Brieﬂy, the assays were carried out in a ﬁnal
volume of 50ml containing 0.1% bovine serum albumin, 1mM
EGTA (ethylene glycol-bis(b-aminoethyl ether)-N,N,N’,N’,-
tetraacetic acid), 120mM NaCl, 40mM HEPES, pH 7.4, 1mM
dithiothreitol, 1mM glycerophosphate, 7mMMgCl2 (buffer E).
Lipid vesicles (30 ml containing 320mM phosphatidylethanola-
mine, 300 mM phosphatidylserine, 140 mM phosphatidylcholine,
30 mM sphingomyelin, supplemented with 40mM PI-4,5-P2 in
buffer E) were sonicated 1 h and incubated on ice 10min. Some
aliquots were preincubated with LY294002, 0.5 mM (Calbio-
chem (EMD Biosciences, Inc, an Afﬁliate of Merck KGaA,
Darmstadt, Germany)) at 371C. The immunoprecipitates were
added to the lipid mixture and incubated for 10min at 41C in a
ﬁnal volume of 40ml. The reaction was started by adding 40mM
ATP (1 mCi of [-32P]ATP in 10 ml of the assay buffer at 301C.
After 15min, the reaction was stopped with ice-cold 150ml
HCl (1 N) on ice. The lipids were extracted by vortexing the
samples with 500ml of chloroform/methanol (1:1). After
centrifugation the organic phase was washed twice with
200 ml of 1N HCl. Phosphorylated lipids were separated by
TLC, detected by autoradiography and quantiﬁed with
Phosphor-Imager.
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ABSTRACT: Epidermal growth factor (EGF) stimulates DNA synthesis
and cytoskeletal rearrangement in human breast cancer (MCF-7) and
human prostate cancer (LNCaP) cells. Both effects are inhibited by estro-
gen (ICI 182,780) and androgen (Casodex) antagonists. This supports the
view that crosstalk exists between EGF and estradiol (ER) and androgen
(AR) receptors and suggests that these receptors are directly involved in
the EGF action. Our recent work shows that EGF stimulates ER phos-
phorylation on tyrosine and promotes the association of a complex be-
tween EGFR, AR/ER, and the kinase Src. The complex assembly triggers
Src activity, epidermal growth factor receptor (EGFR) phosphorylation
on tyrosine, and the EGF-dependent signaling pathway activation. In
these cells, the AR/ER/Src complex is required for the EGF action, as the
growth factor effects are abolished upon receptor silencing by specific
SiRNAs and steroid antagonists or Src inhibition by the kinase inhibitor
PP2.
KEYWORDS: androgen receptor; estrogen receptor; signal transduction;
epidermal growth factor
INTRODUCTION
Crosstalk between growth factors and steroid receptors in the nuclear
compartment leads to ligand-independent activation of the steroid receptor–
dependent transcription. Serine phosphorylation of steroid receptors by growth
factor–activated signaling kinases triggers this activation. Recent data and find-
ings described herein reveal that a crosstalk between growth factors and steroid
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receptors occurs in a bidirectional way also at a nontranscriptional level. In-
terestingly, epidermal growth factor (EGF) signaling is strongly enhanced by
the functional interplay between the EGF receptor/erb-B2 heterodimer and the
estradiol receptor (ER)–androgen receptor (AR) complex in MCF-7 cells. ER
tyrosine phosphorylation, triggered by growth factors, causes the assembly
of the EGFR/ER/AR/Src signaling complex, which, in turn, induces EGFR
phosphorylation on tyrosine. Since growth factors and steroid receptors are
known to dramatically contribute to breast cancer progression, these findings
contribute to the understanding of their action.
EGF activity converges on the ER in human mammary cancer–derived cells
as well as in uterus, thereby triggering DNA synthesis and cell proliferation.
EGF can also activate genes regulated by estrogen-responsive elements.1–3 An
increase in uterine weight and proliferation of the uterine epithelial cells follows
EGF or insulin-like growth factor-I (IGF-I) treatment of ovariectomized mice.
Interestingly, these effects are not observed in ER- knockout mice, indicating
that ER- is required in this growth factor activity.3 Elevated Src activity
has been found in breast tumor specimens and cell lines.4 Moreover, both
EGFR and Src are overexpressed in a subset of human breast tumors and
a wealth of evidence indicates physical and functional associations between
EGFR and Src (reviewed in Ref. 5). Expression of dominant negative Src in
murine fibroblasts interferes with EGF-induced mitogenesis and cytoskeletal
changes.6 Therefore, steroid receptors and Src seem to be components of the
signaling pathway elicited by EGF.
In MCF-7 and LNCaP cells, ER and AR, once activated by steroid hormones,
stimulate a mitogenic signaling network known to be engaged by growth fac-
tors.7,8 We recently observed in these cells an unexpected crosstalk between
EGFR and the extranuclear steroid receptors, which will be analyzed in the
course of this report.
Epidermal Growth Factor Signaling in Mammary Cancer Cells is
Upregulated by Steroid Receptors and Src
Recent evidence from our laboratory9 indicates that steroid receptors and Src
play a key role in EGF-triggered DNA synthesis and stress fiber breakdown.
EGF stimulates the S-phase entry of MCF-7 cells maintained in phenol red–
free medium supplemented with charcoal-treated serum. In accordance with
a previous report,1 the effect of EGF is abolished by ICI 182,780, a pure
antiestrogen. Interestingly, the pure antiandrogen Casodex also abolishes the
growth hormone effect. Effects similar to those of the two steroid antagonists
are observed in the presence of the Src kinase family inhibitor, PP2, as well as
in cells transiently transfected with siRNA silencing ER- or AR. EGF rapidly
induces fan-like membrane protrusions and ruffles in MCF-7 cells. Also in this
case, both steroid antagonists prevent EGF-induced cytoskeletal changes. Src
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activity is also involved in these responses as indicated by the PP2 inhibitory
effect on EGF-induced cytoskeletal changes. In conclusion, the two steroid
receptors and Src have a key role in the EGF-elicited responses in MCF-7
cells.
EGF-Triggered Src Activation in MCF-7 Cells is Inhibited
by Steroid Antagonists
Src family tyrosine kinases are involved in signaling of different growth fac-
tor receptors including EGFR. They can promote initiation of signaling path-
ways required for DNA synthesis and actin cytoskeleton rearrangements.10 In
MCF-7 cells EGF activates Src, whereas ICI 182,780 prevents this activation
as well as the EGF-induced Ras and Erk-2 activities. Therefore, ER- plays
a major role in the regulation of EGF-elicited signal transducing pathway in
MCF-7 cells. Casodex also prevents the EGF-induced activation of Src in
MCF-7 cells, which express AR. Lack of effect of ICI 182,780 on EGF sig-
naling in ER-negative MDA-MB231 cells indicates that inhibition of EGF-
induced Src activation by ICI 182,780 in human mammary cancer cells requires
ER- expression.
EGF Triggers Association of ER- and AR with Src and EGFR
Simultaneous to Src activation, EGF induces association of ER- and AR
with Src and EGFR in MCF-7 cells. A selective inhibitor of the EGFR
tyrosine kinase, Iressa (ZD 1839), and the anti-erb-B2 antibody herceptin
(Trastuzumab), block the EGF-elicited Src activation and ER- tyrosine phos-
phorylation and prevent the association of Src with ER and AR. Transient
transfection of Cos cells with hAR and either hER- (HEG0) cDNAs or the
HEG537 cDNA mutant, lacking the only phosphorylatable tyrosine, that in po-
sition 537,11 shows that this phosphotyrosine is required for the coexpressed
receptors/Src complex assembly.
AR and ER- are Associated with Unstimulated MCF-7 and LNCaP Cells
Co-immunoprecipitations of either AR or ER indicate that 8% of the two
receptors are associated in MCF-7 cells under basal conditions. Interestingly,
a similar association occurs in LNCaP cells between ER and AR. Pull-down
experiments with glutathione S-transferase (GST) fusion protein constructs
show that the association between the two receptors is direct. Association
was previously observed between ER and progesterone receptor-B in human
mammary cancererived cells under basal conditions and in vitro. It is required
in different cell lines for progestin stimulation of signal transducing pathway,
which triggers G1-S transition.12,13,14
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Ligand-Stimulated Epidermal Growth Factor Receptor Tyrosine
Phosphorylation in MCF-7 Cells is Uupregulated by Steroid Receptors
and Src
The above described experiments show that EGF induces ligand-
independent extranuclear steroid receptor activation. Remarkably, steroid re-
ceptors, in turn, regulate the EGFR. In fact, EGFR phosphorylation in EGF-
stimulated MCF-7 cells is strongly reduced when the cells are stimulated by
the growth factor in the presence of either ER or AR antagonists. This finding
suggests a novel, steroid-independent regulatory role of steroid receptors on
EGFR. This conclusion is supported by the strong inhibitory effect on EGFR
phosphorylation observed after the knockdown of ERa or AR gene in MCF-7
cells. In addition to the steroid receptors, Src is required for EGFR phospho-
rylation in MCF-7 cells. EGFR tyrosine phosphorylation triggered by EGF is
much weaker in cells expressing kinase-inactive Src. On this basis we propose
that Src kinase activity plays a key role in the EGF-dependent EGFR phospho-
rylation in MCF-7 cells and that this activity is under the control of the Src-
associated steroid receptors. This possibility is strongly corroborated by the
experiments in Cos cells transiently co-transfected with hAR and the wild-type
hER, or its mutant HEG537. In fact, EGF strongly stimulates EGFR tyrosine
phosphorylation in Cos cells expressing HEG0, whereas a much weaker stim-
ulation was detected in cells expressing HEG537, which is not able to interact
with Src and induce association of AR/ER/Src. Remarkably, comparison of
EGFR tyrosine phosphorylation in cells transfected with the empty vector or
ER- and AR-expressing plasmids shows that in the presence of the two steroid
receptors a much stronger EGFR phosphorylation is triggered by EGF. This
provides additional evidence that the expression of the two steroid receptors
upregulates EGFR phosphorylation.
EGF-Elicited Effects Are Inhibited by Steroid Antagonists in LNCaP Cells
In LNCaP cells, as in MCF-7 cells, EGF induces DNA synthesis. Antian-
drogen and antiestrogen abolish this stimulation. The antagonists also prevent
EGF-induced cytoskeletal changes and the growth factortimulated Src activa-
tion. These findings indicate that also in prostate cancer cells EGF signaling
is regulated by the two steroid receptors.
CONCLUSIONS
On the basis of the results presented, one may envisage a new model of
crosstalk between extranuclear steroid receptors and EGFR. a central role be-
ing played by the physical and functional interactions between EGFR, steroidal
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FIGURE 1.
receptors, and Src (FIG. 1). The EGF-activated Src, which is associated with
the ER/AR complex, strongly acts on the EGFR phosphorylation. Conversely,
when ER and/or AR are locked in an inactive conformation by hormone an-
tagonists or when the steroid receptor levels are downregulated by siRNA,
their action on Src and EGFR is missing or heavily impaired and EGF-induced
EGFR tyrosine phosphorylation is minimal. Interestingly, in MCF-7 cells, si-
lencing of steroid receptor genes abolishes the EGF-elicited DNA synthesis,
further indicating that such an effect requires steroid receptors. Similarly, ER-
is required for EGF-triggered DNA synthesis in uterine epithelial cells in vivo.3
The complexity of the described crosstalk between EGF and the steroid recep-
tor/Src complex is underlined by the observation that steroid receptors also
control, through Src, the EGF-elicited cytoskeletal changes, a classic nonge-
nomic effect in breast and prostate cancer cells. Association of AR with ER in
MCF-7 and LNCaP cells under basal conditions represents a novel and impor-
tant crosstalk between the two receptors, which are linked in their responses to
growth factors or steroid hormones. This study also reveals other aspects of the
molecular assembly that regulates nongenomic steroid receptor action. In the
ER/Src complex triggered by estradiol or androgen in MCF7, LNCaP or T47D
cells,8 phosphotyrosine in position 537 of ER- is crucial for the hormone-
induced association of ER- with Src-SH2 and consequent Src activation and
mitogenesis.8 The same phosphotyrosine residue is required for the associa-
tion of ER- with Src triggered by EGF. On the basis of previous and present
findings, the ER/AR/Src association is crucial for proliferation triggered by
steroid hormone8 or EGF in hormone-responsive cells. This is a point with
important implications since a large number of mammary and prostate cancers
respond to steroid hormones and growth factors. This association represents a
target for a novel, rational, and specific therapy of cancers expressing steroid
receptors.
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